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Neutrophil apoptosis is an important process contributing to the resolution of inflammation. 
This is because it allows the neutrophil membrane to remain intact preventing it’s 
potentially histotoxic contents from being released into the extra-cellular milieu, a process 
that can contribute to the exacerbation of many inflammatory disorders such as rheumatoid 
arthritis. When considering the life-span of a neutrophil and how it can be augmented by 
various inflammatory mediators to allow it to carry out its essential protective role in the 
body’s innate immune defences it is also important to consider how to terminate this 
process when the inflammatory insult has been dealt with or when the system goes awry. It 
is this information that we believe may hold the key to developing novel anti-inflammatory 
therapies. Through exploitation of the mechanisms controlling neutrophil apoptosis, it may 
be possible to selectively target these cells to enter apoptosis, and therefore help aid the 
process of resolution, especially if used in conjunction with treatments that up-regulate 
phagocytosis of apoptotic cells. This is important given that the main treatment for 
disorders of the inflammatory response are glucocorticoids, which whilst proven to be a 
powerful treatment for eosinophil based diseases such as asthma where they increase 
eosinophil apoptosis in conjunction with enhancing phagocytic clearance of apoptotic cells, 
glucocorticoids have been found to have the converse affect on neutrophils, actually 
serving to prolong their life-span potentially exacerbating the condition. Furthermore, it has 
been previously shown that the transcription factor nuclear factor kappa B (NF- B) plays a 
pivotal role in neutrophil apoptosis, becoming activated by inflammatory agents such as 
lipopolysaccharide (LPS) and tumour necrosis factor-alpha (TNF- ). NF- B activation 
results in the transcription of many pro-inflammatory agents and anti-apoptotic proteins 
such as X-linked inhibitor of apoptosis (X-IAP) increasing the life-span of the neutrophil. 
Interestingly, it has also been demonstrated that key neutrophil survival proteins such as 
myeloid cell leukemia-1 (Mcl-1) are not directly regulated by NF- B activation.   Therefore 
it is because of the aforementioned reasons that I have chosen to investigate further 
neutrophil apoptosis including the role played by NF- B.  Thus, I have investigated the 
hypothesis that NF- B-dependent and independent survival proteins critically regulate the 
rates of neutrophil apoptosis and that newly identified pro-apoptotic agents such as the 
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cyclin-dependent kinase (CDK) inhibitor, R-roscovitine interferes with the expression of 
such survival proteins.   
 
It has been previously found by myself and others in our laboratory during the course of 
this thesis that cyclin dependent kinase inhibitor (CDKi) drugs such as R-roscovitine are 
powerful novel anti-inflammatory agents with the ability to up-regulate rates of neutrophil 
apoptosis in vitro and influence the resolution of neutrophilic inflammation in vivo. Whilst 
the exact mechanism of CDK inhibitor drugs on neutrophil apoptosis remains elusive, work 
shown in this thesis demonstrates that R-roscovitine has the ability to over-ride powerful 
anti-apoptotic signals from pro-inflammatory agents such as granulocyte-macrophage 
colony stimulating factor (GM-CSF) and LPS causing the neutrophils to enter apoptosis. 
Furthermore, it has been found that R-roscovitine causes a decrease in levels of the anti-
apoptotic protein Mcl-1 in as little as 2h and that it prevents the maintenance / protective 
effect that GM-CSF has on the Mcl-1 protein levels. In addition R-roscovitine may also 
reduce levels of the NF- B regulated protein X-IAP. The effect of R-roscovitine on X-IAP 
was investigated further using an X-IAP HIV-tat construct, though results from this remain 
inconclusive. This is because although the X-IAP construct appeared to be extending 
neutrophil longevity, it was discovered that LPS contamination of the construct had 
occurred which could therefore pose an alternative explanation for the increase in 
neutrophil life-span. 
 
As X-IAP, TNF-  and LPS are all regulated by NF- B and given that NF- B is already 
known to be a key player in neutrophil biology, the effects of R-roscovitine on this 
important transcription factor were investigated. It was discovered that R-roscovitine does 
not directly activate NF- B, since this CDK inhibitor drug does not cause degradation and 
loss of the cytoplasmic inhibitor of NF- B, I B . This lack of NF- B activation was 
confirmed since R-roscovitine did not mobilize the NF- B subunit, p65, from the 
cytoplasm to the nucleus. Furthermore, R-roscovitine (unlike the NF- B inhibitor 
gliotoxin) does not interfere with the ability of LPS or TNF-  to activate NF- B. Therefore 
these results indicate that NF- B is unlikely to be one of the pathways directly influenced 
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by R-roscovitine to induce apoptosis, although this does not rule out the involvement of 
NF- B at a later stage. 
 
When considering a reagent for possible use as a novel anti-inflammatory agent I think it is 
important to assess what effects it has on the activation state of the neutrophil. Therefore 
the effects of R-roscovitine on the activation markers CD62L, CD11b and shape change 
were assessed. It was found that R-roscovitine alone did not cause any significant 
neutrophil activation as measured using the parameters stated above. Importantly, it was 
also found that R-roscovitine did not interfere with the activation states induced by the 
inflammatory mediators GM-CSF, LPS, TNF-  or leukotriene B4 (LTB4). 
 
Another important consideration is the effect of R-roscovitine on the removal of apoptotic 
cells by macrophage phagocytosis. Results demonstrated that pre-treatment of macrophages 
with R-roscovitine did not augment their uptake of apoptotic neutrophils. In addition R-
roscovitine did not detrimentally affect the increase in phagocytosis that results from 
macrophage treatment with the synthetic glucocorticoid dexamethasone.  
 
The data presented in this thesis suggest that CDK inhibitor drugs such as R-roscovitine are 
novel powerful pro-apoptotic agents for neutrophils with the ability to over-ride anti-
apoptotic signals from multiple pro-inflammatory mediators. It has been discovered that R-
roscovitine causes a reduction in one of the neutrophil’s most prominent anti-apoptotic 
proteins (Mcl-1) whilst not altering the activation state of the neutrophil and furthermore it 
does not interfere with the uptake of apoptotic neutrophils by macrophages or result in any 
alteration to the increase in phagocytosis caused by treatment with dexamethasone. In 
conclusion, CDK inhibitor drugs such as R-roscovitine have the potential to be promising 
candidates for novel anti-inflammatory agents with the ability to selectively target 
neutrophil apoptosis whilst not interfering with steroid induced up-regulation of 
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1.1 The inflammatory response 
 
The inflammatory response is an innate highly complex, evolutionary conserved process of 
inter-related biochemical and cellular events which still remains shrouded in some mystery. 
When controlled effectively the inflammatory response defends the host organism against 
invasion by infectious agents, and/or tissue damage. This is achieved by detection, 
repression and abolition of the invading micro-organism before it can become established 
and compromise the host. The final occurrence essential to successful inflammatory 
responses is the resolution of inflammation, restoring tissue homeostasis (Leitch et al., 
2009, Riley et al., 2006). 
 
The inflammatory response was first defined by Celsus in approximately AD40 as “rubor, 
calor, dolor, tumor” also referred to as redness, heat, pain and swelling. These classical 
symptoms of inflammation are a result of localised vasodilation (in response to e.g. 
histamine production) increasing blood supply to the site of infection/injury and in turn the 
supply of phagocytic leucocytes, such as neutrophils, and plasma proteins, for example 
clotting factors. Histamine production is also responsible for increasing capillary 
permeability enabling movement of the plasma proteins to the site of inflammation. The net 
product of this is localised oedema due to an increase in interstitial fluid osmotic pressure. 
The pain associated with inflammation is a result of distension of the inflamed tissue and 
triggering of primary afferent neurons (Sherwood, 2001). 
 
The main focus of this thesis is the human neutrophil and its role in the inflammatory 
response. Particular interest will be paid to neutrophil longevity as influence by a variety of 
survival factors and the ability of cyclin-dependent kinase inhibitors to efficaciously induce 
neutrophil apoptosis. Therefore, the first section of this thesis will introduce the cells often 
referred to as the main cells involved in innate immune defence, the leucocytes.  
 2 
1.2 Haematopoiesis  
 
All circulating blood cells (granulocytes, monocytes, erythrocytes, megakaryocytes and 
lymphocytes) originate from the same pluripotent proginator stem cell in the bone marrow 
(Figure 1.1). These pluripotent stem cells differentiate into the subsequent cell lineages 
according to the haematopoietic and growth factors they are exposed to. Haematopoietic 
and growth factors continue to influence and regulate blood cells at the inflammatory loci 




Figure 1.1 Haematopoiesis – diagram adapted from Human Physiology Cells to Systems 
Forth Edition (Sherwood, 2001)  
All granulocytes, monocytes, erythrocytes, lymphocytes and platelets are derived from the 
same undifferentiated pluripotent stem cells. Exposure to Haematopoietic and growth 
factors influences the subsequent cell lineage formed. For example neutrophils are 
produced upon stimulation from cytokines such as G-CSF, GM-CSF, SCF, IL-3 and IL-6. 
Undifferentiated 
pluripotent stem cell












Monocytes Erythrocytes Platelets Lymphocytes 
Key: Bone marrow Circulation Lymphoid tissue 
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1.3 Leucocytes  
 
Leucocytes, also known as white blood cells, derive their name from their lack of 
haemoglobin which gives them a colourless appearance. The leucocytes can be subdivided 
into two distinct groups; the granulocytes (polymorphonuclear leucocytes) and the 
agranulocytes (mononuclear leucocytes; namely lymphocytes and monocytes). Leucocytes 
are derived in the bone marrow from a common precursor (Akashi et al., 2000) and this 
helps explain some of the common features between them.   
 
The granulocytes; comprised of neutrophils, eosinophils and basophils obtain their name 
from the abundance of cytotoxic granules contained in their cytoplasm. They are the main 
cells involved in innate immune defence and are amongst the first of the cells to be 
recruited to the site of inflammation in copious numbers. Each type of granulocyte is 
predefined to specific stimuli (Duffin et al., 2010). Neutrophils are the most abundant of the 
circulating leucocytes in human blood, (approximately 50 – 70 %) defending the body 
against bacterial and fungal infections. Eosinophils, on the other hand, usually comprise 
only 1-4 % of the white blood cells in the circulation primarily defending the host against 
parasitic infection. Basophils are scarcer still (< 1 % of circulating leucocytes) and are 
thought to be involved in the resolution of parasitic infections and allergic disease (Riley et 
al., 2006).  
 
1.4 The neutrophil 
 
The majority of the work conducted in this thesis will focus on the neutrophil. This is 
because neutrophils are the one of the most prevalent and rapidly recruited cell types of the 
innate immune system. They are easily identified by their multi-lobed nucleus (Figure 1.2). 
Neutrophils arise from CD34+ pluripotent stem cells located in the bone marrow under the 
stimulation of cytokines such as G-CSF, GM-CSF, SCF, IL-3 and IL-6. Marginated 
populations of mature neutrophils also reside in the microvasculature of various tissues 
such as the lungs; these in conjunction with increased production in the bone marrow are 
responsible for the rapid increase of circulatory neutrophils (approximately 10 fold) during 
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pro-inflammatory incidents. Throughout normal physiological conditions neutrophils are 
functionally dormant and have a very short half life of between 7 and 12 hours following 
which, if they have not infiltrated the tissues, it is proposed that they locate to the bone 
marrow, liver or spleen for disposal (Fox et al., 2010). However, upon functional activation 
neutrophils have a multifaceted role in protecting the host, not only eliminating invading 
pathogens through release of reactive oxygen species (ROS) and proteases, but also 
recruiting other immune cells and increasing the inflammatory response through the release 





Figure 1.2 Photomicrograph of freshly isolated human neutrophils  
In the above picture the distinctive multi-lobed nucleus of the neutrophil can be seen. 
Neutrophils have an average diameter of approximately 7μm. 
 
1.5 Neutrophil recruitment to sites of inflammation 
 
In order for the neutrophils to carry out their defensive role it is essential that they are 
appropriately recruited to the site of infection. The process of neutrophil recruitment can be 









Upon appropriate stimulation the process of rolling commences enabling transient 
interactions between the neutrophil and the endothelium using the selectins (E-selectin, L-
selectin and P-selectin), a family of cell adhesion molecules which slow neutrophils at sites 
of inflammation (Choi et al., 2009, McEver, 2002). A prominent selectin involved in the 
process of rolling is L-selectin (also referred to as CD62L) which is constitutively 
expressed on the neutrophil surface membrane but its activity is potentiated upon neutrophil 
activation (I have measured the loss of expression of CD62L as a marker of neutrophil 
priming/activation later in this thesis). However, P-selectin and E-selectin are expressed on 
endothelial cell surface membranes (Choi et al., 2009). P-selectin is released from Weibel-
Palade bodies upon exposure to either ROS, thrombin or histamine (Lowenstein et al., 
2005). Whereas E-selectin is synthesized a couple of hours post release of the cytokines IL-
1 and TNF-  from damaged cells, or by the presence of LPS from bacterial infection (Patel 
et al., 1995, Cascao et al., 2009). All three selectin glycoproteins are recognised by the P-
selectin glycoprotein ligand (PSGL-1) expressed on both endothelial and neutrophil cell 
surface membranes. The interaction between P-selectin and PSGL-1 is thought to initiate 
the initial tethering of the neutrophil to the endothelium and E-selectin, which is also 
recognised by E-selectin ligand 1 (ESL-1), is thought to be involved in more secure rolling 
(Choi et al., 2009). Rolling enables neutrophils to detect inflammatory chemokines such as 
IL-8 and chemoattractants for example LTB4, PAF and C5a necessary for priming the 




The next stage of the neutrophil’s journey is firm and stationary adhesion to the 
endothelium, mediated by the neutrophil 2-integrins. The 2-integrins are heterodimers 
composed of an  subunit (either CD11a, CD11b or CD11c) and a  subunit CD18. The 
most prevalent 2-integrins are L 2 (LFA-1) comprised of CD11a/CD18 and M 2 (Mac-
1) comprised of CD11b/CD18, which interact with the endothelial cell surface membrane 
by either, ICAM-1, ICAM-2 ( L 2 and M 2), or the receptor for advanced glycation end 
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products (RAGE) ( M 2) (Yonekawa and Harlan, 2005). Chemokines activate integrin 
expression on neutrophils by several pathways such as small GTPases, and adhesion of the 
neutrophil to the endothelium is increased once integrin-ligand binding has occurred 
through conformational changes and clustering of the integrins. L 2 and M 2 integrin 
bindings are enhanced through Src-like protein tyrosine kinases. Neutrophils move by 
locomotion mediated by 2-integrin binding until they reach the closest junction between 




To begin its journey through the endothelium the neutrophil must first overcome VE-
cadherin, the full process of which has not been elucidated and it is not clear if the 
neutrophil’s interaction with and the subsequent vanishing of VE-cadherin is essential for, 
or a product of, migration (Choi et al., 2009). Neutrophil diapedesis is primarily mediated 
by the Ig-superfamily of adhesion molecules, namely platelet endothelial cell adhesion 
molecule-1 (PECAM-1) and junctional adhesion molecules (JAMs) the former being 
expressed by neutrophils and by endothelial cells at junctions whilst the latter is solely 
expressed on endothelial cells at tight junctions. PECAM-1 enables transmigration through 
homophilic interactions, which also act to increase levels of the laminin receptor 6 1-
integrin on neutrophils which aids the neutrophils ability to transverse the basement 
membrane of the endothelium. Interestingly it has been discovered (in mice) that CD99L2, 
expressed on both neutrophils and at endothelial junctions is essential to diapedesis, 
inhibition of which prevents the neutrophils ability to pass through the perivascular 
membrane (Bixel et al., 2004). The mode of action of JAMs is also homophilic; however, 
they can also interact with 2-integrins, JAM-A binding with L 2 and JAM-C with M 2. 
ICAM-1 also has a proposed involvement in the migration of neutrophils through the 
endothelium. Neutrophil movement through the epithelium is triggered by the chemotactic 
secretion of IL-8 from epithelial cells which have experienced an inflammatory insult and 






The final step in the process is mobilisation of the neutrophil to the inflamed tissue along 
chemotactic gradients. Various cells can release different chemoattractants, for example 
PAF is released by endothelial cells, granulocytes, platelets and macrophages. LTB4 is 
produced by monocytes and granulocytes. C5a is produced in the blood during the classical 
complement cascade, invading bacteria release chemoattractive peptides such as formylated 
peptides (FMLP) and stimulate the release of cellular chemokines, a family of 
approximately 40 proteins such as IL-8 produced by a wide range of cells including 
endothelial, epithelial, macrophages, monocytes, platelets, neutrophils and parenchymal 
cells (Wagner and Roth, 2000). It has been proposed that due to the extensive, redundant 
actions of different chemoattractants, crosstalk may occur between receptors and active 
intracellular pathways prioritising one attractant over another and helping guide the 
neutrophil to the area of tissue requiring the most attention. Chemoattractants mainly 
mediate migration through 1, 2 and 3-integrins, enabling the leading edge of the 
neutrophil to adhere, with the help of anti-adhesive molecules such as CD34 detaching the 
rear of the cell (Cascao et al., 2009).   
 
1.6 Neutrophil granules and secretory vesicles 
 
The neutrophil’s cytoplasm contains an abundance of cytotoxic granules. These house an 
arsenal of more than 300 proteins which are deployed upon activation of the neutrophil and 
are involved in vital processes such as adhesion, migration and protecting the host organism 
from invading pathogens (Borregaard and Cowland, 1997). When neutrophils come into 
contact with invading organisms they exploit these granules in one of three ways; they 
either phagocytose the pathogen, releasing into the phagolysosome reactive oxygen species 
and the products of the granules; or they exocytose the granules contents towards the 
organism. In 2007 a third method was discovered by which activated neutrophils can 
defend against foreign bodies, this is the deployment of extracellular traps (Fuchs et al., 
2007, Brinkmann and Zychlinsky, 2007). These traps are comprised of chromatin along 
with granule constituent fibers and capture and kill the target organism. This process, 
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however, is ultimately fatal for the neutrophil as it is accompanied by cell membrane 
rupture. 
 
Neutrophil granules can be subdivided into the following types: azurophil granules which 
are also referred to as primary granules as they are the first of the three distinct types of 
granule to be formed during myeloid cell differentiation or “peroxidase-positive granules” 
due to their high concentrations of myloperoxidase. These can be further classified into 
defensin-poor azurophil granules which precede the later developing classification of 
defensin-rich azurophil granules (Arnljots et al., 1998). Interestingly the azurophil granules 
predominantly function is within the phagolysosome, helping to destroy the engulfed 
pathogen (Joiner et al., 1989) and as a result are not primarily involved in exocytosis 
(Faurschou and Borregaard, 2003). Azurophilic granules are the last of the three types of 
granules to be mobilised as they contain a high percentage of the neutrophil’s anti-
microbial arsenal.  
 
The granules derived, post promyelocyte/myelocyte transition, are formed once the 
production of myloperoxidase has terminated and therefore are referred to as peroxidase-
negative granules. Peroxidase-negative granules can be sub-classified into specific granules 
(also called secondary granules as they are the second type of granule formed during 
neutrophil formation) and gelatinase granules (named after their high concentration of 
gelatinase and also known as tertiary granules as they are the third of the granules to 
appear) (Kjeldsen et al., 1992).  
 
Neutrophils also contain a forth exocytic mechanism called secretory vesicles. These form 
a distinct category from the granules as they contain plasma proteins, identifying them as 
endocytic in origin. They are highly responsive to stimulation, this helps explain the ability 
of the neutrophil to upregulate -2 integrin by chemoattractants which do not stimulate 
movement of the granules to the cell membrane (Hager et al., 2010). The secretory vesicles 
are implicated in neutrophil recruitment to inflammatory loci and thus are the first of the 
granule family to migrate to the cell surface membrane upon stimulation by an extensive 
list of inflammatory stimuli (Fox et al., 2010). The most prominent constituents of the 
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secretory vesicles are complement receptor 1 (CR1), CD11b, CD14, CD16 the Fc III 
receptor, receptors for formylated bacterial proteins (fMLP-receptors) and leukolysin a 
metalloprotease. In conjunction with the mobilisation of the secretory vesicles to the cell 
surface membrane, CD62L (L-selectin) is shed from the surface membrane. This enables 
the neutrophil to initiate firm binding to the activated endothelium at sites of inflammation 
initiating the process of transmigration (Faurschou and Borregaard, 2003). Interestingly it 
has been reported that mobilisation of the secretory vesicles is implicated in increased 
concentrations of the proposed monocytes chemoattractant heparin-binding protein (HBP) 
thus attracting monocytes to the inflamed area which will help aid resolution of 
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Cathepsin D CD16 
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-D-Glucuronidase CD11b   
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Figure 1.3 Table showing the main constituents of neutrophil granules and secretory 
vesicles 
The table above shows the 3 types of granules and secretory vesicles housed within the 
neutrophil. Listed are some of the key factors they contain which are implicated in 





Another cell pivotally involved in the inflammatory response is the monocyte. Monocytes 
are produced by the same pluripotential stem cells in the bone marrow that produce the 
granulocytes, erythrocytes, lymphocytes and platelets. Monocytes play an important role in 
the body’s defence system as they are the precursor cells of phagocytic macrophages (Latin 
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for big eater) and dendritic cells, replenishing populations in the peripheral tissues. 
Furthermore, they also have a direct immune function defending against invading 
pathogens. Monocytes arrive at the site of inflammation later than the neutrophils, 
approximately 8-12 hours post host insult.  
 
There are two distinct sub-classifications of Monocytes defined by their expression of 
CD14 (induced in LPS recognition) and CD16 (Fc RIII immunoglobulin receptor) which 
exhibit discrete functional and phenotypical features. These are the classical human 
CD14high CD16- which comprise 80-90% of monocytes in the circulation (Serbina et al., 
2008) and are implicated in the initiation of inflammation, giving rise to macrophages and 
dendritic cells involved in pathogen clearance, resolution of inflammation and antigen 
presentation (Gordon, 2007). The second group are the non classical human CD14low 
CD16+, accounting for approximately 10 % of the circulating monocytes under normal 
homeostatic conditions (Serbina et al., 2008) which form resident tissue dendritic cells and 
macrophages such as splenic (Gordon, 2007). However, the exact roles of the two sub-
classifications of monocytes have yet to be fully elucidated, as has their precise functions 




Macrophages are key effector cells in both the innate and adaptive immune system 
contributing to the former by phagocytosising invading organisms and cellular debris such 
as apoptotic neutrophils, and to the latter by antigen presentation. 
 
It has been widely reported that at least two distinct phenotypically different types of 
polarised macrophages exist, determined by the environment surrounding them. These are 
M1 classically activated macrophages that are pro-inflammatory in nature, and M2 
alternatively activated macrophages which are considered to be anti-inflammatory. M1 
macrophages are produced upon stimulation by type 1 inflammatory cytokines (produced 
by Type 1 T helper cells) and products from invading organisms. However, M2 
macrophages are the product of a Type 2 T helper cell rich environment and more recently 
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have been reclassified to M2a (induced by IL-4 and IL-13), M2b (induced by agonists of 
IL-1 receptors, TLRs and immune complexes) and M2c (induced by glucocorticoids and 
IL-10) subtypes, defined by the different activation markers they express (Benoit et al., 
2008, Mantovani et al., 2004). Furthermore, another recent discovery of an additional 
phenotype has been identified in the form of the apoptotic cell phagocytosing resolution 
phase macrophage (Bystrom et al., 2008). This has led to the proposal that macrophages 
should not be defined as a set phenotype but instead as polymorphic, able to alter their 
phenotype depending upon their environment, allowing them to participate in all stages of 
inflammation (pro-inflammatory, anti-inflammatory and resolution) (Porcheray et al., 2005, 
Stout and Suttles, 2004, Benoit et al., 2008). The macrophage and its role in the resolution 
of inflammation will be discussed in greater detail later in the chapter. 
 
1.9 Apoptosis 
1.9.1 Structural and cellular changes occurring during granulocyte apoptosis 
Apoptosis is an evolutionary conserved pathway and like virtually all cells, granulocytes 
undergo this form of programmed cell death (Wyllie et al., 1980, Savill et al., 1989). 
Granulocytes, having left the bone marrow, enter the circulation (it is estimated that the half 
life of neutrophils in the circulation is approximately 6 hours) and in response to 
appropriate stimuli enter the tissues. Once their physiological role (e.g., killing and 
digestion of invading organisms) has been accomplished the cells are destined to undergo 
spontaneous or constitutive apoptosis in the tissues. Isolated human neutrophils under 
optimal in vitro culture conditions can survive up to 20-40 hours whereas eosinophils in 
vitro tend to survive longer (40-80 hours) before apoptosis is engaged. Apoptosis can be 
delayed significantly by a number of environmental factors and mediators. However, once 
the process of apoptosis has been initiated (usually by the activation of caspases – see 
below) there is a reduction in granulocyte volume, their chromatin condenses and their 
DNA is cleaved internucleosomally. Most cell types fragment, resulting in the release of 
many membrane encapsulated apoptotic bodies. However, granulocytes tend to stay intact 
resulting in the formation of relatively few apoptotic bodies per cell. The apoptotic bodies 
are membrane enclosed thereby preventing release of the intracellular contents into the 
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extracellular milieu, and preventing damage to neighbouring cells and tissues. Apoptotic 
cells are then rapidly recognised and engulfed by phagocytes (e.g., macrophages) in 
response to the exposure of phagocytosis signals (e.g., phosphatidylserine (PS)) on the 
surface of the apoptotic cell (Savill et al., 2002, Gregory and Devitt, 2004).  
 
Manipulation of this process therefore poses huge potential for the treatment of 
inflammatory disorders. Therefore in order for this to occur it is essential that every aspect 
















Figure 1.4 Factors influencing human granulocyte apoptosis.  
The half-life of granulocytes is regulated at sites of inflammation by numerous mediators 
which can either increase or decrease rates of apoptosis. Some of these, for example, the 
haemopoeietic and inflammatory agents GM-CSF, IL-3, PAF, cAMP and a hypoxic 
environment can inhibit both neutrophil and eosinophil apoptosis, whereas agents such as 
glucocorticoids can enhance eosinophil apoptosis but conversely inhibit neutrophil 
apoptosis. They can also act to modulate the rate at which apoptotic cells are recognised 
and phagocytosed by professional phagocytes. Glucocorticoids, for example, augment the 
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1.9.2 Apoptotic pathways 
 
There are a number of signaling pathways that can regulate the rate of apoptosis in 
granulocytes, like most other cells, apoptosis can be initiated via two conserved pathways, 
commonly known as the extrinsic or the intrinsic pathways. 
 
1.9.2.1 Extrinsic Pathway 
 
The extrinsic pathway brings about apoptosis through the stimulation of cell surface ‘death 
receptors’ for example TNFR, Fas, and TRAILR (all of which are present on human 
neutrophils (Akgul and Edwards, 2003), and eosinophils (Daigle and Simon, 2001) by 
specific counter ligands. Interestingly, the ligands for these receptors not only initiate 
apoptotic pathways but can also impact upon other signaling pathways that influence 
cellular responsiveness. For example, the role of the TNF-  receptors in neutrophils is 
particularly notable as they have the capacity to ‘prime’ the cells for subsequent enhanced 
stimulation by other agonists (e.g., formylated peptides) and infer both pro-apoptotic and 
anti-apoptotic signaling depending upon the length of the incubation period with TNF-α. 
Culture of neutrophils with TNF-  for 12 h or longer have been reported to delay apoptosis, 
whilst conversely periods of culture of 8 h or less appear to trigger apoptosis in sub-
populations of neutrophils (Murray et al., 1997). The pro-apoptotic and anti-apoptotic 
pathways are activated upon binding of TNF-  to TNFR1 (TNF receptor 1) and TNFR2 
(Murray et al., 1997), (Walmsley et al., 2004).  The receptors trimerise inducing proximity 
of their death domains, consequently allowing the death domains of TNFR-associated death 
domain-containing proteins (TRADDs) to bind. TRADD can also induce apoptosis through 
binding to FADD subsequently activating pro-caspase-8 and has the ability to activate the 
transcription factors NF-κB and AP-1 via binding to secondary adaptor molecules such as 
TNFR-associated factor-2 and Receptor-Interacting Protein (RIP). This may implicate 
TNF-  as also having a role in protecting the cell from apoptosis as NF-κB is known to 




1.9.2.2 Intrinsic Pathway 
 
Cellular stress or injury triggered by, for example, UV irradiation or withdrawal of growth 
or survival factors activates the intrinsic apoptotic pathway. In this instance the key players 
in the initiation of apoptosis are a family of proteins called the Bcl-2 family, which control 
the release of cytochrome C and other apoptogenic from the mitochondria by increasing 
outer membrane permeability.  
 
1.9.3 Cysteine-dependent aspartate-specific protease family (Caspases) 
 
As has been mentioned above much of the initiation and execution of apoptosis is mediated 
via the caspase family of enzymes. The caspases are a family of death promoting 
proteolytic enzymes that become activated through the cleavage of their precursor molecule 
to generate an active caspase during apoptosis. They derive their name from ubiquitously 
contained cysteine residues within their active sites, which upon activation of the enzyme, 
cleave aspartic acid residues in their target proteins eliciting a cascade of destruction that 
ultimately brings about the demise of the cell. Caspases involved in apoptosis can be 
divided into two classes: initiator caspases and effector caspases. Initiator caspases 
(caspases 8, 9 and 10) as their name suggests bring about the initiation of the extrinsic (e.g., 
death receptor) apoptotic pathway. Procaspases 8 and 10 do this via binding to adaptor 
molecules, for example, Fas-associated death domain (FADD) using their long death 
effector domain (DED) containing prodomains. In addition initiator caspases can be 
activated by autocatalysis, which is also dependent on their prodomains, as in this instance 
they act to bring about the oligomerization of the initiator pro-caspases aiding 
autoactivation. Consequently, initiator caspases can proceed to activate the downstream 
effector caspases (caspases 3, 6 and 7) via cleavage of the effector procaspases resulting in 
morphological changes. Neutrophils and eosinophils have been shown to possess both 





1.9.4 Cross Talk between Intrinsic and Extrinsic pathways 
 
Although in most circumstances the two pathways described above occur independently, 
they can be integrated by the pro-apoptotic Bcl-2 family member Bid. The crosstalk 
phenomenon is initiated via caspase 8 cleaving Bid to form truncated Bid (tBid) which then 
translocates to the mitochondria increasing the permeability of its outer membrane resulting 
in the release of cytochrome C. Cytochrome C together with Apaf-1 forms the apoptosome 
resulting in induced proximity of procaspase-9 molecules. This results in activation of 
caspase-9, which in turn activates procaspase-3 resulting in the cleavage of substrate 
proteins, inducing the morphological changes associated with apoptosis. Cells in which 
cross talk occurs are referred to as type II cells (in type I cells caspase-8 directly cleaves 
pro-caspase 3) and it has been proposed that neutrophils fall within the type II classification 





Figure 1.5 Diagrammatic representations of the extrinsic and intrinsic apoptotic 
pathways and cross talk between the two. Adapted from (Mandelin and Pope, 2007) 
In certain circumstances cross-talk can occur between the intrinsic and extrinsic apoptotic 
pathways. This occurs when Bid is cleaved by caspase 8 to produce tBid, which can 
increase permeability of the mitochondrial outer membrane allowing the release of 
Cytochrome C. This enables the formation of the apoptosome and subsequently activation 



























1.10 Neutrophil Survival Proteins 
 
One aspect of this study will be the role of anti-apoptotic proteins in regulating human 
granulocyte survival, of which some of the most infamous belong to the Bcl-2 family. 
Interactions between the Bcl-2 family members play an essential role in deciding the fate of 
a cell. Members of the Bcl-2 family are a series of cell death regulatory proteins, of which 
there have been over 20 members identified so far (Baliga and Kumar, 2002). They are 
divided into three subgroups depending upon their function and the number of Bcl-2 
Homology (BH) domains they contain, of which there are four in total. These subgroups are 
the anti-apoptotic Bcl-2 family and the pro-apoptotic family. The pro-apoptotic family can 
be further sub classified into multi-domain pro-apoptotic Bcl-2 members Bax and Bak, 
which are essential for the downstream permeablisation of the mitochondria and activation 
of the caspases, and BH3 domain only pro-apoptotic Bcl-2 members which initiate 
apoptosis through binding to their Bcl-2 anti-apoptotic partners.  Neutrophils and 
eosinophils are known to contain various members of the Bcl-2 family which play an 
essential role in regulating their apoptotic processes (Riley et al., 2006).  
 
Neutrophils whilst lacking the anti-apoptotic protein Bcl-2 are known to express the Bcl-2 
homologue A1 (also referred to as BFL-1) and the anti-apoptotic proteins Mcl-1, Bcl-XL 
and X-IAP a member of the Inhibitor of Apoptosis (IAP) family. The best studied of these 
proteins in neutrophils is Mcl-1. Mcl-1 differs from the other anti-apoptotic multi-domain 
members of the Bcl-2 family (A1, Bcl-2 and Bcl-XL) which contain four BH domains 
whereas Mcl-1 only possesses three. It has been widely reported that Mcl-1 protein levels 
in blood circulating neutrophils decrease preceding the cell entering apoptosis.  
Inflammatory mediators that postpone neutrophil apoptosis do this (at least in part) through 
maintaining or increasing levels of Mcl-1 and/or A1 enabling neutrophils to carry out their 
vital defensive functions. The half lives of both A1 and Mcl-1 mRNA along with the Mcl-1 
protein are known to be short in contrast to the long half lives of the pro-apoptotic Bcl-2 
members. This offers an explanation as to why neutrophils are ‘primed’ for apoptosis when 
in the circulation as de novo synthesis of Mcl-1 and A1 is absent, therefore allowing the 
effect of long lived proapoptotic proteins to pre-dominate (Moulding et al., 1998, Derouet 
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et al., 2004, Edwards et al., 2004). Survival signals in the form of cytokines and other 
mediators found at sites of inflammation induce de novo synthesis of the anti-apoptotic 
proteins, demonstrated through the use of agents that inhibit protein synthesis (e.g. 
cycloheximide and actinomycin D) which prevent increased granulocyte survival and 
directly induced apoptosis (Whyte et al., 1997).   
 
1.10.1 Myeloid cell leukaemia differentiation protein (Mcl-1) 
 
As Mcl-1 has been demonstrated to play a significant role in neutrophil apoptosis particular 
attention has been played to the intricate involvement of this protein. Mcl-1 derived its 
name as it was originally isolated from a human myeloblastic leukaemia cell line. In 2007 
Dzhagalov et al. discovered through the use of conditional Mcl-1 knock out mice that Mcl-
1 is an essential non redundant survival protein in neutrophils demonstrated by severely 
impaired neutrophil survival in the knock out mice. However, this does not appear to be the 
case with macrophages as the knock out mice possessed a normally functioning 
macrophage population (Dzhagalov et al., 2007).  
 
 
Figure 1.6 Diagrammatic representations of the two isoforms of Mcl-1  
Mcl-1 Long is the anti-apoptotic, wild type, full length protein encoded from all 3 exons of 
the Mcl-1 gene. It contains BH domains 1, 2 and 3, a transmembrane domain which targets 
the protein to the mitochondria, and a PEST sequence associated with rapid turnover of the 
protein. Mcl-1 Short, however, is encoded from just 2 exons of the Mcl-1 gene (the second 
exon is skipped) and as a result lacks BH1, BH2 and the transmembrane domain, and 
instead behaves like a member of the pro-apoptotic BH3 domain only family, such as Bid.  




TM = Transmembrane domain which 
targets MCL-1L to the mitochondria 
Mcl-1L protein has an 
approximate molecular 
weight of 40kDa 
Mcl-1S protein has an 
approximate molecular 
weight of 28kDa 
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Mcl-1 is a particularly interesting member of the Bcl-2 family as it can take the form of one 
of two splice variants referred to as Mcl-1 long (Mcl-1L) and Mcl-1 short (Mcl-1S). Mcl-1L 
is the wild type full length protein encoded from all 3 exons which exhibits its infamous 
role as an anti-apoptotic protein. However, Mcl-1S skips the second exon resulting in the 
translated protein retaining the BH3 domain but losing the BH2, BH1 and transmembrane 
domains. Interestingly, as the Mcl-1S protein contains the BH3 domain it therefore 
possesses properties similar to the BH3 only domain family of pro-apoptotic proteins such 
as Bid, Bad and Bim, and when over-expressed has the ability to induce apoptosis (Bingle 
et al., 2000). Furthermore, Mcl-1S has been demonstrated to form dimers with Mcl-1L 
enabling the anti-apoptotic ability of Mcl-1L to oppose the pro-apoptotic action of Mcl-1S. 
This implies that the fate of the neutrophil could be determined by the dominant isoform of 
Mcl-1 expressed in the cells (Bae et al., 2000). This thesis will focus on the wild type Mcl-
1L which from here on will be referred to as Mcl-1 unless otherwise indicated. 
 
Mcl-1 can also be regulated at the transcriptional level and interestingly it has been 
proposed that short nucleotide polymorphisms (6 and 18 nucleotides long) in the promoter 
region of the Mcl-1 gene are associated with increased expression of Mcl-1 mRNA and 
protein in haemopoeietic and epithelial cells (Saxena et al., 2007). These short neucleotide 
polymorphisms have been found in individuals with Chronic Lymphocytic Leukaemia 
(CLL) and healthy individuals, although the prevalence varies between studies from 25 – 
60 % of CLL patients to 4 – 70 % of varying healthy populations (Saxena et al., 2007).  
 
Another feature making Mcl-1 stand apart from its fellow Bcl-2 anti-apoptotic family 
members is that it contains a PEST domain ((P) proline, (E) glutamic acid, (S) serine, (T) 
threonine rich domain) which is associated with proteins that have a short half life (Akgul 
et al., 2000b). However, Akgul et al. made the interesting observation that deletion of this 
domain did not affect the stability of the Mcl-1 protein, indicating that the PEST motif is 
not solely responsible for the rapid turn over of the Mcl-1 protein.  
 
Other proposed methods of regulation are by proteolytic degradation by the caspases 
(Herrant et al., 2004) and granzyme B (Han et al., 2004), or proteasomal degradation 
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(Derouet et al., 2004). MULE a ubiquitin E3 ligase which possesses and BH3 domain 
therefore enabling Mcl-1 directed action has been identified (Zhong et al., 2005). However, 
another layer of complexity was added to the story when it was reported in 2010 that Mcl-1 
regulation is not impeded by the deletion of the sites for ubiquitination and that the turn-
over of the mutated protein resembles that of the wild-type in both normal and apoptosis 
inducing conditions. Furthermore, Mcl-1 could also be degraded by the 20S proteasome in 
an un-ubiquitinated state (Stewart et al., 2010).  
 
Thus to summarise the Mcl-1 protein is subject to multiple redundant methods of steady 
state protein regulation, which perhaps is not surprising for a protein so intricately involved 
in the ultimate fate of the cell.     
 
1.10.2 Mcl-1 function 
 
Like the majority of Bcl-2 family members wild type Mcl-1 is targeted to the mitochondrial 
membrane by the hydrophobic transmembrane domain located at the C-terminus of the 
protein (Akgul et al., 2004). Mcl-1 exerts its pro-survival function via interacting with 
numerous pro-apoptotic proteins.  
 
One major function of Mcl-1 in viable cells is to bind to the multidomain pro-apoptotic 
protein Bak (located on the mitochondrial membrane) and hold it in an inactive 
conformation. Upon initiation of apoptosis, for example by DNA damage, Noxa (a BH3-
only proapoptotic protein) is activated, interaction between Noxa and Mcl-1 results in 
displacement of Bak marking Mcl-1 for degradation by the proteasome. This enables Bak 
to undergo conformational changes and homo-oligomerization triggering permeablisation 
of the mitochondrial membrane and allowing release of cytochrome C and other 
apoptogenic factors. It should be noted that Bcl-XL can also suppress Bak and that in order 




It has also been speculated that Mcl-1 plays a role in the inhibition of Bax, another 
multidomain pro-apoptotic protein responsible for permeablisation of the mitochondrial 
membrane. Unlike Bak, in viable cells Bax mainly resides in the cytoplasm. However, upon 
activation Bax translocates to the mitochondrial membrane and it is here that Mcl-1 is 
proposed to perform its inhibitory function. Interestingly the inhibitory action of Mcl-1 on 
Bax has yet to be fully elucidated and is independent of an interaction between Mcl-1 and 
Bax. Yet in order for Mcl-1 to exert its pro-survival function Bax needs to be present 
(Germain et al., 2008).  
 
As previously mentioned BH3 only pro-apoptotic members function upstream of Bax and 
Bak and can not induce apoptosis in their absence. One such member of the BH3 only 
proteins is Bim. Bim is a promiscuous member of the BH3 only family and can bind to all 
anti-apoptotic members, including Mcl-1 (Adams and Cory, 2007). In viable cells Mcl-1 
binds Bim on the outer mitochondrial membrane and neutralises its proapoptotic ability. 
However, upon initiation of extrinsic TRAIL-mediated apoptotic pathway activation of 
caspase 8 and caspase 3 degrades Mcl-1 relieving its inhibition on Bim. This then enables 
Bim to elicit Bax-dependent apoptosis highlighting a possible second mechanism of cross 
talk between the extrinsic and intrinsic apoptotic pathways (Han et al., 2006). Interestingly, 
Mcl-1 is also involved in classical cross talk between the extrinsic and intrinsic pathways 
(as described in section 1.9.4) as Mcl-1 binds potently to tBid inhibiting mitochondrial 
outer membrane permeabilisation (MOMP) (Clohessy et al., 2006).  
 
1.10.3 Role of Mcl-1 in the neutrophil  
 
As mentioned above survival signals and mediators located at inflammatory loci can 
stimulate production of survival proteins. One such cytokine known to increase neutrophil 
survival that is found elevated levels at sites of inflammation is granulocyte-macrophage 
colony-stimulating factor (GM-CSF). GM-CSF is known to increase the levels of Mcl-1 
protein through stimulating transcription of the Mcl-1 gene (Derouet et al., 2004). Proposed 
mechanisms for the transcriptional upregulation of Mcl-1 are through MAPK influencing 
SRF/Elk-1 (Townsend et al., 1999) (Townsend et al., 1998), or alternatively via the 
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PI3K/Akt CREB transcription factor pathway (Wang et al., 1999). For more information of 
MAPK and PI3K pathways and their roles in granulocyte apoptosis please see 1.11.2 PI3K 
Pathway and 1.11.3 MAPK Pathway. 
 
However this may not be the sole way through which GM-CSF influences Mcl-1 levels. 
Interestingly it has also been shown that GM-CSF increases the cellular concentration of 
Mcl-1 in neutrophils to a more significant level than those achieved through enhanced de 
novo synthesis of the Mcl-1 protein by increasing the stability of the Mcl-1 protein and 
reducing the rate with which it is turned over via the proteasome (Derouet et al., 2004).  
 
As mentioned in 1.9.2 Apoptotic pathways – extrinsic pathway, TNF-  exposure can have 
converse effects on neutrophil apoptosis depending upon the length of exposure (Murray et 
al., 1997, Walmsley et al., 2004), and the concentration neutrophils are exposed to with low 
concentrations of TNF-  having a protective effect whilst high concentrations have a pro-
apoptotic effect on neutrophils (van den Berg et al., 2001). Cross proposed in 2008 that the 
differing concentration dependent actions of TNF-  result from differing pathways being 
triggered in the neutrophil, one of which involves Mcl-1. At low concentrations of TNF-  
(defined as <1ng/ml) induced neutrophil production of the anti-apoptotic protein A1 and 
subsequent neutrophil survival. However at high concentrations (>10ng/ml) TNF-  
stimulated caspase-dependent decrease in Mcl-1 levels priming the cells for apoptosis 
(Cross et al., 2008). Interestingly unlike GM-CSF, TNF-  does not induce transcription of 
Mcl-1 or accelerate turnover of Mcl-1 by the proteasome. 
 
Interestingly Mcl-1 regulation also plays an important role in the ability of the commonly 
prescribed pharmacological agent aspirin to promote resolution of inflammation. Aspirin 
triggers 15-epi-lipoxin A4 (15-epi-LXA4)) and has been demonstrated to decrease levels of 
Mcl-1 in human neutrophils. This is achieved through 15-epi-LXA4 preventing the ability 
of myeloperoxidase (MPO) to induce an increase of Mcl-1 promoting apoptosis and the 




1.10.4 X-Linked Inhibitor of Apoptosis (X-IAP) 
 
Another anti-apoptotic protein of particular interest in this thesis is X-IAP, a member of the 
inhibitor of apoptosis protein family (IAPs) of which to date eight have been identified in 
humans. Members of the IAP family are defined by the possession of one – three 
baculovirus IAP repeat (BIR) zinc-binding motifs (Zangemeister-Wittke and Simon, 2004). 
 
 
Figure 1.7 Structural representation of X-IAP adapted from (Galban and Duckett, 
2010) 
X-IAP is a member of the inhibitor of apoptosis family and contains all 3 of the BIR motifs. 
X-IAP can directly inhibit caspases 3, 7 and 9, a process involving the use of BIR 2 and 
BIR 3. Interestingly, BIR 1 can complex with TAK1 and TAB1 implicating X-IAP in 
regulation of the NF- B signaling pathway. The RING domain enables X-IAP to self 
ubiquitinate enabling protein levels to be regulated, at least partially, by the proteasome. 
The RING domain also enables oligomerization and interaction of X-IAP with c-IAP1. 
 
X-IAP works through directly inhibiting the caspases 3, 7 and 9, but unlike other members 
of the IAP family X-IAP is the only one which has been demonstrated to act as a direct 
competitive inhibitor binding to the caspase catalytic domain (Eckelman et al., 2006). X-
IAP can also associate with Apoptosis Inducing Factor (AIF) however the exact function of 
this interaction is as yet unknown. Studies have demonstrated that interaction of the two 



















does not inhibit the ability of X-IAP to suppress the caspases, although interestingly the 
interaction does appear to reduce intracellular ROS levels (Wilkinson et al., 2007).  
However, the anti-apoptotic capability of X-IAP can be prevented by proteins containing an 
IAP binding motif (IBM) such as Smac/DIABLO which inhibit X-IAP through steric 
hindrance. 
 
Interestingly X-IAP function is not limited to control of the caspases, it also plays an 
integral role in multiple other cellular functions. For example through complexing with the 
serine threonine kinase TGF- -activated kinase 1 (TAK1) and TAK binding protein 1 
(TAB1) X-IAP is implicated in NF- B signaling, although evidence is conflicting as to 
whether TAK1 is essential for X-IAP activation of  NF- B. Interestingly X-IAP can also 
bind copper metabolism domain containing 1 (COMMD1) a suppressor of the NF- B 
pathway (Galban and Duckett, 2010). 
 
Levels of X-IAP appear, at least in part, to be regulated by the proteasome and through its 
RING domain X-IAP possesses the ability to self-ubiquitinate (Yang and Li, 2000a). This 
is not the sole function of the RING domain as it also has a role in oligomerization (Galban 
and Duckett) and is involved in the interaction of X-IAP with c-IAP1 in which c-IAP1 
through use of its E3 ligase RING domain marks X-IAP for proteasomal degradation 
(Cheung et al., 2008).  
 
As is to be expected of any inhibitor of apoptosis, levels of X-IAP decrease in the presence 
of stress inducing and pro-apoptotic stimuli. It has been proposed by  Henson et al. that in 
neutrophils activation of the ERK/MAPK pathway can protect against stress induced 
apoptosis by preventing a decrease in levels of X-IAP (either through inhibiting 
degradation or inducing XIAP synthesis.) In addition oxidants found at sites of 
inflammation are hypothesized to block ERK activity via activating P38 promoting a 





1.11 Intracellular signaling affecting granulocyte survival 
 
Whilst the basic structural and cellular characteristics occurring during apoptosis vary only 
slightly between cell types, the mechanisms controlling apoptosis differ greatly. There are 
key differences in the mechanisms regulating lymphocytes and granulocytes and even 
between types of granulocytes (Haslett, 1997, Ward et al., 1999b). It has been revealed 
through in vitro observations that inflammatory stimuli such as IL-1b, IL-2, IL-8 IL-15, 
TNF-  (>12hr incubation), IFN- , GM-CSF, GCSF, LPS, C5a and hypoxic conditions all 
have the ability to delay neutrophil apoptosis. These pro-survival factors allow neutrophils 
the opportunity to persist at the site of infection ensuring efficient removal of invading 
pathogens. GM-CSF also acts to delay eosinophil apoptosis, while IL-5 another suppressor 
of eosinophil apoptosis has no effect on neutrophil life span (Ward et al., 1999b). The fate 
of the granulocyte at the inflammatory site can therefore be viewed in terms of a fine 
balance between pro-apoptotic and the anti-apoptotic signals from local pro-inflammatory 
mediators. Some of the pathways known to influence apoptosis will be considered. 
 
1.11.1 NF B pathway and role in neutrophil apoptosis 
 
The role of the NF- B pathway in inflammation is notoriously complex given its 
involvement in a plethora of inflammatory processes ranging from the pro-inflammatory 
functions of cell survival, leukocyte recruitment and cytokine production to the pro-
resolving effects of neutrophil apoptosis. Consequently the homeostatic mechanisms in 
place to regulate such complexity are intricately linked and balanced.   
 
As previously mentioned the transcription factor NF- B is a key component in regulating 
the fate of the granulocyte as it is implicated in up-regulating anti-apoptotic genes. It is 
through NF- B that pro-inflammatory mediators such as LPS and TNF-  are thought to 
extend neutrophil survival. The role of NF- B on neutrophil and eosinophil survival has 
been investigated using pharmacological tools such as the NF- B inhibitor gliotoxin, which 
when used in conjunction with exposure to LPS, was found to inhibit the anti-apoptotic 
effects of LPS. Additionally, at early time points gliotoxin dramatically enhances the 
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apoptotic action of TNF-  (Ward et al., 1999a). The importance of NF- B in neutrophil and 
eosinophil survival has also been demonstrated using physiological NF- B inhibitors, 
namely the prostaglandin D2 metabolites D12 prostaglandin J2 (D12PGJ2) and 15-deoxy-
D12,14prostaglandin J2 (15dPGJ2) (Ward et al., 2002). These also increased granulocyte 
apoptosis and prevented mediator induced survival. In addition PGD2 metabolites have 
been shown to possess therapeutic benefits for the treatment of rat pleurisy where they were 
found to induce neutrophil and macrophage apoptosis to bring about resolution of acutely 
inflamed tissue (Gilroy et al., 2003). Although less is known about the pathways mediating 
eosinophil apoptosis, NF- B is thought to be involved (Ward et al., 1999a, Fujihara et al., 
2005, Fujihara et al., 2002). When incubated with TNF- , eosinophils appear to lose 
cytoplasmic IkB-  allowing the released NF- B to travel to the nucleus. In addition, there 
is evidence suggesting that TNF-  triggered eosinophils apoptosis may be more sensitive to 
NF- B inhibition than constitutive apoptosis (Fujihara et al., 2002). Using a cell permeable 
HIV-tat linked super-repressor of the NF- B inhibitor molecule IkB  we have confirmed a 
role for NF- B in the regulation of eosinophil apoptosis as this inhibitor induced direct 
eosinophil apoptosis (Fujihara et al., 2005). Other groups have now verified the importance 
of NF- B activation in the regulation of human granulocyte apoptosis (Arruda et al., 2004, 
Choi et al., 2003, Francois et al., 2005, Wang et al., 2003, Castro-Alcaraz et al., 2002, 
Vancurova et al., 2001). 
 
However, there is a dichotomy in terms of a role for NF- B inflammation where NF- B 
also can have an anti-inflammatory/pro-resolving role during the resolution of acute 
inflammation (Lawrence et al., 2001). The developments of therapeutics that specifically 
manipulate the anti-inflammatory effects of NF- B are currently being investigated. 
Although I B  is an endogenous negative regulator of NF- B, therapeutic administration 
of this molecule itself would not be suitable due to its rapid biodegradation in vivo. 
However, recent studies have shown that a stable chimeric form of this molecule, 
comprising the super-repressor I B  fused to a membrane transducing domain of HIV-tat 
protein, can promote the resolution of inflammation in an acute rat carrageenan induced 
pleurisy model (Blackwell et al., 2004). Furthermore, IKK , an upstream regulator of I B  
and NF- B, has recently been shown to negatively regulate macrophage activation, local 
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inflammation and innate immunity to bacterial infections (Lawrence et al., 2005). IKK  
inhibits NF- B activity by inducing the NF- B subunits RelA and c-Rel and suppressing 
their interaction with pro-inflammatory gene promoters. In addition, genetically modified 
mice that have inactivated IKK  have an exaggerated inflammatory response in a model of 
LPS-induced septic shock (Lawrence et al., 2005). 
 
1.11.2 Phosphoinositide 3-Kinase (PI3K) 
 
PI3K is another vital signaling molecule that is likely to regulate many of the pro-
inflammatory and anti-apoptotic pathways triggered by the inflammatory mediators (e.g., 
LPS, GM-CSF and TNF- ). There are three classes of the PI3K family, class I, class II and 
class III, of which class I PI3Ks are subdivided again according to the organization of their 
catalytic and regulatory subunits along with their mode of action into classes 1A and 1B. 
The class 1A p85/p110 isoform of PI3K appears to be involved in the delay of neutrophil 
apoptosis induced by LPS, GM-CSF and TNF- . However, inhibition of PI3K signaling 
using specific PI3K inhibitors do not influence constitutive rates of neutrophil apoptosis 
(Lindemans and Coffer, 2004). PI3K affects apoptosis via controlling the activation of Akt, 
NF- B and the cAMP response element binding protein (CREB). For example, in PI3K  
knockout mice translocation of NF- B to the nucleus and phosphorylation of CREB were 
decreased. This correlated with reduced expression of the anti-apoptotic proteins Bcl-XL 
and Mcl-1. It was also found that Akt inactivated Bad, Forkhead and GSK-3  through 
phosphorylation, with Akt now known to be an integral enzyme in neutrophil apoptosis as 
it controls Mcl-1 expression through CREB as well as NF- B and Bcl-XL (Yang et al., 
2003). PI3K is also implicated in the regulation of eosinophils recruitment and survival in 
vivo. Recent studies, using PI3K -defient mice and specific PI3K inhibitors, have 
demonstrated that PI3Ks critically regulate the recruitment and survival of eosinophils in a 
model of allergic pleurisy. PI3K inhibitors administered during post antigen challenge 
resulted in a significant increase in apoptotic events and clearance of eosinophils. It was 
concluded that PI3K  is necessary for maintenance of eosinophilic inflammation in vivo 
and that other isoforms of PI3K may be relevant for eosinophils recruitment (Pinho et al., 
2005). 
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1.11.3 Mitogen Activated Protein Kinases (MAPK) 
 
Upstream kinases regulate the three subfamilies of MAPKs by phosphorylation. These 
three types of ubiquitously expressed enzymes are p38, extracellular-signal regulated 
kinases (ERKs) and stress-activated protein kinase/c-jun amino-terminal kinase 
(SAPK/JNK); in most cell types they play a pivotal role in the regulation of survival. 
Inflammatory mediators activate several MAPKs therefore it is proposed that crosstalk 
between MAPKs may be responsible for increasing granulocyte survival. ERK pathways 
are known to be activated by agents that affect granulocyte responsiveness and apoptosis 
(e.g., GM-CSF, LPS, IL-8, IL-15 and C5a). Using MEK inhibitors (especially PD098959) 
it has been suggested that ERK activation is not essential for controlling constitutive 
apoptosis but that it is likely to be important for maintaining survival induced by certain 
inflammatory mediators (e.g., GM-CSF) see (Walker et al., 2003). 
 
Our recent studies have shown that the pro-survival molecules pERK1/2 and Bcl-xL are 
present in inflammatory cells that are predominant at the onset of inflammation and become 
down-regulated during the resolution phase of the inflammatory response (Sawatzky et al., 
2006). Furthermore, we have qualitatively shown that inducing granulocyte apoptosis with 
the ERK1/2 inhibitor PD98059 promotes the resolution of inflammation when given at the 
peak of the inflammatory response in a rat carrageenan-induced pleurisy in vivo model. 
This study shows that the induction of neutrophil apoptosis halts the progression of the 
inflammatory response and pro-actively initiates the onset of resolution. 
 
The importance of p38 and SAPK/JNK in neutrophil survival however remains more 
controversial. p38 may be an important factor in stress induced apoptosis, yet is thought to 
have no involvement in Fas or constitutive apoptosis. In addition in GM-CSF treated 
neutrophils it has been reported that p38 does not play a role in increasing neutrophil 
survival as it fails to become phosphorylated. This is supported by the observation that 
inhibition of p38 by SB203580 fails to affect the anti-apoptotic capacities of GM-CSF. 
However, a possible role for p38 in neutrophil survival could be provided by its apparent 
ability to phosphorylate and thereby inhibit caspases-3 and 8 (Gardai et al., 2004, Alvarado-
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Kristensson et al., 2002, Frasch et al., 1998, Sheth et al., 2001). It has been proposed that 
once the caspases become activated upon the neutrophil entering apoptosis they can result 
in the cleavage and subsequent degradation of ERK and p38. This cleavage of MAPKs is 
thought to be prevented by G-CSF therefore this could pose a possible pathway through 
which apoptosis is inhibited in neutrophils (Alvarado-Kristensson et al., 2004, Suzuki et al., 
2001). 
 
There is a lack of conclusive evidence regarding the role of JNK in neutrophil apoptosis. 
However, the limited data suggest that inflammatory mediators such LPS and TNF-  have 
effects on the JNK pathway to influence function. There is some debate however as to 
whether neutrophil apoptosis is caused by activation of JNK or if it is in fact merely a 
consequence of it. This is because it has been reported that MAPK kinase and MEKK-1 are 
cleaved when the cell undergoes apoptosis and that consequently they can activate JNK 
(Nolan et al., 1999, Avdi et al., 2001). 
 
1.11.4 Cyclic Adenosine Mono Phosphate (cAMP) 
 
Granulocyte apoptosis is also delayed through an increase in cAMP brought about via some 
inflammatory mediators (e.g., prostaglandins) and pharmacological agents that elevate 
cAMP (e.g., the cell permeable analogue db-cAMP) (Martin et al., 2001, Hallsworth et al., 
1996, Peacock et al., 1999, Rossi et al., 1995, Tortorella et al., 1998). The precise 
mechanism of action of cAMP mediated delay of neutrophil apoptosis remains to be 
elucidated. It has been suggested that this effect may be mediated by both a PKA-
dependent (Krakstad et al., 2004, Parvathenani et al., 1998) and PKA-independent 
mechanism (Martin et al., 2001). Similarly cAMP elevation delays eosinophils apoptosis 




Use of agents (e.g. A23187 and thapsigargin) that raise cytosolic free calcium in 
granulocytes have shown that this important second messenger molecule not only regulates 
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granulocyte function but also apoptosis. In neutrophils, raised cytosolic calcium levels have 
been found to delay apoptosis (Whyte et al., 1993, Cousin et al., 1997, Murray et al., 
2003b) whereas increased calcium levels in eosinophils appear to enhance rates of 
apoptosis (Cousin et al., 1997). The reasons for such differential regulation is currently not 
known and it is also apparent that there is a dissociation between raised elevation of 




Glucocorticoids are one of the major forms of treatment for inflammatory diseases and, 
whilst they prove invaluable especially in lymphocytic and eosinophilic dominant diseases 
such as asthma they appear to be less beneficial in neutrophilic-mediated inflammation. 
This may be because whilst glucocorticoids act to up-regulate the phagocytic ability of 
macrophages (Liu et al., 1999, Giles et al., 2001, Heasman et al., 2004) and increase 
eosinophil (Meagher et al., 1996) and lymphocyte (McConkey et al., 1989, Wyllie et al., 
1984, Wyllie and Morris, 1982) apoptosis they extend neutrophil life span (Meagher et al., 
1996, Cox and Austin, 1997, Cox et al., 1995) therefore slowing their removal from the site 
of inflammation. Sivertson K.L et al reported in 2007 that the differing effect of 
dexamethasone on neutrophils and eosinophils is, at least in part, due to differing effects on 
Mcl-1 (Sivertson et al., 2007). Whilst dexamethasone decreases Mcl-1 in eosinophils 
leading to apoptosis, it maintains expression in neutrophils through an as yet unidentified 
post translational mechanism. It is plausible that the same effect may occur in vivo.   
 
There are two known isoforms of the glucocorticoids receptor (GR), GR  and GR , the 
latter of which lacks a steroid binding domain rendering it unable to bind with 
glucocorticoids. Whilst it is known that the predominant isoform of the glucocorticoid 
receptor in neutrophils is the -isoform, little is known about the glucocorticoid survival 
pathway in neutrophils. One theory is that the ability of glucocorticoids to induce apoptosis 
in a cell, revolves around the ratio of GR  to GR  (Strickland et al., 2001). Interestingly it 
has also been shown that other steroids can also affect neutrophil apoptosis. For example, 
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oestradiol and progesterone have an anti-apoptotic effect on neutrophils, a response that is 
reversed by activating the Fas pathway (Molloy et al., 2003). 
 
1.11.7 Nitric oxide 
 
Nitric oxide is not only important in the processes of vasodilatation and neurotransmission 
as it also plays a regulatory role in granulocyte apoptosis (Ward et al., 2000, Taylor et al., 
2003). Its role, however, is not straightforward, as it appears to have both the ability to 
promote, as well as delay granulocyte apoptosis. The general trend in neutrophils however 
appears to be that high concentrations of nitric oxide have a pro-apoptotic/necrotic effect 
possibly via peroxynitrite generation (Taylor et al., 2001). In addition, it is speculated that 
pathways that influence granulocyte survival such as NF- B may be disrupted indirectly by 
the generation of nitric oxide (Fortenberry et al., 2001). On the contrary, low concentrations 
of nitric oxide favour an anti-apoptotic effect that is proposed to involve S-nitrosation of 




There are many other mediators, drugs and agents that influence granulocyte apoptosis that 
have not been specifically covered in detail in this review. Others include, oxidative stress, 
bacteria and their products, and cytokines such as macrophage migration inhibitory factor 
(MIF), many of which have been described in other reviews (Ward et al., 1999b, Walker et 
al., 2003, Akgul et al., 2001, Simon, 2003, Hofman, 2004). For example, MIF an 
inflammatory cytokine that is released by monocytes/macrophages T-cells and eosinophils, 
delays neutrophil apoptosis via inhibiting the apoptotic pathway upstream of the 
mitochondria ultimately preventing activation of caspase-3 (Baumann et al., 2003). MIF 
has also been proposed to be involved in eosinophil-dependent inflammatory disorders, 
such as asthma. Eosinophils have been shown to be an important source of MIF and 
bronchoalveolar lavage fluid samples from asthma sufferers demonstrating increased levels 
of MIF when compared to samples obtained from healthy non-asthmatics (Rossi et al., 
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1998a). It is now recognised that the inflammatory environment is hypoxic (often with a 
p02 < 3%). 
 
Granulocytes function efficiently under these conditions and it is believed that adaptive 
responses to hypoxia are controlled mainly by the transcription factor HIF-1a. Indeed it has 
been shown that HIF-1a is essential for myeloid cell-mediated inflammation in vitro and in 
vivo (Cramer et al., 2003). Hypoxic conditions profoundly delay neutrophil (Hannah et al., 
1995, Mecklenburgh et al., 2002, Murray et al., 2003a, Walmsley et al., 2005) and 
eosinophil (Ward et al., 1999b) apoptosis. The precise mechanism underlying the hypoxia-
mediated neutrophil survival is unknown but good evidence suggests that HIF-1a-
dependent NF- B activity is involved (Walmsley et al., 2005). 
 
1.12 Macrophage removal of apoptotic granulocytes 
 
Resolution of inflammation requires that granulocytes are removed from the site of cellular 
damage by a process involving granulocyte apoptosis and subsequent disposal via 
phagocytosis by tissue resident macrophages or other cells with a capacity for phagocytosis 
(e.g., fibroblasts, endothelial cells). Importantly, there is much evidence suggesting that 
phagocytes when ingesting apoptotic cells increase their expression and release of anti-
inflammatory pro-resolution mediators and down-regulate release of pro-inflammatory 
mediators (Fadok et al., 1998, Liu et al., 1999). Apoptotic cells experience changes to their 
cell membrane allowing recognition and ingestion of the apoptotic cells by phagocytes via 
binding to specific receptors either directly or via bridge molecules.  
 
One such signal suggested to be a key mechanism behind the removal of apoptotic cells is 
the recognition of PS on the apoptotic cell surface by specific PS receptors. PS is located on 
the inner leaflet of the plasma membrane of viable cells and is maintained there by 
aminophospholipid transferase, however it is disruption of this transferase during apoptosis 
which is responsible for PS exposure (Bratton et al., 1997) along with activation of 
phospholipid scramblase by capsase 3 (Frasch et al., 2000). Furthermore recent research 
indicates that in order for PS to be recognised by the phagocyte as an engulfment signal it 
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must first be oxidized by cytochrome C before it is externalized (Jiang et al., 2003). 
However, a further theory is that PS can more accurately be described as an indicator of 
cell death as Brouckaert identified that PS is externalized in death ligand induced necrotic 
cell death, marking these cells for engulfment by macrophages (Brouckaert et al., 2004). 
For some cases of death receptor/ligand binding bridge molecules are required to aid the 
process. For example milk-fat globule epidermal growth factor 8 (MGF-E8) aids binding of 
the vitronectin receptor to the PS ligand (Wu et al., 2006), whilst  binding of PS to the Mer 
kinase receptor is aided by the bridging molecule Gas6. However not all PS receptors 
appear to require the presence of bridge molecules, research by (Park et al., 2008) suggests 
the stabilin-2 receptor binds to the PS without the use of a bridging molecule. 
 
PS is not thought to be the sole ‘eat me’ signal responsible for the removal of apoptotic 
neutrophils (see (Savill et al., 2002, Gregory and Devitt, 2004, Giles et al., 2000)). Other 
cell membrane recognition ligands include calreticulin, stored in the endoplasmic reticulum 
but which is upregulated and presented on the cell surface upon apoptosis. Interestingly it 
has also been postulated that DNA exposed on the cell surface can act as a ligand indicating 
cell death to professional phagocytes (Henson and Hume, 2006). Therefore it has been 
proposed that different mechanisms may be responsible for signaling removal of apoptotic 
cells in different tissue types. Furthermore there is also evidence for “don’t eat me” signals 
transmitted by viable leucocytes in the form of homophilic ligation of CD31, which 
repulses macrophages. This homophilic ligation of CD31 is lacking in apoptotic leucocytes 
enabling tight binding and engulfment of the apoptotic cell by the macrophage (Brown et 
al., 2002).   
 
Interestingly, it has been suggested that apoptotic cells also have the capacity to liberate 
specific agents that promote the recruitment of cells capable of their removal (Lauber et al., 
2003). For example upon apoptosis the enzyme aminoacyl-tRNA synthase is processed into 
two products. One of these products which is released from the dying cell is endothelial 
monocytes-activating polypeptide II (EMAP II) which mediates the infiltration of 
leucocytes and monocytes to the inflammatory loci by acting as a ligand for the interleukin 
8 receptor (IL-8), in addition EMAP II also stimulates TNF- , myeloperoxidase and tissue 
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factor (Wakasugi and Schimmel, 1999). Other molecule expressed by apoptotic cells which 
possesses chemotactic properties for monocytes/macrophages is the lipid mediator 
sphingosine-1 phosphate (S1P) (Gude et al., 2008) and lysophosphatidylcholine (Mueller et 
al., 2007). The chemokine CX3CL1 which is released from apoptotic lymphocytes also acts 
as an attractant for mononuclear phagocytes (Truman et al., 2008). 
 
Just as it is important for the apoptotic cells to express factors which stimulate migration of 
phagocytes towards them it is also essential if effective resolution of inflammation is to be 
achieved that granulocyte migration to the site of inflammation is inhibited. This is 
necessary to prevent an inundation of apoptotic granulocytes, which would over burden the 
phagocytes resulting in the excess apoptotic granulocytes entering secondary necrosis. 
Therefore apoptotic cells secrete lactoferrin, which has been demonstrated to significantly 
inhibit granulocyte migration both in vitro and in vivo (Bournazou et al., 2009) thus 
allowing the release of molecules to attract phagocytes without attracting further 
granulocytes (e.g. the release of nucleotides) (Elliott et al., 2009).  
 
1.13 Resolution of inflammation 
 
During the resolution of the inflammatory response there is a delicate inter-related balance 
between the leucocytes, disruption of which can have catastrophic effects, ultimately 
resulting in the non-resolving inflammation seen in inflammatory disorders such as chronic 
obstructive pulmonary disease (COPD) and Cystic Fibrosis (CF).   
 
COPD is a term that is used to define a number of conditions such as emphysema and 
chronic bronchitis in which airflow to the lungs is limited by an abnormal inflammatory 
response, triggered by noxious particles such as cigarette smoke, leading to increased 
inflammation and susceptibility to infections. The disease is usually progressive and once 
an airway obstruction has become established a return to full previous function is not 
possible (Plataki et al., 2006). Symptoms of COPD include dyspnea, rhonchi, chronic 
coughing and sputum production, and in advanced cases COPD can lead to respiratory 
failure. Neutrophils are key effector cells in the pathogenesis of COPD, accumulating in the 
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airways of sufferers. Furthermore, large numbers of activated neutrophils are found in 
bronchoalveola lavage fluids from patients with COPD (both during exacerbations and 
stable phases of the disease) (Pauwels et al., 2001). The driving force behind this 
neutrophilic inflammation is thought to be activation of respiratory macrophages by 
noxious particles, increasing their production of neutrophil chemoattractants such as IL-8. 
Upon activation neutrophils release proteases (e.g. elastase) exacerbating bronchitis 
through the stimulation of mucus production, and emphysema through remodelling of the 
lung parenchyma (Barnes, 2010).  
 
It remains to be elucidated if the COPD neutrophil exhibits a propensity to evade apoptosis. 
Pletz et al concluded in 2004 that circulating neutrophil apoptosis is inhibited during 
exacerbations of COPD compared to neutrophils from healthy volunteers, however, upon 
remission normal rates of apoptosis appeared to be returned (Pletz et al., 2004). This was 
supported by Milara et al who observed a non sigificant decrease in apoptosis of circulatory 
neutrophils from patients with early onset COPD (Milara et al., 2012). Whereas, when 
differences between circulating neutrophils from healthy volunteers, smokers and COPD 
patients were investigated by Noguera et al in 2004 they reported similar rates of neutrophil 
apoptosis between all groups. Interestingly, they observed that apoptotic neutrophils from 
COPD patients appeared to be activated to a greater extent than those from the other 
conditions, exhibiting decreased levels of CD62L and increased levels of CD11b 
implicating that the COPD neutrophil posesses the potential ability to exacerbate the 
inflammatory response even when undergoing apoptosis, furthermore, increased expression 
of CD11b may impact on macrophage recognition of the apoptotic cell (Noguera et al., 
2004). Limitations of these studies are that circulating neutrophils were examined and these 
would not be subjected to the inflammatory processes under way in the COPD lung (Plataki 
et al., 2006). Rytila et al in 2006 could not find evidence of decreased neutrophil apoptosis 
in sputum samples from patients with COPD compared to healthy smokers or healthy non-
smokers despited the samples from COPD patients and smokers having significantly higher 
numbers of neutrophils (Rytila et al., 2006); although as pointed out by Persson and Uller 
getting an insight into the relationship between apoptosis and phagocytosis in lumen cell 
samples would be complicated due to the non migratory nature of apoptotic cells and 
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further investigation into neutrophil apoptosis in diseased mucosal tissues would be 
benificial (Persson and Uller, 2012).   
 
Whilst the mechanism and impact of evasion of neutrophil apoptosis in COPD remains 
controversial, defects in the apoptosic process of neutrophils have been demonstrated to 
play a pivotal role in Cystic Fibrosis. Cystic Fibrosis is one of the most prevelant 
genetically inherited diseases, with approximately 1 in 20 Caucasians being hetrozygotic 
for one of the Cystic Fibrosis trans-membrane conductance regulator gene mutations. It is a 
devastating disease which results in persistant neutrophillic inflammation, repeated 
respiratory infections and ultimately respiratory failure (Hayes et al., 2011). CFTR 
mutations have been demonstated to have an anti-apoptotic effect on epithelial cell lines 
(Gottlieb and Dosanjh, 1996, Jungas et al., 2002) and perturbations in the apoptotic 
mechanisms of CF neutrophils have been observed providing a prossible explanation for 
the prevelance of neutrophils in CF associtated respiratory infections. Circulatory 
neutrophils from CF patients were found to have reduced expression of the TNF-  death 
receptor TNF-1 possibly indicating decreased efficiency of the extrinsic apoptotic pathway 
in CF neutrophils (Downey et al., 2007, Hayes et al., 2011). An increase in the actin 
binding protein coronin-1 was also found in neutrophils from CF patients and was 
associated with an inhibition of apoptosis (Moriceau et al., 2009, Hayes et al., 2011). 
Futhermore, inhibition of CF neutrophil apoptosis appears to be a phenomenon common to 
all CFTR mutations and not always dependent on whether or not an infection is present. 
Interestingly delayed neutrophil apoptosis was also observed in CFTR heterozygotes, with 
normal rates of neutrophil apoptosis being restored upon administration of R-roscovitine or 
the thiol-oxidising agent diamide, implying that neutrophil survival in CF patients is related 
to the CFTR mutation and is not simply a consequence of chronic infection (Moriceau et 
al., 2010).  
 
If tissue homeostasis is to be restored to the inflammatory loci it is essential that neutrophil 
recruitment is halted and that apoptotic neutrophils are removed in a safe and controlled 
manner through engulfment by professional phagocytes. Apoptotic neutrophils act to halt 
the influx of neutrophils by releasing lactoferrin and the presence of protectins and 
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resolvins upregulates the expression of CC-chemokine receptor 5 (CCR5) on apoptotic 
neutrophils. This decreases levels of CCR5-binding chemokines such as CCL3 and CCL5 
which have a chemotactic influence on viable neutrophils. Monocyte influx to the 
inflammatory milieu is also increased by apoptotic neutrophils through release of 
lysophosphatidylcholine (LPC), nucleotides which increase monocytes recruitment through 
P2Y2 and, CX3C-chemokine ligand 1 (CX3CL1) attracting monocytes by their CX3C-
chemokine ligand receptor 1 (CX3CR1). Macrophages also contribute to the inhibition of 
neutrophil recruitment through release of lipoxin and resolvin lipid mediators, which in 
addition also increase the influx of monocytes. Furthermore once the macrophages have 
removed the apoptotic neutrophils via phagocytosis transcription of pro resolution genes is 
activated initiating the liberation of interleukin 10 (IL-10) and transforming growth factor-  
(TGF ) (Soehnlein and Lindbom, 2010) see Figure 1.9.   
 
Fascinatingly it appears that the relationship between apoptotic neutrophils and their 
engulfment by professional phagocytes could provide a mechanism for homeostatic 
regulation of granulopoiesis. Once apoptotic neutrophils have been engulfed by 
macrophages and dendritic cells the professional phagocytes decrease secretion of IL-23. 
IL-23 controls the production of IL-17 by neutrophil regulatory T cells therefore a decrease 
in IL-23 leads to a subsequent decrease in IL-17 production. IL-17 in turn regulates G-CSF 
production and therefore granulopoiesis. A decrease in IL-17 results in a decrease in G-CSF 
and subsequently a reduction in granulopoiesis and neutrophil production (Stark et al., 
2005). 
 
1.13.1 Resolution of inflammation: the role of the neutrophil 
 
It was once thought that the reduction in neutrophils at the inflammatory loci during 
resolution of inflammation occurred via a passive process where the pro-inflammatory 
mediators in the inflamed tissue simply became diluted removing the chemotactic gradient 
that draws the neutrophils. However there is now a wealth of evidence that this process is 
far from passive. Upon completing its defensive mission the neutrophil can switch from its 
pro-inflammatory phenotype, defined by the release of chemoattractants such LTB4 
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(synthesised from arachidonic acid)  to an anti-inflammatory pro-resolution phenotype in 
which fatty acids are instead synthesised into resolution promoting lipoxins (derived from 
arachidonic acid), resolvins (from omega-3 fatty acids) and protectins (from the omega-3 
fatty acid docosahexaenoic acid). The release of which halts the influx of viable neutrophils 
and attracts macrophages to remove apoptotic neutrophils in a safe, pro-resolving manner 
(Serhan et al., 2008).   
 
Figure 1.8 Interaction between leucocytes during resolution of inflammation 
The above diagram represents some of the ways in which leucocytes inter-relate during the 
resolution of inflammation. For example, apoptotic neutrophils inhibit neutrophil 
infiltration by expressing CCR5; they also release lactoferrin, LPC, nucleotides and 
CX3CL1 all of which recruit monocytes. Activated neutrophils also draw monocytes to 
areas of inflammation through an increase in HBP. Once at the inflammatory foci 
monocytes mature to macrophages and remove apoptotic neutrophils. Phagocytosis of 
apoptotic neutrophils triggers macrophages to release lipoxins and resolvins which further 






















































1.14 Non resolving inflammation 
 
As is often the case with events which are as complex and intricately linked as 
inflammation, dysregulation of the delicate process of resolution can have a dramatic 
impact on the host organism. Failure of timely and complete resolution of inflammation is 
known to contribute to the progression and pathogenesis of an extensive list of chronic 
disorders such as asthma, neurodegenerative disease, inflammatory bowel disease, multiple 
sclerosis, chronic obstructive pulmonary disease, rheumatoid arthritis, cancer, 
atherosclerosis and obesity. In such incidents it is the inflammatory response of the host 
organism which is the main cause of tissue damage and not infection from the pathogen 
(Nathan and Ding, 2010).  
 
A pertinent contributor to the aforementioned paradigm of non resolving inflammation is 
the neutrophil. During the efficient resolution of inflammation the neutrophil, once it has 
overcome the infectious agent, must be timely removed from the site of inflammation. The 
neutrophil enters apoptosis, exposing specific phospholipid and glycolipid signals on its 
cell membrane, which prompt professional phagocytes, namely the macrophages to engulf 
the apoptotic neutrophil (Haslett et al., 1990). This in turn converts the macrophages to a 
pro-resolution phenotype. As previously mentioned failure of the neutrophil to enter 
apoptosis in a timely manner or failure of phagocytic removal of the apoptotic cells can 
lead to the exacerbation of many inflammatory diseases. This has been eloquently 
demonstrated by Uysal et al. 2009, they showed that upon apoptosis or necrosis neutrophils 
release the enzyme cytosolic peptidyl arginine deiminase which when in the presence of 
high calcium (present in the neutrophil cytoplasm during both types of cell death) becomes 
activated and can citrullinate joint proteins such as fibrinogen and collagen. These 
citrullinated proteins have been found to react with antibodies found in the synovial fluid of 
rheumatoid arthritis patients, which are rarely present in healthy individuals (Uysal et al., 
2009). Therefore an abundance of apoptotic and necrotic neutrophils can exacerbate this 
reaction which in turn recruits more neutrophils forming a vicious circle of destruction 
(Nathan and Ding, 2010).   
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1.15 Targets for pharmacological intervention 
 
If this process of resolution is defective, it is believed that tissue damage can ensue due to 
the accumulation of apoptotic cells and subsequent liberation of histotoxic contents. 
Manipulation of the resolution phase of the inflammatory process is a promising area to 
provide novel anti-inflammatory therapies, selectively accelerating apoptosis in specific 
inflammatory cells and enhancing their subsequent clearance by exploiting their differences 
in intracellular regulation. Inhibition of the pro-survival signals found at the inflammatory 
site (for example GM-CSF and IL-5) and selective induction of specific receptors such as 
Fas to bring about apoptosis in chosen inflammatory cells would increase the rate of 
apoptosis at inflammatory sites thereby aiding the resolution process. Another optimistic 
area for pharmacological intervention is the regulation of the uptake of the apoptotic cells 
by phagocytes. It has been demonstrated that the ability of macrophages to internalize 
apoptotic cells can be adjusted, for example by using prostaglandins such as PGE2 to 
elevate macrophage levels of cAMP, thereby activating PKA and transforming adhesion 
patterns. Macrophages treated as such have a reduced capacity to uptake apoptotic 
neutrophils therefore implying a possible link between adhesion and macrophage 
phagocytic abilities (Rossi et al., 1998b). Furthermore the internalization of apoptotic 
neutrophils by macrophages can be upregulated via ligating the transmembrane adhesion 
receptor CD44 (Hart et al., 1997). This molecule has been found to be of particular 
importance in the resolution of lung inflammation (Teder et al., 2002). Other means which 
have also been found to alter macrophage ability to internalize apoptotic cells are; by 
activating macrophage signaling pathways (e.g., PKC) (Hu et al., 2002, Todt et al., 2004, 
Todt et al., 2002), ligating extracellular matrix receptors (Hart et al., 1997, Hart et al., 
1998), use of certain cytokines (e.g., IL-10, GM-CSF, TGF- ) (Ren and Savill, 1995, 
Ogden et al., 2005, Godson et al., 2000, Mitchell et al., 2002) or eicosanoids (e.g., 
lipoxins). Recent breakthroughs regarding the ability of glucocorticoids to increase the 
phagocytic potential of macrophages to remove apoptotic cells by innocuous non-
inflammatory means have proved invaluable in aiding the understanding of their action (Liu 
et al., 1999, Heasman et al., 2004, Giles et al., 2001, McColl et al., 2009, McColl et al., 
2007). This could be linked to studies revealing that glucocorticoids have the ability to 
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transform the cytoskeletal organization and the protein generating ability of monocytes 
driving them to become highly phagocytic macrophages (Giles et al., 2001). Interestingly, it 
has been proposed that the cytokine environment present at the site of inflammation may 
influence the effectiveness of glucocorticoids having implications on their therapeutic use. 
For example, IFN-  has the ability to counteract the increased phagocytic ability of 
macrophages obtained from glucocorticoid treated monocytes without altering their 
morphology (Heasman et al., 2004). This increase in the phagocytic ability of macrophages 
through exposure to glucocorticoids complements glucocorticoids capacity to up-regulate 
eosinophil and lymphocyte apoptosis, possibly explaining why the use of glucocorticoids 
proves to be a successful treatment for a range of inflammatory diseases. 
 
1.16 Therapeutic applications and drug discovery 
 
The safe engulfment and removal of apoptotic cells is an emerging target for the treatment 
of inflammatory diseases. Indeed, this mechanism has now been attributed to many of the 
drugs that are already in clinical use, such as the glucocorticoids and NSAIDs. 
Glucocorticoids have been shown to induce apoptosis of inflammatory cells (except 
neutrophils), and importantly, to promote phagocytosis of these effete cells ensuring their 
safe removal thus limiting tissue damage and injury. In addition, there are many 
endogenous ‘brake’ mechanisms that halt inflammation and actively drive the resolution of 
inflammation. These include the cyclopentenone prostaglandins, NF- B p50/50, 
lipoxins/resolvins, annexin 1 (formerly known as lipocortin 1) and caspases, as previously 
discussed in this review. These have been shown to induce apoptosis and/or phagocytosis 
in addition to their other known anti-inflammatory properties (Gilroy et al., 2004, Gilroy et 
al., 2003). Stable analogues and structurally related analogues of cyclopentanone 
prostaglandins and lipoxins show some promise in various in vivo models of inflammation 
and may prove useful in the treatment of non-resolving inflammatory disorders, such as 
arthritis, psoriasis and asthma (Gilroy et al., 2004). There are now a number of novel anti-
inflammatory strategies under development that target the regulation of apoptosis. In 
particular there are promising drugs that interfere with caspase activation to influence 
apoptosis already in phase I and phase II clinical trials for the treatment of rheumatoid 
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arthritis, sepsis, hepatitis and stroke (Murphy et al., 2003a, Murphy et al., 2003b, Reed, 
2002). 
 
The forced selective induction of apoptosis is thought to be beneficial for the treatment of 
inflammatory diseases due to a variety of reasons. Primarily, the removal of potentially 
cytotoxic cells in a safe manner that maintains membrane integrity prevents potential 
damage to surrounding tissues. Also, phagocytosis of apoptotic cells leads to the generation 
of anti-inflammatory cytokines, such as IL-10 and TGF- 1 and also may have other 
unknown endogenous pro-resolving mechanisms that aid resolution of inflammation. 
Indeed, previous research has shown that the exogenous administration of apoptotic cells 
induces resolution in an experimental model of inflammation (Huynh et al., 2002). 
Interestingly, autologous administration of apoptotic cells has also been clinically proven to 
prevent heart, kidney and lung transplant rejection (Morelli and Thomson, 2003) and limit 
the need for immunosuppressive drugs, which have many associated side effects and 
weakens the patient’s immune system to kill invading pathogens and bacteria. Recent 
research shows that the engulfment of the apoptotic cells induces tolerogenic changes of 
immature dendritic cells, which then stimulates inhibitory T regulatory cells to suppress 
immune rejection (Lamioni et al., 2005). This clearly shows that the administration of 
apoptotic cells and their safe engulfment in humans has a role in the adaptive and the innate 
immune system by improving tolerance and promoting the resolution of inflammation. 
 
Autoimmunity may occur due to the failure to clear apoptotic cells resulting in necrosis 
with the loss of cell membrane integrity, which causes the release of cytotoxic contents that 
initiates damage to surrounding tissues. This has been shown in approximately half of the 
patients with systemic lupus erythematosis where failed clearance leads to the prevalence of 
apoptotic cells, which has been correlated with disease severity (Mevorach, 2003). It would 
be beneficial to assess if the clearance defects of the phagocytic cells could be overcome in 
order to promote the safe removal of these unwanted cells and what outcome this strategy 
could have on limiting disease progression or give an improved prognosis for these 
patients. It is thus becoming clearer that the induction of apoptosis of inflammatory cells 
could be a beneficial target for the treatment of inflammatory diseases, not only to ensure 
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their safe removal preventing tissue damage but also to elicit an anti-inflammatory cascade 
of events that promote the resolution of inflammation. 
 
1.17 Cyclin-dependent kinases  
 
An exciting new area of research in the field of apoptosis is the role of the CDKs. This is 
because the processes of cell death, proliferation and cell survival are all intricately linked 
by common pathways / molecules which have evolved, to some extent, as a safety 
mechanism to help prevent potentially harmful mutations in key pathways from becoming 
established. This is because if the mutation effects more than one process it is more likely 
to be noted and either repaired or for the cell to enter apoptosis and be safely removed by 
the professional phagocytes. For this reason we believe that CDKs, originally thought to be 
exclusive to cell cycle regulation and proliferation are also pivotal to the apoptotic process. 
 
CDKs are a family of serine/threonine protein kinases, so named as they because of their 
interaction with the cyclins regulating the transition between phases of the cell cycle.  The 
cell cycle is divided into the G1, S, G2, M and G0 phases.  In G1 the cell commences the 
process of division and once the restriction point is passed at approximately 8-10 hours the 
cell is committed to the cycle, if the restriction point is not passed the cells enter the G0 
phase where they reside in a quiescent state. During this phase the cyclins and cyclin 
dependent kinases are no longer present and the cell cycle machinery is dismantled. 
However if the cell progresses through G1 the G1/S checkpoint must be passed in order to 
progress onto the S phase in which DNA is synthesized, if they fail they will be committed 
to apoptosis. From here the cell proceeds through the G2/M checkpoint where chromosome 
arrangement and DNA duplication is checked and again if faults are present the cell will 
enter apoptosis. The M phase is the stage in which mitosis occurs, depending on if the cell 
passes the spindle checkpoint which ensures the chromosomes are correctly attached to the 
spindles (Sridhar et al., 2006, Knockaert et al., 2002). The CDKs are positively regulated 
via association with the cyclin and by a CDK activating kinase phosphorylating the 
threonine on the T-loop. The level of CDKs stay relatively constant throughout the cell 
cycle whereas levels of cyclins are phase dependent fluctuating due to degradation and de 
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novo synthesis. To date there have been 25 cyclins and 13 CDKs identified (Meijer and 
Raymond, 2003, Leitch et al., 2009) (please see figure 1.9).  
 
 
Figure 1.9 Schematic representation of CDK/cyclin complexes involved in the 
eukaryotic cell cycle. 
The above diagram shows the eukaryotic cell cycle, which can be split into 5 phases: G0 
(quiescent phase), G1 (the cell commences the process of division), S (DNA synthesis), G2 
(Chromosome arrangement checked) and M (Mitosis). The CDKs and their associated 
cyclins regulate transition between the phases. 
 
As previously mentioned CDKs sole function is no longer considered to be regulation of 
the cell cycle: CDKs 1 and 2 have a minor role in transcription and there is also some 
debate over their implication in the process of apoptosis (Golsteyn, 2005), for example, 
inhibition of CDK2 has been associated with a decrease in Mcl-1 and decreased 
phosphorylation of RNA Pol II in large B cell lymphoma cells (Faber and Chiles, 2007); 
CDKs 4 and 6 have been linked to the inflammatory process, for example, Liu et al 
demonstrated that leukocyte recruitment and adhesion is inhibited in CDK4 knockout mice 
with bleomycin induced lung injury (Liu et al., 2008), furthermore, a specific inhibitor of 
CDK4/6 exhibits resolution of inflammation in models of rheumatoid arthritis (Sekine et 













a pivolal role in neurons (e.g. neuronal migration) and interestingly has been implicated in 
GTP-dependent granual secretion in neutrophils (Rosales et al., 2004); CDKs 7 and 9 are 
key players in the regulation of transcription, please see 1.17.2 for more information. Less 
is known about the remaining CDKs [CDK3 (involved in G0 exit), CDK8 (also implicated 
in transcription), CDK10 (required for passage from G2 to M) and CDK11 (potentially 
implicated in transcription)] and these provide interesting areas for further study (Leitch et 
al., 2009).  
 
In turn, levels of CDKs are regulated by endogenous CDKis. These, like the cyclins, 
fluctuate in concentration providing control over the more constant CDKs. They can be 
subdivided into two main families Cip/Kip (p21, p27, p57) and Ink4 (p15, p16, p18, p19), 
with the Ink4 family enabling arrest of the cell cycle at G1 through inhibition of the CDK4-
cyclin D and CDK6-cyclin D complexes thorough competitive inhibition of the CDK 
binding site, whilst the Cip/Kip family also lead to arrest of the cell cycle at G1 only 
through inhibition of the CDK2-cyclin E complex. In addition members of the Cip/Kip 
family are also implicated in the regulation of apoptosis as in certain cells p21 has the 
ability to sequester pro-caspase 3, and p21 can also be induced by the TGF-  and STAT 
pathways having a negative effect on apoptosis induced by TGF-  (Leitch et al., 2009). 
 
1.17.1 The role of CDKs in granulocytes 
 
Given that it is widely regarded that neutrophils are terminally differentiated cells which 
are at rest in G0 there appears to be a lack of requirement for CDKs in the traditional cell 
cycle regulatory role. Before the effects of CDKi on neutrophils had been investigated it 
was discovered that CDKi prevented apoptosis in terminally differentiated neurons 
(Monaco and Vallano, 2003). If this were to be extrapolated to neutrophils it would be 
anticipated that CDKi may exert a similar effect halting apoptosis. However, our laboratory 
observed that conversely to the effect observed in neurons, the CDKi R-roscovitine was 
found to significantly increase rates of neutrophil apoptosis (Rossi et al., 2006) and 
eosinophils apoptosis, which are also terminally differentiated cells (Duffin et al., 2009). 
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Whilst the presence of CDK1, CDK2 (Rossi et al., 2006) and CDK5 (Rosales J.L., et al. 
2004) has been confirmed in neutrophils, CDK1 and CDK2 do not appear to be direct 
targets for degradation during either constitutive or pharmacologically triggered neutrophil 
apoptosis. The reasoning behind this that there is no alteration in levels of protein 
expression of CDK1 or CDK2 between freshly isolated, aged, GM-CSF treated or R-
roscovitine treated neutrophils (Rossi et al., 2006). Furthermore this is supported by the 
levels of CDKs remain fairly constant throughout the cell cycle, with regulation occurring 
through the fluctuation in levels of the cyclins and the cells endogenous CDKi (Knockaert 
et al., 2002). Interestingly whilst the levels of CDK1 and CDK2 remain constant 
throughout neutrophil apoptosis, when neutrophils were exposed to the Fas activating (pro-
apoptotic) antibody CH11 a distinct decrease in the functionality of CDK1 occurs prior to 
apoptosis (Rossi et al., 2006) implicating the importance of the CDKs in neutrophil 
longevity.   As is evident in Figure 1.9 CDK5 is not thought to play a role in regulation of 
the eukaryotic cell cycle, although it has been found to phosphorylate pRb, and thus is not 
regulated by the cyclins. Instead CDK5 is implicated in the nervous system binding to the 
regulatory proteins p35 and its homologue p39 (Sridhar et al., 2006). However, its presence 
in neutrophils opens up the possibility that CDK5 may also be implicated in neutrophil 
apoptosis through as yet to be identified regulatory partners.  
 
1.17.2 The role of CDKs in transcription 
 
Another important cellular function in which CDKs1, 2, 7, 8 and 9 have been implicated is 
the modulation of transcription through phosphorylation of RNA Pol II (Leitch et al., 
2009). During the process of RNA Pol II dependent transcription the carboxyl-terminal 
domain (CTD) of the largest catalytic subunit of RNA Pol II can be reversibly 
phosphorylated. This enables the CTD to bind a range of factors essential for not only 
transcription but also mRNA modifications such as capping, splicing, cleavage and 
polyadenylation (Hirose and Manley, 2000).  
 
As is depicted in Figure 1.10 phosphorylation of the CTD is critical as it regulates mRNA 
production. Two of the key sites for phosphorylation are serine 5 and serine 2, which can be 
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phosphorylated by CDK7 and CDK9 respectively. Phosphorylation of serine 5 by the 
CDK7 subunit of TFIIH forms an active RNA Pol II complex allowing transcription 
initiation, activation of factors which cap the 5’ end of the nacent RNA (Ho and Shuman, 
1999) and enables binding of the inhibitors of elongation DSIF and NELF (Wada et al., 
1998). As a result of this the CDK9 containing positive elongation transcription factor (P-
TEFb) can phosphorylate serine 2 of the CTD (Peterlin and Price, 2006). CDK9 also 
phosphorylates for removal DSIF and NELF both of which are essential for recognition by 
the elongation factors and assembly of the elongation competent RNA Pol II  (Ivanov et al., 
2000, Kim and Sharp, 2001, Fujinaga et al., 2004).  
 
Perturbation of these essential phosophorylations would lead to inhibition of RNA 
synthesis and thus a decrease in cellular levels of the protein which it is translated into. This 
would have particular impact on proteins which are subject to rapid turn over, such as Mcl-
1, which has a notably short half life for both its mRNA and protein. Given that CDKs 1, 2, 
5, 7 and 9 fall within the inhibitory range of R-roscovitine it is highly probable that in cells 
exposed to this trisubstituded purine analogue transcription by RNA Pol II will be disrupted 
(Farahi et al., 2011). This has been eloquently portrayed by MacCallum D.E et al. in 2005 
who demonstrated that phosphorylation of serine 2 and serine 5 of the CTD domain on 
RNA Pol II in myeloma cells was prevented by exposure to R-roscovitine. Consequently 
mRNA and protein levels of Mcl-1 decreased inducing apoptosis (MacCallum et al., 2005).  
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Figure 1.10 Diagrammatic representation of the role of CDK7 and CDK9 in 
eukaryotic transcription  
CDK7 is required in eukaryotic transcription as it phosphorylates Ser 5 on the CTD of 
RNA Pol II. This forms an active RNA Pol II complex and a scaffold complex. It also allows 
binding of the inhibitors of elongation. CDK9 is responsible for removal of the inhibitors of 
elongation and also for phosphorylation of Ser 2 of the CTD allowing recognition by 




CDK7 phosphorylates Ser 5 of the CTD. This 
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1.18 Pharmacological CDK inhibitors 
The first specific inhibitors of CDKs were discovered in the 1990’s during the hunt for 
novel anti-cancer treatments due to the postulation that by halting mitosis replication of 
mutant cells could be prevented. Until then the only inhibitors identified which successfully 
attenuated CDK function were non specific kinase inhibitors such as Staurosporine from 
Streptomyces, a potent inhibitor of phospholipid/calcium-dependent protein kinases. 
However, upon the discovery of the ability of the purine analogue olomoucine to target 
kinase inhibition to the CDKs (although some action against MAPKs was still present) a 
family of 2,6,9 trisubstituded purine CDKi came to light, of which there are approximately 
50 members (Meijer and Raymond, 2003, Bach et al., 2005). 
 
Non Specific Specific to CDK 1,2,5 
and 7  
Specific to CDK 4,6 
Flavopiridol Olomoucine Fascaplysin 
 R-roscovitine PD0183812 
 Purvalanol B  
 
Figure 1.11 Table showing the specificity of some of the purine analogue CDK 
inhibitors 
 
1.19 Effects of R-roscovitine on neutrophils 
 
Figure 1.12 Structural representation of R-roscovitine 
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The best studied of the purine analogue CDKis is R-roscovitine, which in vitro has been 
demonstrated to decrease the proliferation index of 19 cancers (McClue et al., 2002). Other 
CDKis currently in clinical trials as potential novel cancer therapies are PD0332991, which 
is highly specific for CDK4 and CDK6; the pan-CDK inhibitor BAY1000394 and 
SCH727965 which inhibits CDKs 1, 2, 5 and 9. For more information please see Chapter 
3.1    
 
Whilst R-roscovitine is widely regarded as a selective inhibitor of CDKs 1, 2, 5, 7 and 9 
cyclin dependent kinases are not the sole targets of its inhibitory abilities (Farahi et al., 
2011). It has been demonstrated through tests on an extensive panel of kinases, 
identification of binding partners in various tissues by affinity chromatography and the 
effects of R-roscovitine on cells devoid of its target CDK 2 that R-roscovitine is not 
specific for CDKs alone. Although it is not active on a wide range of cellular kinases other 
targets for R-roscovitine include pyridoxal kinase, which activates vitamin B6, and protein 
kinases ERK1 (extracellular-signal related kinase 1), ERK2 and GSK3 (Knockaert et al., 
2002, Bach et al., 2005).  
 
The notion that R-roscovitine could be producing some of its varied potential therapeutic 
benefits in disorders ranging from glomerulonephritis to neurodegenerative diseases 
through inhibition of other ATP-binding kinases apart from the CDKs can not be fully 
disregarded. However there is compelling evidence to support the theory that R-roscovitine 
is exerting its beneficial effects, at least in some instances, through inhibition of the CDKs. 
Notably the observation that structurally distinctive inhibitors of CDKs exert comparable 
effects (Knockaert et al., 2000).  
 
As the ERK pathway can be activated by inflammatory stimuli such as GM-CSF, LPS, IL-
8, IL-15 and C5a to influence granulocyte longevity and responsiveness, it is essential to 
consider the possibility that CDKi could be exerting, at least partially, some of their pro-
apoptotic, pro-resolution properties through inhibition of ERK and not the CDKs. 
Especially given that use of the ERK1/2 inhibitor PD98059 has implicated that ERK, whilst 
it is redundant in the initiation of constitutive apoptosis, does appear to play an important 
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role in maintaining neutrophil longevity induced by mediators such as GM-CSF (Walker et 
al., 2003). Furthermore research by Sawatzky D.A. et al, 2006 (Sawatzky et al., 2006) 
demonstrated that pERK1/2 and Bcl-XL are down regulated during resolution of 
inflammation. Also the administration of PD98059 at the peak of the inflammatory 
response induces granulocyte apoptosis in carrageenan-induced pleurisy models of acute 
inflammation. Although the previous provides a strong argument for the involvement of the 
ERK pathway in the resolution of inflammation it is unlikely that R-roscovitine and other 
CDKis are implementing their apoptosis inducing ability in neutrophils by the ERK 
pathway. This is because of the differing effects of CDKi and ERK inhibitors on neutrophil 
apoptosis. Whilst R-roscovitine has been convincingly demonstrated to elicit apoptosis in 
neutrophils PD98059 has not. Another interesting observation supporting this that unlike in 
vascular smooth muscle cells where R-roscovitine inhibits ERK activation by angiotensin II 
(Rosales and Lee, 2006) in neutrophils the effect of R-roscovitine on LPS-induced ERK 
phosphorylation is notably decreased compared to PD98059 implicating that the R-
roscovitines ability to induce neutrophil apoptosis is probably not caused by diminished 
ERK phosphorylation. Furthermore R-roscovitine does not inhibit the ability of LPS and 
TNF-  to activate ERK, however it can over-ride survival signals which are known to 
activate the ERK pathway (Leitch et al., 2010). A more likely explanation for this 
phenomenon is that R-roscovitine elicits its effects downstream of direct inhibition of ERK 
(Sawatzky et al., 2006) in such a way that dominates events upstream. 
 
The most recent advances in increasing the specificity of R-roscovitine are through the 
development of novel bioisosteres, where atoms or groups of atoms are exchanged for other 
similar atoms. Four of these R-roscovitine bioisosteres, pyrazolo[1,5- ]-1,3,5-triazines, 
pyrazolo[1,5 ]pyrimidines, pyrazolo[1,5 ]pyridines and pyrazolo[4,3 d]pyrimidines have 
recently been reported by Jorda et al to have superior biological functions compared to R-
roscovitine (Jorda et al., 2012) and these provide an exciting avenue to pursue in the hunt 










The main hypothesis investigated in this thesis is that the cyclin-dependent kinase (CDK) 
inhibitor drugs (especially R-roscovitine) can efficaciously induce apoptosis in human 




The aim of this thesis was to further understand the mechanism through which the CDK 
inhibitor R-roscovitine induces apoptosis in neutrophils, a terminally differentiated cell 
which has no use for cyclins in the traditional sense of cell cycle regulation. The first 
results chapter of this thesis (Chapter 3) aims to establish the effects of R-roscovitine on 
neutrophil apoptosis and any similarities in action between R-roscovitine and the fungal 
metabolite gliotoxin. Gliotoxin was chosen as it induces neutrophil apoptosis in a similar 
time scale to that of R-roscovitine and its mechanism of action is better understood. This 
could potentially cast insight into the as yet unknown pathways through which R-
roscovitine induces neutrophil apoptosis.  Another aspect of the investigations in this 
chapter was to scope the potential suitability for the use of R-roscovitine as a novel 
treatment for neutrophil dominant inflammatory disorders such as Cystic Fibrosis. This was 
achieved through examining the effect of R-roscovitine on several pertinent markers of 
neutrophil activation, and probing the effects of R-roscovitine on macrophage clearance of 
apoptotic neutrophils. The second results chapter (Chapter 4) aims to investigate potential 
mechanisms of action for R-roscovitine. These include the following pathway and survival 
proteins which are known to play pivotal roles in the delicate regulation of neutrophil 
apoptosis: NF- B; the NF- B regulated survival protein XIAP; and the survival protein 





Chapter 2  
 




All reagents, unless otherwise stated, were obtained from Sigma-Aldrich (Dorset). Iscove’s 
Modified Dulbeccos Medium (IMDM) and Hanks balanced salt solution were purchased 
from PAA. Dextran T-500 was obtained from G.E. Healthcare, as was PercollTM.  Isotonic 
saline was purchased from Baxter U.K and Diff-QuikTM was purchased from Dade Behring, 
Germany. R-roscovitine (R)-2-[[9-(1-methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-
yl]amino]-1-butanol was obtained from A.G.Scientific,  PVDF was purchased from 
Immobilon-P, Millipore, Kodak Biomax light film was obtained from Kodak USA and 
Enhanced Chemiluminescence (ECL) was purchased from Amersham Biosciences. 
Annexin V-fluos (FITC) was purchased from Roche. Recombinant human TNF- , GM-
CSF and IL-8 were all purchased from R&D Systems whilst LTB4 was from Merck and 
Dexamethasone was from Organon.  LPS (E.Coli serotype 0127:B8), C5a and budesonide 
were from Sigma-Aldrich as were PAF, gliotoxin and dbcAMP. Mcl-1 primers were from 
MGW Oligo Synthesis. DIFF- QUIKTM was from Gamidor and the Limulus Amoebocyte 
Lysate Chromogenic Endpoint Assay was from Hycult. MG-132 (N-cbz-Leu-Leu-leucinal) 
was from Biomol, Affinity Research Products and zVAD-fmk (benzylocarbonyl-Val-Ala-




All antibodies were purchased from Santa Cruz unless otherwise stated. Monoclonal anti -
actin was purchased from Sigma-Aldrich, anti-human I B  was obtained from Abcam and 
anti-human X-IAP was purchased from R and D Systems. Anti-CD62L-PE and anti-
CD11b-APC were obtained from BD Bioscience. Anti-Caspase-3 was purchased from Cell 
Signaling Technologies and Goat anti-mouse and rabbit HRP-conjugated antibodies were 
purchased from Dako. 
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2.3 Isolation of mononuclear and polymorphonuclear leucocytes from whole blood. 
 
Aliquots of 40 ml of human peripheral blood were collected from healthy volunteers, 
according to Lothian Research Ethics Committee approval #08/S1103/38 or #1702/95/4/72, 
into 50 ml Falcon tubes containing 4 ml of 3.8 % sodium citrate (Phoenix Pharmaceuticals 
Ltd., Gloucester, UK). Each Falcon tube was then gently inverted 3 times to ensure that the 
blood was adequately mixed with the anti-coagulant. The blood was then centrifuged at 
room temperature at 350g, acceleration 5 and deceleration 0 for 20 min to separate out the 
platelet rich plasma. The top layer consisting of the platelet rich plasma was aspirated and 
converted into autologous serum by adding 10 ml to a glass tube containing 200 μl of 1 M 
calcium chloride. This tube was mixed by gently inverting and incubated in a 37 oC water 
bath for approximately 1.5 h, enabling the platelets to aggregate.  
 
To the bottom layer containing the erythrocytes and leucocytes, 2.5 ml of 6 % (w/v) 
Dextran T500 per 10 ml of haematocrit was added into each of the tubes. The volume was 
then made up to 50 ml with 0.9% saline which had been incubated to 37 oC, the Falcon 
tubes inverted 3 times and the lids loosened. Any excess blood that had collected within the 
lid following mixing was aspirated and any bubbles removed. The lid was rested back on 
the tube and incubated at room temperature for 25 min or until the erythrocytes had 
sedimented to the 25 ml mark. Whilst the erythrocyte rich layer was sedimenting, PercollTM 
gradients were prepared for the separation of the mononuclear cells and the granulocytes. 
100 % PercollTM was diluted to 90 % using 10 X Dulbecco’s Phoshpate Buffered Saline 
(PBS) without calcium or magnesium cations. PercollTM densities of 81 %, 68 % and 55 % 
were prepared by adding 8.1 ml 90 % PercollTM to 1.9 ml 1 X PBS (without Ca2+/Mg2+), 
6.8 ml 90 % PercollTM to 3.2 ml 1 X PBS (without Ca2+/Mg2+), and 5.5 ml 90 % PercollTM 
to 4.5 ml 1 X PBS (without Ca2+/Mg2+) respectively. At this point the leukocyte rich upper 
layer was gently aspirated off into fresh Falcon tubes and the volume made up to 50 ml 
with saline.  The tubes were then centrifuged (350g, acceleration 9, deceleration 9, 6 min, 
RT) to form a cell pellet. Whilst the tubes were being centrifuged, 3 ml of the 68 % 
PercollTM density was carefully layered on top of the 81 % PercollTM density in a 15 ml 
Falcon tube.  After centrifugation, the supernatant from the 50 ml Falcon tubes was 
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carefully discarded and the pellets resuspended in 3 ml of 55 % PercollTM, this was then 
carefully added as the final layer to the gradient. Gradients were then centrifuged at 720g, 
acceleration 0 and deceleration 0 for 20 min at room temperature. The mononuclear cells 
were harvested from the 68 % / 55 % interface and the granulocytes harvested from the 
68% /81 % interface. The purified cells were then washed twice with 50 ml of PBS 
(without Ca2+/Mg2+) and counted using a haemocytometer. A single drop of the washed 
granulocytes was placed on the haemocytometer slide and visualised under a light 
microscope, the number of neutrophils present in 25 squares were counted (cell activation 
by shape change could also be observed at the same time). The number obtained was equal 
to the number of neutrophils per 0.1 μl PBS, to calculate the number of neutrophils in 1 ml 








Figure 2.1 Diagrammatic representation of the isolation of human granulocytes from 
whole blood 
Peripheral blood is drawn from a healthy volunteer is separated by centrifugation allowing 
removal of the platelet rich plasma from the erythrocytes and leucocytes. Dextran 
sedimentation is then used to enable aspiration of the leucocyte rich upper layer. The 
leucocyte rich upper layer once exposed to centrifugal force produces a leucocyte rich 
pellet, which is separated out into mononuclear cells and granulocyte cells by Percoll 
density gradient separation.  
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Figure 2.2 Photograph demonstrating separation of freshly isolated human blood cells 
by Percoll
TM
 density gradient  
Two distinct bands and a pellet are produced; the smaller top band contains the 
mononuclear cells comprised of monocytes and lymphocytes, the larger lower band 
contains the granulocytes – neutrophils, eosinophils and basophils, and the pellet is 
comprised of the erythrocytes. 
 
2.4 Assessment of Neutrophil Purity and Viability 
 
The purity of the preparations was checked using flow cytometry as follows; the percentage 
of neutrophils was assessed by labeling the PMN fraction with anti-human CD16 RPE 
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Figure 2.3 Flow cytometric dot plots of freshly isolated human granulocytes and 
monocytes demonstrating the cell populations. 
Flow cytometry allows the purity of the preparations to be assessed. As can be seen in the 
flow plot on the left the granulocyte fraction is mainly comprised of neutrophils. The flow 
plot on the right (mononuclear cells) shows two distinct populations: lymphocytes and 
monocytes.  
 
Cytocentrifuged cells stained with DIFF QUIKTM were used to calculate the percentage of 
eosinophils so that only preparations in which the granulocyte layer comprised of < 5% 
eosinophils and > 95% neutrophils were used and from this point on will be referred to as 
neutrophils. The typical yield using this method of cell isolation was approximately 200 – 












Figure 2.4 Freshly Isolated Diff-Quik
TM
 stained granulocytes and mononuclear cells 
(x1000 magnification)  
Neutrophils are identified by the light pink stain of their cytoplasm, as they are less 
permeable to the stain Eosin than eosinophils, in which Eosin results in the appearance of 
a dark pink cytoplasm. Neutrophils also have a distinctive multi lobed nucleus as opposed 
to the eosinophils bi-lobed nucleus. Basophils are rarely seen as they comprise < 1 % of 
the circulating leucocytes. The monocytes are identified by their larger size and cytoplasm 
and by the irregular shape of their nucleus. In comparison lymphocytes are usually 
smaller, possess a smaller cytoplasm and have a more regularly shaped nucleus.  
 
2.5 Methods of assessing neutrophil apoptosis 
 
2.5.1 Cell Morphology 
 
The morphology of neutrophils was examined by cytocentrifugation (100 μl of 5x106 
cells/ml at 300 rpm for 3 min). The cells were then fixed for 1 min in 100 % methanol and 
stained using DIFF QUICKTM as follows: 1 min incubation in the Eosin stain followed by a 
1 min incubation in the Haematoxylin stain. Slides were then rinsed with water and left to 
dry prior to mounting using DPX. Cells were viewed under oil immersion light microscopy 
x 1000 magnification. Figure 2.4 shows the morphological changes that take place in the 
neutrophil during apoptosis; there is a reduction in granulocyte volume, the chromatin 
condenses and the DNA is cleaved internucleosomally resulting in loss of the multi lobed 
appearance of the nucleus. The cellular membrane remains intact during apoptosis 
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preventing the unregulated release of the neutrophils histotoxic contents into the extra 




Figure 2.5 Viable and apoptotic Diff-Quik
TM
 stained human neutrophils 20 h (x 1000 
magnification) 
The photograph above depicts neutrophils which have been aged for 20 h. Apoptotic 
neutrophils are identified by the loss of the multi lobed appearance of their nucleus. 
 
2.5.2 Annexin V / Propidium Iodide (PI) Staining 
 
This method is used to quantify apoptosis as recombinant human Annexin V (labelled with 
Fluorescein isothiocyanate (FITC)) binds to phospholipids and has a strong affinity for 
phosphatidylserine (PS).  On viable cells PS is located on the inner monolayer surface of 
the plasma membrane. However, when a cell undergoes apoptosis, PS becomes exposed on 
the outer leaflet of plasma membranes allowing the FITC labelled Annexin V to bind. The 
FITC label can be detected using flow cytometry and therefore apoptosis can be assessed. 
Propidium iodide (PI) is a fluorescent molecule which intercalates into DNA upon loss of 
membrane integrity and therefore is used as it is a marker for necrosis. Annexin V was 
diluted 1/500 in binding buffer (Hanks balanced salt solution +) and 280 μl added to 20 μl 
of cells (5x106 cells/ml). Samples were then incubated on ice at 4 oC for 10 – 15 min. Then 










2.6 Western Blotting for Mcl-1, X-IAP and I B  
 
Western Blotting was used to investigate the anti-apoptotic proteins Mcl-1 and X-IAP at 
the translational level. It was also used to assess the presence of I B , which inhibits the 
NF B heterodimer holding it in the cytoplasm and prevents the translocation of the 
transcription factor into the nucleus where it can initiate the synthesis of anti-apoptotic 
proteins such as X-IAP. Cells at a concentration of 5x106 /ml per condition were incubated 
at 37 oC on a shaking heat block, incubation time varied depending upon the focus of the 
investigation (please see figure legends for incubation times, reagents and concentrations). 
Cells were then lysed as follows. 
 
2.6.1 Neutrophil lysis 
 
Cells were pelleted using a bench top centrifuge at 6000g for 30 s. The pellet was 
resuspended in 180 μl of whole cell lysis buffer [500 μl Sigma protease cocktail P8340 – 
1/50 dilution in 1 x TBS, plus 30 μl 1 x TBS plus 20 μl AEBSF (100 mg to 834 μl H2O), 
20 μl Aprotinin (5 mg in 5 ml H2O), 20 μl Leupeptin (50 mg in 5 ml H2O), 40 μl Pepstatin 
A (5 mg in 5 ml methanol), 20 μl Sodium Vanadate (0.5 g in 2.72 ml H2O pH 10), 20 μl 
Benzamidine (0.1 g in 1.277 ml H2O), 20 μl Levamisole (1 g in 2.076 ml) and 60 μl -
Glycerophosphate (1g in 1389 μl H2O)]. Such an extensive array of protein inhibitors was 
required to overcome the numerous proteases contained within the neutrophils which form 
part of its arsenal against invading pathogens. If these proteases were not adequately 
inhibited cleavage of proteins could occur during the lysis process. Samples were then 
incubated on ice for 10 min. Following this, 20 μl of 10 % NP-40 was added and samples 
quickly vortexed before being incubated on ice for a further 10 min. The samples were then 
centrifuged at 8000g in a bench top centrifuge at 4 oC for 20 min. The supernatant was 
removed and transferred to a fresh Eppendorf, 100 μl of 4 x sample buffer (30 % glycerol; 
10 % β-mercaptoethanol; 8 % SDS; 0.25 M Tris HCl pH 6.8, 0.02 % bromophenol blue) 
was then added and the samples boiled on a 95 oC heat block for 5 min. Samples can be 
stored at -20 oC for a maximum of 2 days. 
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2.6.2 Sodium Dodecyl Sulphate Polyacrylamide gel Electrophoresis (SDS-PAGE) 
 
Samples were loaded into wells on a 4.5 % acrylamide stacking gel; the stacking gel allows 
the proteins to become concentrated at the dye front. A 12 % separating gel was also used 
as a higher percentage of acrylamide results in the proteins migrating at a slower rate 
through the gel, this enables lower molecular weight proteins to undergo adequate 
separation whilst still remaining on the gel. 
 
4.5% Stacking gel solution 
 
For one gel: 
Distilled water                                                                     4.3 ml 
Stacking Buffer (0.5 M Tris pH 6.8)                                  2.5 ml 
Acrylamide/Bisacrylamide Mix                                           1.5 ml 
20 % SDS                                                                              100 l 
10 % APS                                                                              60 l 
TEMED                                                                                30 l 
 
12% Separating gel solution 
 
For one gel: 
Distilled water                                                                      3.4 ml 
Separating Buffer (1.5 M Tris pH 8.8)                                  2.4 ml  
Acrylamide/Bisacrylamide Mix                                           4 ml 
20 % SDS                                                                              50 l 
10 % APS                                                                              40 l 






2.6.3 Western Blotting 
 
Gels were run at 70 V (stacking gel) and 150 V (separating gel). The gels were then 
transferred at either 60 V for 1 h at room temperature (or 150 V for 30 min in a cold room) 
onto polyvinylidene difluoride (PVDF) membrane. The membranes were blocked for 1 h 
on a shaking plate at room temperature in 5 % Marvel / TBS / 0.1 % Tween-20) which 
blocks non specific binding sites. Blots were washed 3 x 5 min in TBS / 0.1% Tween-20 
and the primary antibody (diluted in 5 % Marvel / TBS / 0.1 % Tween-20) added and 
incubated for 1 h on a shaking plate (Mcl-1 and X-IAP antibodies) (or overnight at 4 oC for 
the IkB  antibody). Subsequently blots were washed 3 x 5 min in TBS / 0.1% Tween-20 
and the secondary antibody (HRP labelled), which was diluted 1 / 2500 in 5 % Marvel / 
TBS / 0.1 % Tween-20 was added and incubated for 1 h at room temperature on a shaking 
plate. Blots are then washed 3 x 5 min in TBS / 0.1% Tween-20 and bands visualized using 
electrochemiluminescence (ECL) reagent which results in chemiluminescence at sites 
where the HRP labelled protein is bound to the membrane antigens due to peroxidise 
catalysed oxidation of luminol. 
  
2.7 Immunohistochemistry and Confocal analysis.  
 
2.7.1 Annexin V Binding and Propidium Iodide Staining 
 
Freshly isolated neutrophils at 2.5x106 /ml were aliquoted at 100 l into a flat bottomed 
flexiwell plate, centrifuged at 400g, 4 ºC for 4 min and the supernatants removed. Cell 
pellets were resuspended and fixed for 20 min in 3 % PFA. After washing the cells were 
resuspended in 5 l of goat serum (to block non specific binding sites) and blocked for 1 h. 
Cells were then centrifuged (as before), the supernatant removed, cells resuspended and 
incubated with 50 l of the p65 primary antibody diluted 1:50 and 50 l of PI (2 l in 1 ml) 
for 1 h. Once washed the cells were incubated with 50 l of alexa fluora green frag 1:500 
for 1 h, washed and resuspended to 150 l. 100 l were removed, cytocentrifuged onto 
slides and visualized on confocal. 
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2.7.2 Phagocytosis assay for apoptotic neutrophils. 
 
2.7.2.1 Cell isolation and culture 
 
Freshly isolated monocytes at 4x106 /ml in IMDM were plated at 500 l/well and incubated 
for 1 h at 37 oC in a 5 % CO2 environment. The cells were then washed and the medium 
replaced with IMDM + 10% autologous serum (for reagent concentrations see figure 
legends) and cultured into macrophages over 5-7 days via a process of selective adherence 
(where the macrophages adhere to the plate allowing the other cells to be washed off).  
 
2.7.2.2 Aging neutrophils 
 
Freshly isolated neutrophils were resuspended at 20x106 /ml in IMDM and were labeled for 
15 min at 37 oC, 5 % CO2 using 1 l CM green / 10x10
6 cells/ml. Following this the cells 
were centrifuged at 200g for 5 min at room temperature and the supernatant removed. They 
were resuspended at 4x106 /ml in IMDM plus 10% autologous serum and then incubated at 




The greened neutrophils were centrifuged at 200g for 5 min at room temperature and then 
resuspended in IMDM at 4x106 /ml. 500 l of neutrophils per well were added to the 
washed macrophages and incubated for 1 h at 37 oC, 5 % CO2. Following this the medium 
was removed and the macrophages detached by incubating with 0.25 % trypsin / 1 mM 
EDTA at 37 oC for 15 min prior to a 15 min incubation at 4 oC. The cells were then 





2.7.3 Assessment of CD62L, CD11b and Shape Change 
 
Neutrophils were resuspended at 5x10 6/ml in PBS + cations and treated with reagents as 
detailed in the appropriate figure legend. Treatments took place on a 37 oC shaking heat 
block. 50 l of cells were then added to a facs tube containing 150 l ice cold PBS without 
cations and treated with 2 l of either the control APC/PE antibodies or with antibodies for 
CD62L, CD11b for 30 min prior to running the samples on the flow cytometer.  
 
2.8 X-IAP HIV –tat 
 
The X-IAP HIV-tat protein was a kind gift from Dr Brigitte Onteniente.  
 
The primers 5-VGGG CTC GAG ATG ACT TTT AAC AGT TTT GAA GG-3V(sense) 
and 5-VGGG GAA TTC TTA AAA CAT AAA AAT TTT TTT GCT TG-3V(antisense) 
were used to isolate the cDNA reading frame of rat X-IAP by PCR. The purified fragments 
were then cloned into a pPTD-HA vector at the XhoI/EcoRI sites.  
 
Final protein encoded: 
 
6-histidine residues tag, PTD (YGRKKRRQRRR), hemaglutinin (HA) tag 
(YPYDVPDVA), and X-IAP 
 
The E.coli strain BL21(DE3) pLysS was used to express the plasmids and 500 AM 
isopropyl 1-thioh-d-galactoside was used to induce protein production, these were then 
extracted in 8 M urea HEPES buffer and purified by a Ni-NTA superflow agarose column. 
A Sephadex G-25M column was used to remove salt by gel filtration, collecting the 






2.8.1 Effects of X-IAP-tat construct and R-roscovitine on neutrophil apoptosis at 18h.  
 
Freshly isolated Neutrophils (10 x 106 /ml) were treated in IMDM + 10 % autologous 
serum in either with IMDM + 10 % autologous serum (control), 1 M X-IAP-tat, 20 M R-
roscovitine or a combination of 1 M X-IAP-tat + 20 M R-roscovitine (XR) and incubated 
at 37 ˚C for 18 h before staining with annexin-V and PI, levels of which were assessed by 
flow cytometry (see Annexin V Staining and Propidium Iodide Binding). 
 
2.8.2 Effects of X-IAP-tat construct and R-roscovitine on neutrophil apoptosis at 4h.  
 
Neutrophils (10 x 106 /ml) were treated in IMDM + 10 % autologous serum as follows. 
Control/Control in the absence of any agents for 4 h. Control/R-roscovitine in the absence 
of any agents for 1 h and then 20 M R-roscovitine added for 3 h. LPS/Control treated with 
100 ng/ml LPS for 4 h with media added after 1 h for the remaining 3 h. LPS/R-roscovitine 
treated with 100 ng/ml LPS for 4 h with 20 M R-roscovitine added after 1 h for the 
remaining 3 h. X-IAP/Control treated with 1 M X-IAP-tat for 4 h with media added after 
1 h for the remaining 3 h. X-IAP/R-roscovitine treated with 1 M X-IAP-TAT for 4 h with 
20 M R-roscovitine added after 1 h for the remaining 3 h. Samples were then stained with 
annexin-V and PI levels of which were assessed by flow cytometry 
 
2.8.3 X-IAP-tat construct effect on neutrophil shedding of CD62L and Shape Change 
 
Neutrophils were resuspended at 5x106 /ml in PBS + cations. Half of the samples were 
treated with media that contained 10 % autologous serum and half were treated without 
serum. Within each of these two conditions one sample was treated without any additional 
reagents (control) one was treated with 100 ng/ml LPS and one with 1 M X-IAP-tat for 30 
min prior to incubation with anti-human anti-CD62L for 30 min. Samples were then 





2.9 Limulus Amoebocyte Lysate Chromogenic Endpoint Assay (LAL Assay) 
 
As the X-IAP-tat construct was produced in a bacterial vector it is important to check that 
the protein produced has not been contaminated with the bacterial endotoxin LPS, as LPS 
has a lifespan prolonging effect on neutrophils.  
 
The kit used was purchased from Hycult, the reconstituted standard was diluted with 
endotoxin free water to give a concentration of 30 EU/ml which was vortexed for 30 s. To 
produce the readings for the standard curve 16 wells of the plate were filled with 50 μl of 
endotoxin free water. 25 μl of the 30 EU/ml standard was added to well 1 and thoroughly 
pipetted to mix, 25 μl was then removed from well 1 and added to well 2  (diluting 1:3), 
this process was repeated up to well 7. 25 μl was discarded from well 7 and well 8 became 
a control value from which the standard dilution process was repeated for wells 9-16. 
 
Duplicate 50 μl X-IAP-tat samples (which had been diluted 1:10 with endotoxin free water) 
were pipetted into their assigned wells. To each well 50 μl of reconstituted LAL reagent 
was added (to sample controls 50 μl of endotoxin free water was added instead). The plate 
was covered and incubated at room temperature for 30 min until the standard conditions 
produced a clear colour formation. The tray was then gently tapped to eliminate air bubbles 
and mix the samples and placed in a spectrophotometer which measured the absorbance of 
the samples at 450 nm. The OD value of the control was subtracted from the OD value of 
the samples and the standard curve produced from the standard conditions. This was used 
to determine the endotoxin concentration in the X-IAP-tat sample. 
 
2.10 RT-PCR for Mcl-1 
 
Freshly isolated neutrophils (25x106 /sample) were pelleted and resuspended in 1 ml Trizol. 
They were then incubated at room temperature for 5 min, following which 0.2 ml of 
chloroform was added and the tubes shaken vigorously for 15 s, they were then incubated at 
room temperature for 2-3 min. After this the samples were centrifuged at 12000g for 15 
min at 4 oC, this results in separation into an RNA rich upper fraction, a protein interphase 
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and a lower fraction of protein and DNA. The upper fraction was removed into a clean tube 
and 0.5 ml of isopropanol added, they were then incubated on ice for 20 min and then 
centrifuged at 12000g for 10 min at 4 oC. At this point a pellet of RNA can be seen and the 
supernatant was removed. The pellet was then washed with 75 % ethanol after which it was 
votexed and centrifuged at 7500g at 4 oC for 5 min. The RNA pellet was then air dried for 
10 min and then the pellet dissolved in 20 μl of RNase free water and incubated at 55 oC for 
10 min after which the sample could be stored at -70 oC. 
 
2.10.1 DNase treatment of RNA samples 
 
0.1 volume of RNA was added to 10x DNase I buffer, to this 1μl of DNase I enzyme was 
added. This was mixed gently and incubated for 20-30 min at 37 oC. Then 5 μl of DNase 
inactivation buffer was added and the samples incubated at 37 oC for 2 min. Samples were 
centrifuged at 8000g for 1 min and the supernatant removed into a fresh tube and stored at -
80 oC. This was performed to remove any contaminating DNA from the samples. 
 
2.10.2 Making cDNA from RNA 
 
1 μl of oligo DT was added to 2 μg of RNA (13.3 μl of RNA) and to this 4 μl of first strand 
buffer, 2 μl of DTT (0.1 M), 0.5 μl of 20 mM dNTP and 0.5 μl of RNase inhibitor mix 
were added. This was incubated at 42 oC for 2 min, then 1 μl of superscript enzyme was 




19 μl of water was added to 0.5 μl of 10 x buffer, 0.5 μl of dNTP 10 mM, 0.75 μl of 50 
mM MgCl, 0.5μl of forward primer, 0.5 μl of reverse prime, 1 μl of cDNA and 0.25 μl of 





Heated lid 105 oC 
Heated lid before program on  
Pause before program off 
Initial denaturation 5 min at 94 oC 
Hot start disabled  
Number of cycles 35 
Seg max c/s 30 s, 94 oC 
Seg max c/s 30 s, 56 oC 
Seg max c/s 30 s, 72 oC 
Final hold 4 oC 
Products were stored at -4 oC 
 
2.10.4 PCR primers 
 
GAPDH:              Forward 5’-TGCCTCCTGCACCACCAAGTG-3’ 
(control)  Reverse 5’-AATGCCAGCCCCAGCGTCAAAG-3’ (450bp) 
 
Mcl-1:                        Forward 5’-GAGGAGGAGGAGGACGAC-3’ 
                      Reverse 5’-CCAGCTCCTACTCCAGCAAC-3’ (530bp)        
 
2.10.5 1% Agarose Gel and Running Buffer 
 
0.6 g of agarose was added to 60 ml 0.5 TBE which was then heated and once cooled 
slightly 2.5 ml of ethidium bromide added. This was then poured into a mould, a well comb 
added and left to set. The running buffer was made as follows: 
 
Stock 5x TBE 
1960 ml distilled water 
40 ml, 0.5 M EDTA, pH 8 
108 g Tris 
55 g Boric acid 
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Samples were ran on the 1 % (w/v) agarose gel and visualised by ethidium bromide 
staining under UV light. 
 
2.11 Statistical Analysis 
 
Experiments were analysed by analysis of variance (ANOVA) and Student-Newman-Keul 
multiple comparison post hoc test (InStat software). Data are expressed as the mean +/- 
s.e.m. and values of P < 0.05 were considered significant. P<0.05 = *, P<0.01 = **, 


























Regulation of neutrophil apoptosis by the CDK inhibitor R-roscovitine and its effects 




The inflammatory response is a highly regulated and intricately linked complex series of 
biochemical reactions and cellular events which have evolved to defend and repair the host 
organism against infection and injury and restore tissue homeostasis.  
 
As mentioned in the introduction, the neutrophil is an important cell in the innate immune 
response helping remove invading pathogens. Functionality of the neutrophil is strongly 
influenced by the surrounding environment. The presence of agents such as GM-CSF, G-
CSF, LPS, C5a, IL-1 , IL-2, IL-8, IL-15, INF- , TNF-  (incubation periods greater than 12 
h), glucocorticoids, cAMP, LTB4 and hypoxia all have a lifespan prolonging effect on 
neutrophils, allowing them greater time to remove foreign bodies. However, if IL-4, 
theophylline or PGD2 metabolites are encountered neutrophil death is triggered (Riley et 
al., 2006). Therefore a delicate balance between the signals received from the inflammatory 
environment and the neutrophil’s default pro-apoptotic state exists. Timely death of the 
neutrophil by apoptosis and subsequent removal by professional phagocytes is vital for the 
resolution of inflammation as disruption of this can exacerbate chronic inflammatory 
disorders through dysregulation of cellular function and subsequent tissue damage (Leitch 
et al., 2009).   
 
3.1.1 CDKs and the neutrophil 
 
Cyclin-Dependent Kinase Inhibitors (CDKis) such as R-roscovitine are serine/threonine 
kinases inhibitors and are currently in clinical trials for use as novel chemotherapeutic 
agents, inducing apoptosis in actively proliferating cancerous cells through the Bcl-2 family 
members and activation of the caspases (Hui et al., 2009). Oral R-roscovitine is currently in 
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phase II clinical trials to evaluate its anti-tumour activity on advanced solid tumours (in 
skin and peripheral blood mononuclear cells) when administered sequentially with oral 
sapacitabine (a drug which is under investigation for its ability to interfere with DNA 
synthesis). The study which commenced in February 2009 is currently recruiting 
participants and the trail is due for completion in September 2012.  
 
A further phase I clinical trial investigating the maximum tolerated dose of R-roscovitine in 
combination with liposomal doxorubicin is also being established for patients with 
metastatic triple negative breast cancer. The study is scheduled to run from September 2012 
until September 2015. 
 
R-roscovitine was investigated as a potential treatment for non-small cell lung cancer 
although this trial was unfortunately terminated at the phase II stage. However, the CKDi 
PD0332991 which inhibits CDK4/6 is currently in phase II clinical trails for previously 
treated, advanced non-small cell lung cancer patients with wildtype retinoblastoma protein 
and inactive (CDK)N2a and is due for completion in February 2014. The efficacy of 
PD0332991 is also being tested on recurrent ovarian cancers which demonstrate an Rb-
proficiency and low p16 expression (phase II trails due for completion in January 2014); 
advanced refractory colorectal cancer (phase I study in combination with 5-fluorouracil and 
oxaliplatin) and in combination with bortezomib for patients with relapsed mantle cell 
lymphoma. Other CDKis currently being investigated in clinical trails for their anti-cancer 
abilities are BAY1000394 (in phase I trials for advanced malignancies) and SCH727965 (in 
phase II trials for multiple myeloma). 
 
The name cyclin-dependent kinase is derived because of their interaction with the cyclins, a 
family of proteins which control passage between the phases of the cell division cycle. 
Fascinatingly, although neutrophils are terminally differentiated cells that remain in the G0 
phase, therefore would have no use for CDKs in the traditional sense, neutrophils have been 
found to contain several CDKs including CDK1, CDK2 and CDK5. Contrary to the effect 
of CDKis on fully proliferated neurons, where they have an anti-apoptotic effect (Monaco 
and Vallano, 2003), our laboratory has postulated that CDKs present in neutrophils may 
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have an important role in apoptosis and has discovered that CDKis including R-roscovitine 
have a powerful ability to induce neutrophil apoptosis (Rossi et al., 2006). Interestingly, it 
has recently been discovered in our laboratory (Leitch and Rossi, unpublished) that the 
repertoire of CDKs present in neutrophils is greater than first thought and now includes 
CDK7 and CDK9, an exciting premiss seen that these two CDKs are particularly important 
in eukaryotic translation (MacCallum et al., 2005). This finding is also supported by Farahi 
et al. who reported in 2011 that eosinophils contain CDKs 1, 2, 5, 7 and 9 (Farahi et al., 
2011).  
 
The mechanism(s) through which CDKis and the different CDKs influence neutrophil 
apoptosis have yet to be elucidated. Therefore, the purpose of the investigations in this 
chapter was to further study the apoptosis inducing effect of R-roscovitine on neutrophils. 
When contemplating this it is important to consider the inflammatory milieu and the 
survival mediators that the neutrophil may encounter. Therefore in this set of experiments 
R-roscovitine was used in conjunction with agents commonly found at sites of 
inflammation. Another focus of this chapter was to examine the effects of R-roscovitine on 
important markers of neutrophil activation; CD62L and CD11b expression and neutrophil 
shape change (assessed by flow cytometry). Perturbation of the above could potentially 
influence recruitment of neutrophils from the circulation to sites of inflammation. 
Furthermore, I also examined how R-roscovitine interacts with other cells important in the 
resolution of inflammation, namely the macrophages, and their ability to aid resolution at 
the inflammatory loci through removal of apoptotic neutrophils.  
 
The effect of R-roscovitine on neutrophil activation and macrophage phagocytosis of 
apoptotic cells are both extensive areas that, in their own rights, could be the subject of a 
thesis. However, it was chosen to investigate these areas, at least partially, as a gap in the 
market exists for a novel anti-inflammatory agent that possesses the ability to induce 
neutrophil apoptosis in conditions where this is compromised (such as Cystic Fibrosis) 






3.2.1 Effect of TNF-  and the NF- B inhibitor gliotoxin on neutrophil apoptosis at 2 h 
 
The first sets of experiments were performed to establish parameters and confirm the 
previously documented effects of a well known inducer of neutrophil apoptosis, gliotoxin. 
The fungal metabolite, gliotoxin, belongs to the epipolythiodioxoperazine family and is 
thought to influence neutrophil longevity through a well documented mechanism of NF- B 
inhibition to bring about neutrophil apoptosis (Ward et al., 1999a). In order to try and gain 
some insight into the as yet unidentified mechanism through which R-roscovitine induces 
neutrophil apoptosis, the effects of gliotoxin were examined. Gliotoxin was chosen as it has 
been suggested that R-roscovitine can induce apoptosis in cancer cell lines, such as the 
adenocarcinomic human alveolar basal epithelial cell line A549, through inhibition of I B-
kinase preventing effective phosphorylation of I B  and subsequently defective 
suppression of NF- B (Dey et al., 2007). 
 
In this set of experiments the effects of gliotoxin on neutrophil apoptosis at 2 h and on the 
inflammatory mediator, TNF- , known to activate the NF- B pathway in neutrophils was 
examined (Ward et al., 1999a).  The aim of this was to gain further insight into neutrophil 
apoptosis resulting from inhibition of NF- B. This could then be further investigated later 
in the thesis to see if any similarities were present between this and the effects of R-
roscovitine, which may suggest a potential role for NF- B inhibition in R-roscovitine 
induced neutrophil apoptosis. 
 
The effects of gliotoxin and the inflammatory cytokine TNF-  on neutrophil apoptosis were 
examined at 2 h. Investigations were conducted using flow cytometric analysis of Annexin 




























































Figure 3.2.1 Effects of gliotoxin and TNF-  on neutrophil apoptosis at 2 h.  
Neutrophils (5x10
6 
/ml) resuspended in IMDM + penicillin/streptomycin supplemented with 
10% autologous serum were incubated for 2 h with either media (control), gliotoxin (0.1 
μg/ml), TNF-  (10 ng/ml) or gliotoxin (0.1 μg/ml) + TNF  (10 ng/ml). Annexin V FITC 
was added and samples incubated at 4 
o
C for 10-15 min. PI was added to each sample just 
prior to reading on the flow cytometer. Data represents mean of 4 separate experiments, 
each performed in triplicate (** P < 0.01). 
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Neutrophils (5x106 /ml in 250 μl aliquots) were resuspended in IMDM + 
penicillin/streptomycin supplemented with 10% autologous serum and incubated for 2 h 
with either media (control), gliotoxin (0.1 μg/ml), TNF-  (10 ng/ml) or gliotoxin (0.1 
μg/ml) + TNF-  (10 ng/ml). Reagent concentrations were chosen from previous work 
performed in the laboratory. 
 
As previously mentioned TNF-  can have either a pro- or anti-apoptotic affect on 
neutrophils depending upon the duration of incubation; as can be seen in Figure 3.2.1 TNF-
 and gliotoxin alone at 2 h cause little apoptosis (at later time points e.g. 4-8 h significant 
apoptosis is caused. (Ward et al., 1999a). However, when TNF-  is incubated for 2 h in 
conjunction with gliotoxin the average percentage apoptosis increased from 1.7 % to 21.1 
% (P < 0.01) with no necrosis evident. This indicates the importance of the NF- B pathway 
in regulation of neutrophil apoptosis (see discussion). 
 
3.2.2 Effect of R-roscovitine on neutrophil apoptosis in vitro at 4 h. 
 
Key occurrences in the resolution of inflammation are the timely death of the neutrophil by 
apoptosis and its removal from the site of infection by professional phagocytes. Many 
inflammatory conditions can be exacerbated as a result of prolonged survival of activated 
neutrophils. This results from untimely release of their defensive arsenal of proteolytic 
enzymes and reactive oxygen species, causing damage to the surrounding tissues (Fox et 
al., 2010). It is for this reason that novel methods are being sought to stimulate neutrophil 
apoptosis in systems where desirable rates of apoptosis are compromised. In this set of 
experiments the ability of the CDK inhibitor R-roscovitine to induce neutrophil apoptosis at 
early time points was investigated, this is the first step towards identifying potential 
therapeutic agents for use in the aforementioned capacity. 
 
Figure 3.2.2.1 shows a freshly isolated neutrophil photographed under an oil immersion 












Figure 3.2.2.1 Photomicrograph (x1000 magnification) of freshly isolated neutrophils.  
Photomicrograph of cytocentrifuge preparations of neutrophils (250 μl 5x10
6 
/ml) freshly 
isolated from peripheral blood visualised by staining with Eosin and Haematoxylin and 
viewed under oil immersion microscopy. Two eosinophils (indicated by the arrows) are 
present in the centre of the picture. These are identified by darker staining of their 











Figure 3.2.2.2 Photomicrograph the effect of R-roscovitine on neutrophil morphology 
at 4 h. 
Photomicrograph (x1000 magnification) of neutrophils (250 μl 5x10
6 
/ml). Cells were 
cultured in either media (A) or 20 μM R-roscovitine (B) for 4 h at 37 
o
C. Cytocentrifuge 
preparations were made. Slides were stained using Eosin and Haematoxylin  and viewed 
under oil immersion microscopy. 
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R-roscovitine was used at a concentration of 20μM as previous studies have shown this 
concentration to inhibit CDKs specifically (De Azevedo et al., 1997, Meijer et al., 1997, 
Bach et al., 2005) and experiments in our laboratory supported use of this concentration on 
neutrophils (Rossi et al., 2006).  
 
After 4 h incubation at 37 
oC on a shaking heat block the appearance of the cells differs 
little from the freshly isolated neutrophils and the distinctive polymorphic multilobed 
nucleus and pale cytoplasm are clearly evident (Figure 3.2.2.1 (A)). However, after 4 h 
incubation with R-roscovitine (20 μM) at 37 oC on a shaking heat block (Figure 3.2.2.2 
(B)) apoptosis has been induced in a number of neutrophils identified by the condensed 
circular nucleus, blebbing and a darker cytoplasm. This demonstrates that R-roscovitine has 
the ability to over-ride the neutrophil’s anti-apoptotic mechanisms in as little as 4 h to 
induce apoptosis. 
 
3.2.3 Stimuli affecting neutrophil apoptosis at 20 h 
 
In order to compare and contrast the effects of R-roscovitine and gliotoxin on neutrophil 
apoptosis it is important to take into consideration the environment in which neutrophils in 
an inflammatory disorder reside and critically the survival factors which may be 
encountered. This is an essential consideration for a novel anti-inflammatory agent targeted 
to induce neutrophil apoptosis, as it is imperative the agent possess the ability to over-ride 
powerful survival signals present at sites of inflammation which are responsible for the 
neutrophils longevity. Lack of this ability would render any agent which induces neutrophil 
apoptosis useless at the site of inflammatory disorders.  
 
This set of experiments was designed to demonstrate the effects of key pro- and anti- 
survival factors on neutrophil apoptosis, creating a set of standards with which to compare 
further experiments investigating the combined administration of apoptosis inducing agents 
with neutrophil survival agents. This will provide insight into which agents prevail in 
tipping the delicate balance between death and survival to decide the neutrophil’s fate. A 
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time point of 20 h was chosen as by this time a significant proportion of neutrophils would 
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Figure 3.2.3 Stimuli effecting neutrophil apoptosis at 20 h.  
Neutrophils (5x10
6 
/ml) resuspended in IMDM + penicillin/streptomycin supplemented with 
10% autologous serum were incubated for 20 h, 37 
o
C, 5 % CO2 with either media 
(control), dexamethasone (1 μM), budesonide (1 μM), C5a (1 μM), dbcAMP (0.2mM), GM-
CSF (50 ng/ml), IL-8 (100nM), LPS (100ng/ml), leukotriene B4 (1 μM), platelet activating 
factor (1 μM), R-roscovitine (20 μM), gliotoxin (0.1 μg/ml) or TNF-  (10 ng/ml). Annexin 
V FITC was added to samples which were incubated at 4 
o
C for 10-15 min. PI was added to 
each sample just prior to reading on the flow cytometer. Data represents mean of 4 
separate experiments, each performed in triplicate. (* P < 0.05, ** P < 0.01, *** P < 
0.005). 
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Neutrophils (5x106 /ml in 250 μl aliquots) were resuspended in IMDM + 
penicillin/streptomycin supplemented with 10% autologous serum and incubated for 20 h, 
37 oC, 5 % CO2 with either media (control), dexamethasone, budesonide, the complement 
component C5a, N6,2'-O-dibutyryladenosine 3':5' cyclic monophosphate (dbcAMP), GM-
CSF, IL-8, LPS, Leukotriene B4 ( LTB4), Platelet-Activating Factor (PAF), R-roscovitine, 
gliotoxin or TNF- . Samples were then stained with Annexin V and PI and analysed by 
flow cytometry.  
 
Figure 3.2.3 demonstrates that both glucocorticoids (P < 0.01) along with dbcAMP (P < 
0.005), GM-CSF (P < 0.005), LPS (P < 0.005), LTB4, PAF, TNF-  and to a lesser extent at 
the concentrations used C5a (P < 0.05) and IL-8 all exert a cytoprotective effect on 
neutrophils, prolonging their lifespan compared to the control, untreated, neutrophils. 
However, R-roscovitine and gliotoxin both exert a pro-apoptotic affect on neutrophils 
significantly increasing the rate of neutrophil apoptosis at 20 h compared to the control.  
 
This thesis aims to investigate how a CDKi can induce apoptosis in the terminally 
differentiated neutrophil. 
 
3.2.4 Effect of R-roscovitine on markers of neutrophil activation 
 
In this section we investigated how R-roscovitine and gliotoxin affect the activational state 
of the neutrophil as this can impact on the longevity of the cell. The effects of R-roscovitine 
and gliotoxin were examined both independently and in conjunction with prevalent survival 
factors often encountered at sites of inflammation to ascertain if the pro-apoptotic agents 
being investigated had any detrimental effect on pertinent markers of neutrophil activation. 
CD62L shedding, CD11b upregulation and shape change (as assessed by a shift in forward 














Figure 3.2.4.1 Flow cytometric scatter plots showing unstimulated neutrophils and 




/ml) in PBS + cations were incubated either in PBS + cations alone 
(control) or with TNF-  (10 ng/ml) for 30 min at 37 
o
C. Samples were stained with control 
antibodies APC/PE on ice for 30 min and change in forward scatter measured on the BD 
Calibur flow cytometer. The figure depicts the characteristic shape change that occurs in 
neutrophils when they are primed by appropriate stimuli. This shape change can be 
detected as a shift in forward scatter. 
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Figure 3.2.4.2 Effect of R-roscovitine and gliotoxin on neutrophil activation assessed 
by shape change induced by GM-CSF, LPS, LTB4 and TNF-  
Neutrophils (5x10
6 
/ml) in PBS + cations were pre treated for 30 min on a 37 
o
C shaking 
heat block as follows: (A) in PBS + cations alone (control), (B) in 20 M R-roscovitine, (C) 
in 0.1 μg/ml gliotoxin. To (A), (B) and (C) either PBS + (control), GM-CSF (50 ng/ml), 
LPS (100 ng/ml), LTB4 (1 μM) and TNF-  (10 ng/ml) were added for 30 min at 37 
o
C. 
Samples were stained with control antibodies APC/PE on ice for 30 min and change in 
forward scatter measured on the BD Calibur flow cytometer. Data represents the mean of 4 
separate experiments, each performed in triplicate. * = significant compared to its own 
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Figure 3.2.4.3 Effect of R-roscovitine and gliotoxin on neutrophil activation assessed 
by CD62L expression induced by GM-CSF, LPS, LTB4 and TNF-  
Neutrophils (5x10
6 
/ml) in PBS + cations were pre treated for 30 min on a 37 
o
C shaking 
heat block as follows: (A) in PBS + cations alone (control), (B) in 20 M R-roscovitine, (C) 
in 0.1 μg/ml gliotoxin. To (A), (B) and (C) either PBS + (control), GM-CSF (50 ng/ml), 
LPS (100 ng/ml), LTB4 (1 μM) and TNF-  (10 ng/ml) were added for 30 min at 37 
o
C. 
Samples were stained with the control antibodies APC/PE, and anti-CD62L on ice for 30 
min. Change in expression of CD62L was measured on the BD Calibur flow cytometer. 
Data represents the mean of 4 separate experiments, each performed in triplicate. * = 
significant compared to its own control, = significant when compared to the equivalent 










































































































































Figure 3.2.4.4 Effect of R-roscovitine and gliotoxin on neutrophil activation assessed 
by expression of CD11b induced by GM-CSF, LPS, LTB4 and TNF-  
Neutrophils (5x10
6 
/ml) in PBS + cations were pre treated for 30 min on a 37 
o
C shaking 
heat block as follows: (A) in PBS + cations alone (control), (B) in 20 M R-roscovitine, (C) 
in 0.1 μg/ml gliotoxin. To (A), (B) and (C) either PBS + (control), GM-CSF (50 ng/ml), 
LPS (100 ng/ml), LTB4 (1 μM) and TNF-  (10 ng/ml) were added for 30 min at 37 
o
C. 
Samples were stained with the control antibodies APC/PE, and anti-CD11b on ice for 30 
min. Change in expression of CD11b was measured on the BD Calibur flow cytometer. 
Data represents the mean of 4 separate experiments, each performed in triplicate. * = 
significant compared to its own control, = significant when compared to the equivalent 





Neutrophils (5x106/ml, 250 μl aliquots) in PBS (with Ca2+/Mg2+) were pre-treated for 30 
min with either R-roscovitine (20 μM), the NF- B inhibitor gliotoxin (0.1 μg/ml), or PBS + 
cations (control), following which either PBS with Ca2+/Mg2+ (control), GM-CSF (50 
ng/ml), LPS (100ng/ml), LTB4 (1 μM) and TNF-  (10 ng/ml) were added for 30 min to 
each of the three conditions, and the effects on the activation state of neutrophils measured 
on a BD Calibur flow cytometer. The concentrations of the reagents were optimised in 
previous experiments (data not shown) and because they represent the likely concentrations 
of the inflammatory mediators encountered by the neutrophil in the inflammatory milieu. 
Neutrophil activation was investigated as it is an important process in the functional 
progression of the cell. Upon encountering inflammatory stimuli neutrophils become 
‘primed’, a term which encompasses an increase in neutrophil responsiveness, enabling 
chemotactic migration and upregulation of anti microbial capacity.  
 
When a neutrophil becomes activated it stimulates polarisation of the cell, the cytoskeleton 
becomes reorganised causing the cell to spread and increase in size. This can be detected by 
an increase in forward scatter. As can be seen in Figure 3.2.4.2 (B) R-roscovitine when 
used alone or in conjunction with the other inflammatory agents does not cause any 
significant perturbation from the expected shape change response demonstrated in the 
control (Figure 3.2.4.2 (A)). However, gliotoxin (Figure 3.2.4.2 (C)) causes several 
alterations in activation as assessed by shape change when compared to the control; it 
significantly inhibits the ability of LTB4 and TNF-  to elicit the neutrophil shape change 
and partially reduces the extent of the shape change induced by GM-CSF (from an average 
of 70 % to an average of 47 %) indicating that gliotoxin impairs the ability of LTB4, TNF-  
and to a certain extent GM-CSF to prime the neutrophils into an active state. Independently 
neither R-roscovitine nor gliotoxin appear to be eliciting shape change when compared to 
the control. 
 
Other markers of neutrophil activation investigated were CD62L and CD11b. The adhesion 
molecule CD62L (L-selectin), resides on the cell membrane of un-primed neutrophils 
playing a vital role in the first stages of neutrophil attachment to the endothelium, is shed 
upon neutrophil activation by proteolytic cleavage to make way for tight adhesion and 
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diapedesis, regulated by the 2 integrins such as CD11b. Upon activation CD11b is 
mobilised from the secondary granules within the neutrophil to the cell membrane also 
indicating activation of the cell.  
 
Figure 3.2.4.3 shows the effects of R-roscovtine (B) and gliotoxin (C) on the cell activation 
marker CD62L. R-roscovitine has no discernable affect on CD62L expression either when 
alone or in conjunction with one of the four inflammatory mediators used, a slight 
reduction in CD62L expression of 21 % can be observed in the R-roscovitine/Control 
compared to Control/Control. However, when gliotoxin is examined it appears to have the 
ability to induce CD62L shedding, indicating activation of the neutrophil, causing a 53 % 
reduction in CD62L shedding compared to control condition. In addition gliotoxin also 
increases CD62L shedding when incubated in conjunction with LPS (a decrease of 29.1 % 
compared to the control). However, it inhibits the ability of TNF-  to stimulate CD62L 
shedding in neutrophils, evident by CD62L expression being 590 % higher in the gliotoxin 
TNF-  condition compared to its control. Gliotoxin also inhibits shedding of CD62L 
induced by GM-CSF (by 20.6 % compared to the control) and LTB4 (by 24.9 % compared 
to the control). 
 
CD11b expression does not appear to be altered as greatly by gliotoxin (Figure 3.4.4 (C)) as 
CD62L. However, when incubated in conjunction with TNF-  a significant reduction in 
CD11b expression (70.2 %) compared to the control can be observed. This indicates a 
notable inhibition of the ability of TNF-  to stimulate movement of the specific granules to 
the neutrophil cell surface membrane. A slight increase in expression of CD11b was 
evident in the gliotoxin conditions which were treated in conjunction with GM-CSF, LTB4 
and LPS of 25.7 %, 15.1 % and 12 % respectively when compared to the relevant controls. 
Again R-roscovitine (Figure 3.2.4.4 (B)) appears to be well tolerated by neutrophils in 
relation to CD11b regulation with results mirroring closely those of the control with only a 
minor deviation being apparent, a reduction of 29.2 % in the up-regulation of CD11b 
caused by TNF-  when compared to its control. However, this is still notably less 
significant an impact on CD11b levels than that of gliotoxin. The pro-survival agents LPS 
and LTB4 in the control condition did not induce as great a level of CD11b upregulation as 
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anticipated, this could be due to the concentrations at which the reagents were used or the 
duration of the incubation period was not optimum for the assay conducted. 
 
These results are promising for possible pharmacological use of R-roscovitine as unlike 
other agents, such as gliotoxin, which induce apoptosis in neutrophils it appears that R-
roscovitine is well tolerated by neutrophils in relation to pertinent markers of activation 
both alone or when in the presence of neutrophil survival factors often encountered at the 
inflammatory milieu, allowing their vital roles to be carried out unperturbed. 
 
3.2.5 Effect of R-roscovitine on macrophage phagocytosis of apoptotic neutrophils in 
vitro 
 
An important consideration to take into account when researching novel anti-inflammatory 
treatments for neutrophil dominant disorders, such as Cystic Fibrosis, through induction of 
neutrophil apoptosis is to ensure that the agents do not have a detrimental effect on the 
professional phagocytes. For example, if R-roscovitine were to induce macrophage 
apoptosis, an abundance of apoptotic neutrophils would accumulate at the site of 
inflammation, potentially entering secondary necrosis if they failed to be removed in a 
timely manner. This would result in the release of the neutrophils cytotoxic contents into 
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Figure 3.2.5 Effect of R-roscovitine and gliotoxin on macrophage phagocytosis of 
apoptotic neutrophils in the presence and absence of dexamethasone 
Freshly isolated monocytes (4x10
6 
/ml, 500 μl) were cultured into macrophages over 5-7 
days via a process of selective adherence in IMDM + penicillin/streptomycin supplemented 
with 10% autologous serum either in the absence (control) or presence of R-roscovitine 20 
μM; Dexamethasone 1 μM; gliotoxin 0.1 μg/ml; R-roscovitine 20 μM + Dexamethasone 1 
μM; gliotoxin 0.1 μg/ml + Dexamethasone 1 μM. Neutrophils were aged by resuspending 
cells at 20x10
6 
/ml in IMDM + penicillin/streptomycin supplemented with 10 % autologous 
serum and incubating with CM Green at 37 
o
C, 5 % CO2 for 20 h. The greened neutrophils 
were resuspended at 4x10
6 
/ml in IMDM and incubated with the washed macrophages for 1 
h, 37 
o
C, 5 % CO2. Macrophages were then detached by incubation with 0.25 % trypsin / 1 
mM EDTA for 15 min, 37 
o
C, cells were then incubated at 4 
o
C for 15 min and analysed by 
flow cytometry. Data represents mean of 5-7 separate experiments, each performed in 





Freshly isolated monocytes (4x106 /ml, 500 μl) were plated and matured to macrophages 
over 5-7 days via a process of selective adherence in IMDM + penicillin/streptomycin 
supplemented with 10% autologous serum either in the absence (control) or presence of R-
roscovitine 20 μM; Dexamethasone 1 μM; gliotoxin 0.1 μg/ml; R-roscovitine 20 μM + 
Dexamethasone 1 μM; gliotoxin 0.1 μg/ml + Dexamethasone 1 μM. Neutrophils were aged 
by resuspending cells at 20x106 /ml in IMDM + penicillin/streptomycin supplemented with 
10 % autologous serum and incubated with CM Green to label the apoptotic cells, at 37 oC, 
5 % CO2 for 20 h. The effect of R-roscovitine on macrophages (exposed to R-roscovitine as 
monocytes and present during their maturation) was investigated to see if it impacts upon 
their ability to phagocytose apoptotic neutrophils. Dexamethasone was used as it is one of 
the most prevalent treatments for inflammatory disorders. It increases macrophage 
phagocytosis of apoptotic leucocytes (as shown in Figure 3.2.5), and also causes apoptosis 
in eosinophils making steroids highly effective treatments for allergic inflammatory 
diseases such as asthma. However, in neutrophil dominant disorders such as rheumatoid 
arthritis steroids, such as dexamethasone, whilst increasing macrophage phagocytosis of 
apoptotic cells aiding resolution actually prolongs neutrophil survival (as can be seen in 
Figure 3.2.3) allowing activated neutrophils to keep on secreting their cytotoxic arsenal and 
potentially exacerbating the inflammatory disorder. This makes the search for neutrophil 
apoptosis inducing agents for potential use in conjunction with glucocorticoids an 
important area of research. If this were successful a double pronged approach to the 
treatment of chronic neutrophil inflammation could be employed increasing neutrophil 
apoptosis and macrophage clearance of apoptotic cells. 
 
As can be seen in Figure 3.2.5 gliotoxin had no macrophages present, the likely cause of 
which is death and premature detachment of the macrophages during the maturation 
process resulting in removal during the washing proceedure. However, R-roscovitine when 
administered alone or in conjunction with dexamethasone did not affect the macrophages 
ability to phagocytose apoptotic neutrophils, even producing a slight increase of 9 % in the 
amount of cells phagocytosed when used in conjunction with dexamethasone, probably 
because of the increased presence of  apoptotic neutrophils as a result of R-roscovitine.  
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Taken in conjunction, the results demonstrated in Figures 3.2.4 and 3.2.5 are in keeping 

































The CDK inhibitor R-roscovitine is currently in phase II clinical trials for use as a novel 
chemotherapeutic agent for various cancers. CDK inhibitors are proving successful in the 
fight against cancer as cyclin dependent kinases are not only involved in regulation of the 
cell cycle but also play a crucial regulatory function in RNA polymerase II-mediated 
transcription (Krystof and Uldrijan, 2010). 
 
However, cancer research is not the only field in which CDKis are eliciting prospective 
clinical benefits. Our laboratory has demonstrated that R-roscovitine also has potential 
therapeutic use as a novel treatment for inflammatory disorders. It can effectively induce 
neutrophil apoptosis in vitro in as little as 4 h despite the fact that neutrophils are terminally 
differentiated cells in which CDKs were thought to be redundant. The exact role which 
CDKs play in neutrophils and the mechanism by which R-roscovitine can induce apoptosis 
has yet to be elucidated; however, in this chapter it has been demonstrated that R-
roscovitine can induce neutrophil apoptosis in as little as 4 h (as assessed by morphology 
and Annexin V/PI staining) and our laboratory has also demonstrated that R-roscovitine can 
induce neutrophil apoptosis in a time-and concentration-dependent manner (Rossi et al., 
2006).  The affects of R-roscovitine were compared to the effects of the apoptosis inducing 
fungal metabolite gliotoxin, which is known to induce apoptosis through inhibition of the 
NF- B pathway and also 20S proteasome activity (Paugam et al., 2002). Previous research 
in our laboratory has demonstrated that the NF- B pathway plays an important role in the 
inflammatory process and neutrophil apoptosis (Ward et al., 1999a) as it is hypothesised 
that the NF- B pathway is involved in the prolongation of the neutrophil lifespan induced 
by the inflammatory mediator TNF-  and the bacterial toxin LPS. This was supported by 
the observation that by blocking protein synthesis the pro-apoptotic ability of TNF-  (at 
time points 8 h or less) is enhanced. This led to the hypothesis that TNF-  is triggering the 
NF- B pathway and activating transcription of anti-apoptotic protein(s).  
 
Furthermore, it has been demonstrated that NF- B can stimulate transcription of pro-
survival proteins such as BCXl, CIAP1, CIAP2, X-IAP and A1 therefore it is possible that 
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one or several of these proteins may regulate TNF-  induced neutrophil survival (Ward et 
al., 2004, Gyrd-Hansen and Meier, 2010). As the mechanism for gliotoxin induced 
apoptosis in neutrophils has been identified, gliotoxin was compared to R-roscovitine to see 
if there were any similarities between their affects on neutrophil apoptosis which could 
potentially implicate the NF- B pathway in the mechanism of R-roscovitine induced 
apoptosis in neutrophils. 
 
R-roscovitine was dissolved in the solvent DMSO. The DMSO present in the diluted 
experimental concentration (20μM) is 0.1%. At this concentration DMSO has been 
repeatedly shown within our laboratory to not have any effect on the parameters of 
neutrophil apoptosis investigated in this thesis, therefore the decision was taken not to 
control for DMSO in these experiments. 
 
R-roscovitine was compared to an extensive list of survival factors and the neutrophil 
apoptosis inducing agent gliotoxin at 20 h, it was evident that the ability of R-roscovitine to 
induce neutrophil apoptosis at this time point was even greater than that of gliotoxin. 
Importantly our group has also demonstrated that R-roscovitine can overcome the anti-
apoptotic effects of a plethora of inflammatory mediators, a promising finding in the hunt 
for a novel anti inflammatory agent (Rossi et al., 2006, Leitch et al., 2010).   
 
When researching potential novel anti inflammatory agents it is essential that their general 
toxicity is examined, gliotoxin has been shown in vivo to possess a very narrow line 
between toxicity and therapeutic benefits (Fitzpatrick et al., 2000). Therefore, the general 
tolerability of R-roscovitine in comparison with gliotoxin was examined. An interesting 
observation that can be concluded from these studies is that R-roscovitine appears not 
affect the activation state of neutrophils, and importantly also does not affect the activation 
state of the neutrophil when co-administered with the key pro-survival agents GM-CSF, 
LPS, LTB4 and TNF- . This is an important finding as it infers that the recruitment and 
migration of neutrophils from the circulation to the site of inflammation will not be 
perturbed by R-roscovitine, as CD62L and CD11b play a pivotal role in the regulating 
neutrophil adhesion to the vascular endothelium. Also, it is imperative that neutrophils are 
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not untimely primed which renders them susceptible to activation. This has the potential to 
result in inappropriate release of the neutrophils cytotoxic arsenal and generation of 
superoxide anion, negatively impacting on the resolution of inflammation. If this process 
were augmented, as indicated by the result obtained from the gliotoxin treated conditions, it 
would imply disruption of the process of neutrophil recruitment to the sites of inflammation 
and infection. The lack of effect of R-roscovitine on pertinent markers of neutrophil 
activation is also supported by additional work conducted in our laboratory. It has been 
demonstrated that R-roscovitine does not affect the aggregation of neutrophils stimulated 
by either the chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine (fMLP) or the 
phorbol ester PMA. In addition unlike the protein kinase C inhibitor Ro-31,8220 (Davis et 
al., 1989) R-roscovitine does not appear to affect the production of superoxide anion by 
PMA (as assessed by intracellular oxidation of dihydrorhodamine by flow cytometry). This 
assay also supports the data presented in this thesis as it confirmed that neutrophil shape 
change (assessed by forward scatter) was unaltered by R-roscovitine (Leitch et al., 2010). 
 
Previous research by Rosales et al., 2004 demonstrated that guanosine triphosphate (GTP)-
dependent secretion in neutrophils is regulated by CDK5 (a small CDK which it has been 
suggested does not function in regulation of the cell cycle). Incubation with R-roscovitine 
prevented lactoferrin secretion (which resides in the specific (secondary) granules) and 
decreased levels of CD63 and CD66b localised to the surface membrane. From this it can 
be inferred that CDK5 in conjunction with its activator p35 (also present in neutrophils) is 
necessary for optimum GTP-regulated secretion from the azurophil (primary) and specific 
granules. As CD11b also resides in the specific granules it would therefore be expected that 
levels of CD11b would be reduced by incubation with R-roscovitine. However, as the 
results in Figure 3.2.4.3 show this was not the case and no significant reduction in CD11b 
was observed when compared to the controls. An explanation for this is that CDK5-p35 
regulated GTP-induced secretion of azurophil and specific granules in neutrophils is being 
compensated by other mechanisms. This is supported by only partial inhibition being 
achieved in the Rosales study (Rosales et al., 2004) implying that GTP-induced secretion is 
redundant. Taken together these findings suggest that R-roscovitine possesses potential for 
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use as a novel anti-inflammatory agent in the treatment of neutrophil dominant 
inflammatory diseases. 
 
Another interesting observation obtained from the results in this chapter is that the R-
roscovitine does not appear to perturb monocyte derived macrophages ability to recognise 
and phagocytose apoptotic neutrophils, and in addition does not interfere with the ability of 
dexamethasone to up-regulate macrophage phagocytosis of apoptotic neutrophils (Liu et al., 
1999) which is one of the main forms of treatment for inflammatory diseases. Furthermore 
dexamethasone has been previously been shown to prolong neutrophil life-span (also 
evident in Figure 3.3) (Meagher et al., 1996), which is not ideal in the treatment of 
neutrophil dominant inflammatory disorders such as Cystic Fibrosis. This is because 
inhibition of neutrophil apoptosis prolongs the presence of activated neutrophils at the site 
of inflammation increasing the likelihood of the release of their cytotoxic products and 
generation of superoxide anions. Prolonged neutrophil activation at sites of inflammation 
contributes to tissue damage and exacerbation of the inflammatory condition. Therefore, 
the ability of R-roscovitine to induce apoptosis in neutrophils but not affect the ability of 
the macrophage to phagocytose neutrophils that have undergone apoptosis, or the ability of 
glucocorticoids to up-regulate phagocytosis of the apoptotic cells is a promising finding. 
 
The results obtained in this chapter contribute towards the search for novel treatments 
specifically targeted to neutrophil dominant inflammatory disorders. They indicate the 
potential for a possible double pronged approach through use of a neutrophil apoptosis 
inducing agents such as R-roscovitine in conjunction with glucocorticoids to aid resolution 
at the inflammatory loci and facilitate clearance of the apoptotic cells. Interestingly support 
for the use of R-roscovitine to aid resolution of inflammation has been proposed by Du et 
al. in 2009 when they concluded that R-roscovitine may help attenuate inflammation by 
inhibiting macrophage ability to produce LPS-induced nitric oxide helping quell some of 
the tissue damage that can occur in exacerbated inflammatory responses when regulatory 
mechanisms have gone awry (Du et al., 2009). Consolidation of the above provides hope 
that R-roscovitine could have pleiotropic effects benefiting the resolution of inflammation.  
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However, gliotoxin had a detrimental effect on the ability of macrophages to phagocytose 
apoptotic neutrophils culminating in a lack of data being obtained for the gliotoxin or the 
gliotoxin/ dexamethasone condition. There are several possible reasons for this, one is that 
gliotoxin is causing death of the macrophages either by apoptosis or necrosis. Waring  
elucidated that at high concentrations gliotoxin induces apoptosis of peritoneal 
macrophages mediated by reactive oxygen species (Waring et al., 1988). Further support 
for the fatal effect of gliotoxin on macrophages was reported by Anselmi K., et al., 2007 
who noted that gliotoxin induces death of hepatic macrophage Kupffer cells by apoptosis, 
followed by secondary necrosis (Anselmi et al., 2007). Alternatively, gliotoxin could be 
preventing adhesion of the macrophages to the plastic wells resulting cells becoming 
detached and lost during the washes. This is supported by findings from Müllbacher A., et 
al., who demonstrated that aspergillus fumigatus produced metabolites, namely gliotoxin 
which prevented adhesion of thioglycollate-induced peritoneal macrophages to plastic and 
also suppressed their phagocytic ability (Mullbacher and Eichner, 1984). This could also 
account for our observation and is supported by Comera C. et al., who also found that when 
gliotoxin was incubated with neutrophils it prevented their ability to phagocytose zymosan, 
caused reorganisation of the actin cytoskeleton resulting in cell shrinkage and removed 
filopodia (Comera et al., 2007). Therefore, gliotoxin may stimulate similar changes to occur 
in macrophages preventing their ability to phagocytose. Anyone of the aforementioned or a 
combination of the above would explain the lack of data obtained in the conditions where 
macrophages were exposed to gliotoxin. 
 
Interestingly Comera C. et al., also observed that gliotoxin did not affect the ability of 
neutrophils to exocytose specific granules (one of the granules in which CD11b resides) 
(Comera et al., 2007). This supports the findings in Figure 3.2.4.3 in which the gliotoxin 
control condition caused little variance (a decrease of only 2.3 %) in the release of CD11b 
compared to the control condition. However, whilst on its own gliotoxin may not affect 
exocytosis of specific granules, when incubated in conjunction with survival factors, such 
as TNF- , their ability to activate neutrophils (assessed by regulation of CD11b, CD62L 
and shape change) is drastically augmented, observed by deviations from the expected 
parameters shown in the control conditions. The implication of this is that on some level 
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gliotoxin is reducing the ability of the survival factors to induce exocytosis of at least one 
of the neutrophils stores of CD11b, be it the specific granules, tertiary granules, the 
secretory vesicles or a combination of all three. This is a serious implication when 
considering gliotoxin as a possible anti-apoptotic agent for therapeutic use. 
 
To summarise, R-roscovitine is a powerful effector of neutrophil longevity inducing 
apoptosis in as little as 4 hours and dramatically increasing the expected rate of neutrophil 
apoptosis at 20 h compared to the untreated control. At 20 h R-roscovitine induces 
neutrophil apoptosis to a similar extent as the fungal metabolite gliotoxin. Unlike gliotoxin, 
R-roscovitine does not perturb the neutrophils activation response to key survival factors. 
Furthermore, in contrast to gliotoxin, R-roscovitine has no apparent detrimental effects on 
the ability of macrophages to phagocytose apoptotic neutrophils; and interestingly appears 
to enhance levels of phagocytosis. The likely cause of which is the increase in apoptotic 
neutrophils available for phagocytosis in the R-roscovitine treated conditions. 
 
Whilst further studies are necessary to fully elucidate the full effects of R-roscovitine on 
neutrophil activation and on macrophage phagocytosis of apoptotic neutrophils the results 
here indicate greater exploration into the potential therapeutic use of R-roscovitine in 
















The effect of R-roscovitine on NF- B and NF- B dependent and independent survival 




The lifespan of the neutrophil can be regulated by inflammatory mediators using a plethora 
of often interlinking, sometimes redundant signaling pathways. Some of the most prevalent 
in the neutrophil are: phosphoinositide 3-kinase (PI3K) which can be triggered by LPS, 
GM-CSF, TNF-  and IFN ; the mitogen-activated protein kinases (MAPK) activated by 
IL-8, IL-15, C5a, GM-CSF and LPS; Protein Kinase A stimulated by cAMP; and NF- B 
elicited by TNF- , LPS and IL-1 (Riley et al., 2006, Leitch et al., 2009). It is the fluctuation 
in levels of these inflammatory stimuli which likely determine the longevity of the 
neutrophil through stimulation of the above signal transduction pathways. For example, 
inflammatory cytokines such as GM-CSF and bacterial toxins, including LPS, if elevated at 
sites of inflammation prolong the lifespan of the neutrophil. Whereas upon resolution, once 
invading bacteria have been removed and levels of inflammatory stimuli have decreased the 
balance is shifted towards neutrophil apoptosis. More details on the aforementioned 





Figure 4.1.1 Schematic representations of some of the signaling pathways involved in 
neutrophil survival and apoptosis 
A depiction of some of the pro-inflammatory mediators and the pathways triggered within 
the neutrophil to promote survival. These pathways can share common points, for example 
GM-CSF activating PI3K and phosphorylating Akt can promote neutrophil survival 
through the inhibition of Bad, the activation of CREB to promote transcription of survival 
proteins such as Mcl-1, and the activation of NF B pathway leading to transcription of 
anti-apoptotic proteins such as A1.  
 
4.1.1 The NF- B pathway 
 
As mentioned above the NF- B pathway is one of the key pathways implicated in 
regulating the fate of the neutrophil and is a pathway of particular interest in this thesis. The 
NF- B dimer is a transcription factor comprised of either a homo or hetero-dimer of the 
following five subunits: p50/NF- B1 (processed from the precursor p105); p52/NF- B2 
(derived from the precursor p100); p65/RelA; RelB; and c-Rel. It is negatively regulated by 
members of the I B family (such as I B , I B , p100 and p105) responsible for holding 
NF- B in the cytoplasm by masking the nuclear localisation signal (Bakkar and Guttridge, 
TNF--  

































2010). Interestingly, however, the NF- B pathway can provide negative feedback through 
stimulating transcription of the inhibitor I B  (de Martin et al., 1993). In turn the I B 
family is regulated by the I B kinase complex (IKK), which is comprised of the kinases 
IKK , IKK  and the regulatory IKK . IKK is responsible for controlling degradation of the 
inhibitory I B protein, with IKK  activating the canonical pathway (which also requires the 
presence of IKK ) (Zandi et al., 1997) whereas, IKK  alone is necessary for the activation 
of the alternative pathway (Senftleben et al., 2001, Ghosh and Karin, 2002).  
 
4.1.1.1 Classical/Canonical NF- B Pathway 
 
The classical pathway is the NF- B pathway implicated in innate immunity and cell 
survival. It is also proposed to be the pathway activated in a variety of inflammatory 
diseases such as COPD and rheumatoid arthritis (Lawrence T. 2010). Furthermore the 
classical pathway has been associated with NF- B dimers containing p65 or c-Rel (Karin 
and Ben-Neriah, 2000).   
 
One of the most well documented stimuli for the classical NF- B pathway is the cytokine 
TNF- , which activates NF- B through stimulation of the TNF receptors [a more detailed 
account of the TNF-  pathway can be found in Chapter 1 (1.9.2.1 Extrinsic Pathway)]. 
Transcription of target NF- B genes are activated by phosphorylation of the I B  by the 
IKK  subunit of IKK. This marks I B  for proteasomal degradation releasing the NF- B 




Figure 4.1.2 Simplified pictorial representation of the classical NF- B pathway (Ward 
et al., 1999a) 
Activation of the classical NF- B pathway, for example by stimulation of the TNFR1 and 
TNFR2 by TNF- , and subsequent binding of TRADDs, can activate the transcription 
factor NF- B by interaction with secondary adaptor molecules such as TNFR-associated 
factor-2 and RIP. 
 
4.1.1.2 Alternative NF- B Pathway 
 
For years it was considered that only one activation pathway existed for of NF- B, the 
classical/canonical pathway. However, in 2000 Jimenez et al., observed that NF- B 
activation can occur in the absence of I B  degradation and Senftleben et al., 2001 
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reported an alternative mechanism of NF- B activation which involved the alternative IKK 
kinase IKK  (Figure 4.1.3) (Jiménez et al., 2000, Senftleben et al., 2001).  
 
IKK  has an integral role in the alternative NF- B activation pathway, which is 
independent of I B  degradation and is regulated via processing of NF- B p100 
(alternatively known as NF- B2) to form the NF- B subunit p52. When in its native form 
p100 acts as an inhibitor of NF- B, binding to cytoplasmic Rel-B. However, 
phosphorylation by IKK  induces interaction with NF- B-inducing kinase (NIK) marking 
p100 for proteolytic processing to form p52 (Senftleben et al., 2001).  
 
The alternative NF- B pathway is implicated in the B-lymphocyte function and lymphoid 
organogenesis (Senftlenen et al., 2001), being activated by TNF-family cytokines but not 
TNF-  itself (Lawrence, 2009).   
 
4.1.2 NF- B dependent and NF- B independent survival proteins 
 
Many of the previously mentioned pathways prolong neutrophil lifespan through 
stimulating production of anti-apoptotic proteins. Neutrophils have been demonstrated to 
contain varied pro-survival proteins, several of which are regulated by NF- B (X-IAP, A1, 
cIAP1 and cIAP2) (Gyrd-Hansen and Meier, 2010, Akgul et al., 2001). X-IAP, a member 
of the Inhibitor of Apoptosis protein family has been particularly well documented in 
relation to the neutrophil and for this reason was selected as one of the proteins for further 
investigation. One of the aims of this chapter is to determine if R-roscovitine could be 
influencing neutrophil survival via the disruption of the NF- B pathway and subsequent 










Figure 4.1.3 Diagrammatic representations of the classical and alternative NF- B 
pathways. Modified from (Lawrence, 2009). 
The classical/canonical pathway can be activated by inflammatory mediators such as LPS, 
stimulating TLRs resulting of phosphorylation of I B  by IKK marking I B  for 
proteasomal degradation and freeing the NF B hetero-dimer allowing translocation to the 
nucleus. The canonical pathway is implicated in inflammatory diseases such as COPD. The 
alternative pathway can be triggered by binding of lymphotoxin- , sequestering TNF 
receptor associated factors and activating NIK which phosphorylates the IKK  homo-
dimer. This triggers processing of P100 to P52 by proteolysis, enabling the P52-RelB 
hetero-dimer to translocate to the nucleus. The alternative pathway is implicated in B-
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4.1.2.1 X-IAP  
 
As mentioned in Chapter 1, X-IAP exerts its effects by inhibiting the caspases 3, 7 and 9 by 
direct competitive inhibition (Eckelman et al., 2006). Interestingly, however, this does not 
appear to be its sole function. Whilst X-IAP is one of the genes transcribed by NF- B 
(Stehlik et al., 1998) it also appears to provide a means of homeostatic regulation of the 
NF- B pathway linking environmental stimuli to the response of the cell. For example, X-
IAP has been demonstrated to provide positive feedback to the NF- B pathway. This is 
achieved either through induced activation of the classical NF- B pathway by X-
IAP/TAK1 mediated activation of IKK  (Hofer-Warbinek et al., 2000), or via binding the 
NF- B inhibitor COMMD1 which regulates the stability of NF- B sub-units (Galban and 
Duckett, 2010).  
 
A fascinating discovery in mice has also implicated an important role for X-IAP in immune 
regulation. Mice deficient in X-IAP had reduced survival rates when infected with Listeria 
monocytogenes as X-IAP was required to potentate NF- B activation and extend JNK 
phosphorylation in response to bacterial infection. Furthermore, the presence of X-IAP 





A survival protein which in humans is unlikely to be induced by NF- B activation was also 
studied. Mcl-1 was chosen as it is known to play a critical role in the regulation of 
neutrophil apoptosis.  
 
Transcription of the Mcl-1 gene can be regulated by a varied array of transcription factors. 
Akgul et al. characterised the Mcl-1 promoter region identifying the following potential 
transcription factor binding sites in the 5’ region of the murine Mcl-1 gene: STAT; Ets; 
CRE-BP; and NF- B. However, there is significant variation between the murine 5’ 
promoter region of Mcl-1 and the human 5’ promoter region. Through generation of a 
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series of mutants Akgul and colleagues concluded that it is doubtful that the human gene 
contains a true NF- B binding site (Akgul et al., 2000b). STAT3 appears to be of particular 
importance in the regulation of Mcl-1 transcription being triggered by IL-6, IL-3 and 
VEGF. Furthermore, areas of inflammation are generally hypoxic and hypoxic conditions 
have been demonstrated to increase Mcl-1 transcription through hypoxia-inducible factor 
1  (Thomas et al., 2010). For more information on Mcl-1, including post translational 
modifications and the role of Mcl-1 in the neutrophil please see Chapter 1 (1.10 Neutrophil 
Survival Proteins). 
 
The aim of this chapter was to attempt to unravel the pathway(s) through which R-
roscovitine signals to induce neutrophil apoptosis. It has been previously proposed by Dey 
et al in 2008 that R-roscovitine inhibits IKK activity in tumorigenic cells thereby 
suppressing activation of NF- B (Dey et al., 2008). Therefore, we chose to study the effect 
of R-roscovitine on NF- B activation to explore the possibility of a similar mode of action 
in the inflammatory neutrophil. This was extended by examining the effect of R-roscovitine 
on levels of the NF- B regulated survival protein X-IAP. Furthermore, the effect of R-
roscovitine on the survival protein Mcl-1 was also considered as it has also been reported 
that R-roscovitine interferes with RNA pol II disrupting transcription of the highly liable 
















4.2.1 Effect of mediators of neutrophil survival and R-roscovitine on I B  in 
neutrophils. 
 
As it has been widely reported that NF- B plays a key role in the initiation of neutrophil 
apoptosis, this pathway was chosen as a hopeful candidate in which to start investigation 
into the mechanism through which R-roscovitine induces apoptosis.   
 
In order to establish/confirm agents that result in degradation of the I B  inhibitor of NF-
B in neutrophils the following investigations were performed. This subsequently allowed 
us to determine if the chosen agents could be activating the canonical pathway in 
neutrophils. 
 
Freshly isolated neutrophils at 5x106 / ml in IMDM plus 10 % autologous serum were 
incubated with either 50 ng/ ml of GM-CSF, 10 ng/ml TNF- , 1 M PAF, 100 ng/ml LPS, 
1 M LTB4 or IMDM plus 10% autologous serum (control) for 15 min on a shaking heat-
block at 37 ˚C before lysing and performing SDS PAGE on a 12 % gel. Figure 4.2.1 A. 
shows that LPS and TNF-  both cause degradation of I B , demonstrated by an absence of 
a band in the appropriate lanes compared to the control -actin blot (where bands are 
present demonstrating equal loading). Therefore, it can be concluded that they free the NF-
B heterodimers from inhibition by I B , leaving it able to translocate to the nucleus. The 
cytokine GM-CSF and the lipid mediators PAF and LTB4 do not cause degradation of 
I B , observed by the presence of bands in the appropriate lanes and therefore it can be 
concluded that they do not cause activation of NF- B via degradation of I B , at least 
under the conditions used in this experiment.  
 
To discover if R-roscovitine causes I B  degradation in neutrophils and therefore could be 
acting, at least in part, through NF- B activation, the above experiment was repeated only 
this time the experimental conditions used were Control (IMDM plus 10% autologous 
serum), 100 ng/ml LPS, 10 ng  TNF- , 1 M C5a, 0.2mM dbcAMP, 100 nM IL8 and 20 
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M R-roscovitine. As can be seen in Figure 4.2.1 B. LPS and TNF-  both cause 
degradation of I B  (as shown in A.), whilst complement component C5a, dbcAMP and 
the chemokine IL8 do not. Interestingly, R-roscovitine does not appear to activate 
degradation of I B , indicating that the NF- B hetero-dimer remains under its inhibition in 
the cytoplasm of the neutrophil. This implies that apoptosis inducing effect of R-roscovitine 
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/ml) resuspended in IMDM with 10% autologous serum were 
incubated for 15 min at 37 
o
C on a shaking heat block with either IMDM alone (control), 
GM-CSF (50 ng/ml), TNF-  (10 ng/ml), PAF (1 μM), LPS (100 ng/ml) or LTB4 (1 μM). 
Cells were then lysed (as described in Chapter 2 Materials and Methods) and the lysates 
separated on a 12 % separating gel by SDS electrophoresis. Western Blots were performed 
onto PVDF membrane and blocked in 5 % Marvel / TBS / 0.1 % Tween-20 for 1 h at room 
temperature. Blots were washed 3 x 5 min. in TBS / 0.1 % Tween-20, then incubated with 
the Santa Cruz antibody I B  (C21) SC-371diluted 1:200 in 5 % Marvel / TBS / 0.1 % 
Tween-20 overnight at 4 
o
C with gentle agitation. Blots were washed and then incubated 
with the secondary antibody goat anti rabbit HRP-conjugated diluted 1:2000 in 5% 
Marvel/TBS/0.1% Tween-20 for 1 h. at room temperature. Blots were visualised using 
electrochemiluminescence. Data represents results from 3 separate experiments.  
Histogram represents the ratio of the experimental I B  bands to the relevant -actin 
control of the blots depicted in Figure 4.2.1 A, analysed by Image J. 
 
B. Same protocol as A. Concentration of additional reagents: Roscovitine (20μM), C5a 
(1μM), dbcAMP (0.2mM), IL8 (100nM). Data represents results from 3 separate 
experiments.  
Histogram represents the ratio of the experimental I B  bands to the relevant -actin 











4.2.2 Effect of R-roscovitine on the ability of LPS and TNF-  to activate NF- B. 
 
Given the results obtained in the previous experiment, that R-roscovitine does not directly 
induce degradation of I B , it was decided to investigate if R-roscovitine could be 
inhibiting the ability of pro-survival agents, such as LPS and TNF- , to pro-long neutrophil 
lifespan through activation of NF- B and subsequent transcription of survival proteins such 
as X-IAP. Gliotoxin was used as a positive control as it has been previously demonstrated 
to inhibit LPS and TNF-  induced activation of NF- B by preventing the loss of I B  
(Ward et al., 1999a). 
  
Neutrophils at 5x106 /ml in IMDM plus 10 % autologous serum were incubated for 30 min 
with either IMDM + 10 % autologous serum (control), R-roscovitine (20 M) or gliotoxin 
(0.1 g/ml). Following this either IMDM + 10 % autologous serum (control), LPS (100 
ng/ml), or TNF-  (10 ng/ml) was added and samples were incubated for a further 15 min.  
 
From figure 4.2.2 it can be seen that the control/control condition did not cause degradation 
of I B , whilst the control/LPS and the control/TNF-  conditions did. Furthermore, the 
gliotoxin/control condition did not lead to I B  degradation, and when gliotoxin was pre-
incubated with either LPS or TNF-  degradation of I B  was prevented indicating that NF-
B was not activated. R-roscovitine, however, again did not lead to degradation of I B  in 
the R-roscovitine/control condition and in addition it did not prevent the ability of LPS or 
TNF-  to degrade I B . This therefore indicates that R-roscovitine does not induce 
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Figure 4.2.2 Effect of inflammatory mediators on I B  degradation in neutrophils 
pre-treated with either R-roscovitine or gliotoxin.  
Neutrophils (5x10
6 
/ml) resuspended in IMDM with 10 % autologous serum were incubated 
for 30 min at 37 
o
C on a shaking heat block with either IMDM alone (control conditions), 
R-roscovitine (20 μM), or gliotoxin (0.1 μg/ml). These conditions were then treated for 15 
min at RT with either IMDM alone (control), LPS (100 ng/ml), or TNF-  (10 ng/ml). Cells 
were then lysed (as described in Chapter 2 Materials and Methods) and the lysates 
separated on a 12% separating gel by SDS electrophoresis. Western Blots were then 
performed onto PVDF membrane. These were blocked in 5 % Marvel / TBS / 0.1 % Tween-
20 for 1 h at room temperature. The blots were washed 3 x 5 min in TBS / 0.1 % Tween-20, 
then incubated with the Santa Cruz antibody I B  (C21) SC-371diluted 1:200 in 5% 
Marvel / TBS / 0.1 % Tween-20 overnight at 4 
o
C with gentle agitation. Blots were washed 
and then incubated with the secondary antibody, goat anti-rabbit HRP-conjugated, diluted 
1:2000 in 5% Marvel / TBS / 0.1 % Tween-20 for 1 h at room temperature. Blots were 
visualised using electrochemiluminescence. Data represents results from 4 separate 
experiments. Histogram represents the ratio of the experimental I B  bands to the relevant 
-actin control, analysed by Image J. 
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4.2.3 Confocal micrographs of p65 translocation in neutrophils. 
 
As it has been previously reported that on rare occasions NF- B activation can occur in the 
absence of I B  degradation (Jiménez et al., 2000), the p65 subunit of the NF- B hetero-
dimer was stained using alexa-fluora green whilst the nucleus was stained red with PI, 
allowing the translocation of the p65 subunit upon NF- B activation to be followed. This 
was performed to ensure that R-roscovitine was not triggering NF- B activation 
independently I B  degradation.  
 
The same conditions were used as the previous experiment. Neutrophils (2.5x106 /ml) were 
cultured in IMDM with 10 % autologous serum either in the absence of any additional 
agents (control), R-roscovitine (20 M) or gliotoxin (0.1 g/ml) for 30 min. Samples were 
then incubated with either IMDM + 10 % autologous serum (control), LPS (100 ng/ml), or 
TNF-  (10 ng/ml) for a further 15 min before staining with propidium iodide and anti-
human anti-p65 antibody (1:50). 
 
In cells where the p65 subunit of NF- B has not translocated the cytoplasm will remain 
green and the nucleus red. However, upon activation of NF- B, translocation of p65 to the 
















Gliotoxin Gliotoxin + TNF- Gliotoxin + LPS
R-roscovitine R-roscovitine + TNF- R-roscovitine + LPS  
 
Figure 4.2.3 Effect of R-roscovitine and gliotoxin on LPS and TNF-  mediated 
movement of p65. 
 
Confocal micrographs (Plan-Apochromat 100 x / 1.4 oil Ph 3)  
Neutrophils (2.5x10
6 
/ml) were cultured in IMDM + 10 % autologous serum with either 
media (Control), 0.1 μg/ml of gliotoxin, or 20 μM R-roscovitine for 45 min. Either IMDM 
with 10 % autologous serum (Control), 10 ng/ml TNF-  or 100 ng/ml LPS was added after 
30 min for the remaining 15 min of the incubation. Samples were stained with propidium 
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As can be seen in Figure 4.2.3 (A) The control demonstrates that there has been no NF- B 
activation as the cytoplasm remains green indicating that the p65 subunit, and therefore NF-
B, is localised in the cytoplasm and has not translocated to the nucleus, which remained 
red. In panel (B) when neutrophils were treated with TNF-  the nuclei have distinct yellow 
patches indicating that the green p65 has translocated into the red nucleus. The same can be 
seen in panel (C) (LPS) therefore, again p65 has been released from its inhibitor and 
allowed to translocate to the nucleus. The positive control, gliotoxin, also yielded the same 
results as the previous experiment as demonstrated in panel (D) where neutrophils treated 
with gliotoxin exhibited a green cytoplasm and a red nucleus i.e. no translocation, this was 
also seen in panels (E) and (F) (gliotoxin/TNF-  and gliotoxin/LPS respectively). However, 
when the neutrophils were treated with R-roscovitine (G) the nuclei remain red and the 
cytoplasm green demonstrating that NF- B is not being activated by R-roscovitine in the 
absence of I B  degradation. Furthermore, these results confirmed that R-roscovitine was 
not preventing the translocation of p65 when incubated with either TNF- , or LPS visible 
by the yellow patches of co-localisation within the nuclei of panels (H) and (I) respectively. 
 
4.2.4 Identification by Western Blotting of cIAP, X-IAP and A1 in human neutrophil 
lysates. 
 
Whilst all cells do not express all anti-apoptotic proteins it has been reported that 
neutrophils express cIAP, X-IAP and A1 (Riley et al., 2006). To confirm the presence of 
these inhibitors of apoptosis at a protein level in human neutrophils (5 x 106 /ml) in PBS 
(without Ca2+/Mg2+) were lysed immediately. Samples were then run on a 12 % gel and 
Western Blotting analysis was conducted according to the protocol in Chapter 2. Blots were 
blocked for 2 h in 5 % Marvel / TBS / 0.1 % Tween-20, and incubated with the primary 
antibody overnight. The antibodies used were at the following concentrations (A1 sc-8351 
1:200, cIAP1/2 sc-12410 1:200, X-IAP AF8221 1:1000). Blots were visualised by 
diaminobenzidine staining (DAB).  
 
As can be seen in figure 4.2.4 the presence of X-IAP, cIAP1/2 and A1 can be confirmed in 
human neutrophils. X-IAP can be observed on SDS-PAGE at a molecular weight of 55 
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kDa, cIAP1 at a molecular weight of 70 kDa and cIAP2 at 68 kDa (a combined antibody 
from Santa Cruz was used which visualises cIAP1 and 2 together in one band at 
approximately 69 kDa). The observation that A1 appears at a slightly higher molecular 
weight when run on SDS-PAGE than the anticipated 20 kDa was also evident. A possible 


































Figure 4.2.4 Identification of the anti-apoptotic proteins cIAP, X-IAP and A1 in 
neutrophil lysates. 
 
Freshly isolated human neutrophils (5 x 10
6 




) were lysed 
immediately. Samples were then run on a 12 % gel and Western Blotting analysis 
performed. Primary antibodies were incubated at the following concentrations overnight 
(A1 sc-8351 1:200, cIAP1/2 sc-12410 1:200, X-IAP AF8221 1:1000). Blots were visualised 
by DAB staining.  
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4.2.5 Identification of Mcl-1 mRNA and protein in human neutrophil lysate. 
 
A protein of particular interest in this thesis is Mcl-1. This is because the function of Mcl-1 
has been particularly well documented, in the human neutrophil, as being pivotal to the 
initiation of apoptosis (Edwards et al., 2004). Therefore, it is highly likely that R-
roscovitine will exert some of its apoptosis inducing ability through regulation of this 
protein, be it directly or indirectly. The presence of Mcl-1 in neutrophils has been observed 
at both the translational and transcriptional level (Figure 4.2.5). Western Blot analysis was 
used to identify the Mcl-1 protein. Freshly isolated human neutrophils were lysed 
immediately at a concentration of 5x106 cells/ml in PBS (without Ca2+/Mg2+). Samples 
were run on a 12 % gel and western blotted according to the protocol in Chapter 2. The cell 
lines A43l (human skin carcinoma squamous cells) and K562 (chronic myelogenous 
leukemia cells) were run as positive controls. The blots were as transferred onto PVDF and 
incubated with the primary antibody (S19: SC-189) at 1:200 for 1 h. The band 
demonstrating Mcl-1 ran at approximately 40 kDa (the molecular weight of Mcl-1 is 37 
kDa). However, in the neutrophil two further bands are evident at a slightly lower 
molecular weight, reasons for this will be discussed in the results section.  
 
The presence of Mcl-1 at the transcriptional level was confirmed by the use of reverse 
transcription polymerase chain reaction (RT-PCR) as detailed in Chapter 2. RNA was 
harvested from freshly isolated neutrophils (25x106 /ml) and converted into cDNA. The 
PCR process was then carried out, the product of which was run on a 1 % agarose gel and 
visualised by ethidium bromide staining under UV light. The house keeping gene GAPDH, 
known to be expressed at significant levels in human neutrophils, was used as a positive 
control to demonstrate the effective nature of the RT-PCR process. The Mcl-1 band was 



















Figure 4.2.5 Identification of Mcl-1 in neutrophils by Western Blot analysis and RT-
PCR  
 








) were lysed 
immediately. The cell lines A43l and K562 were run as positive controls. Samples were run 
on a 12 % gel and analysed by Western Blot according to the protocol in Chapter 2. The 
blots were as transferred onto PVDF and blocked in 5 % Marvel / TBS / 0.1 % Tween-20 
for 1 h at room temperature. Blots were incubated with the primary antibody (S19: SC-819) 
at 1:200 for 1 h. They were visualised using electrochemiluminescence. Data represents 
results from 3 separate experiments.  
 
B) RNA was harvested from freshly isolated neutrophils (25x10
6 
/ sample) and converted 
into cDNA. The PCR process was then carried out according to the protocol in Chapter 2. 
The PCR product was run on a 1 % agarose gel and visualised by ethidium bromide 
staining under UV light. The house keeping gene GAPDH was used as a positive control. 
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4.2.6 Effect of R-roscovitine on GM-CSF induced neutrophil survival and Mcl-1 
 
In order to investigate if the CDKi R-roscovitine could be influencing neutrophil survival 
by affecting levels of the important regulator of neutrophil apoptosis Mcl-1, expression of 
the Mcl-1 protein was studied using Western Blot analysis. As it had been previously 
demonstrated in neutrophils that Mcl-1 protein levels are maintained by the neutrophil 
survival mediator GM-CSF (Derouet et al., 2004) it was decided to investigate whether 
treatment of neutrophils with R-roscovitine had any effect on the ability of GM-CSF to 
maintain Mcl-1 levels. This is of particular importance as GM-CSF levels are increased at 
sites of inflammation, and is one of the many factors attributed to increased longevity of the 
neutrophil at inflammatory foci.  
 
Freshly isolated human neutrophils at a final concentration of 5 x 106 cells/ml in IMDM + 
10% autologous serum were either lysed immediately (0h) or after 2 h incubation in a 
shaking water bath at 37 0C either with GM-CSF (50 ng/ml), R-roscovitine (20 M), GM-
CSF (50 ng/ml) + R-roscovitine (20 M) or IMDM 10% autologous serum (2 h control). 
Samples were resolved on a 12 % gel and analysed by western blotting according to the 
protocol in Chapter 2 (as can be seen in Figure 4.2.6 A). The same experiment was also 
performed with a 4 h incubation (Figure 4.2.6 B.). Figure 4.2.6.C. depicts GM-CSF induced 
neutrophil survival at 20 h, as assessed by flow cytometric analysis of Annexin V binding.  
 
Interestingly, it was observed that in as little as 2h, the level of Mcl-1 protein in neutrophils 
declined markedly; tipping the delicate balance of the Bcl-2 family member proteins 
towards apoptosis. Upon incubation with R-roscovitine Mcl-1 protein levels were also 
reduced and to a slightly larger extent than if R-roscovitine was not present. However, this 
decline in Mcl-1 protein was prevented by the addition of GM-CSF. Furthermore, when R-
roscovitine was co-administered with GM-CSF, R-roscovitine inhibited the GM-CSF 
mediated upregulation of Mcl-1 protein levels. This is a significant finding when 
contemplating the use of R-roscovitine as a novel anti-inflammatory agent, as GM-CSF is 
often found elevated in diseases such as COPD and allergic rhinitis, exacerbating disease 


































Key: G = GM-CSF, R = R-roscovitine
Mcl-1 37 kDa
actin 43 kDa


















































































































































































































Figure 4.2.6 Effect of R-roscovitine on GM-CSF induced neutrophil survival and the 











Figure 4.2.6 Effect of R-roscovitine on GM-CSF induced neutrophil survival and the 
anti-apoptotic protein Mcl-1 
 
A) Mcl-1 levels in neutrophils (final concentration 5x10
6
 /ml) were measured by Western 
blot analysis immediately after isolation (0 h) or after 2 h incubation in a shaking water 
bath at 37 
o
C either with GM-CSF (50 ng/ml), R-roscovitine (20 M), GM-CSF (50 ng/ml) 
+ R-roscovitine (20 M) or IMDM + 10 % autologous serum (2 h control). n = 4.  
 
B) Mcl-1 levels in neutrophils (final concentration 5x10
6
 /ml) were measured by Western 
blot analysis using the same conditions as A) only with an incubation period of 4 h. Blots 
were stripped and reprobed for -actin to check for equal loading. The histogram 
represents the average ratio of the experimental Mcl-1 bands to the relevant -actin 
controls, analysed by Image J (n = 4) P<0.01 = **, P<0.001 = ***. 
 
C) Histogram showing percentage of apoptotic neutrophils as measured by Annexin V 
binding and flow cytometry. Neutrophils were plated at a final concentration of 5x10
6 
/ml 
in IMDM + 10 % autologous serum and incubated for 20 h at 37 
o
C, 5 % CO2 in either 
IMDM + 10 % autologous serum (control), GM-CSF (50 ng/ml) or R-roscovitine (20 M). 
GM-CSF caused a significant decrease in apoptosis and R-roscovitine caused a significant 












4.2.7 Effect of R-roscovitine on GM-CSF, TNF-  and LPS induced neutrophil survival 
and the anti-apoptotic protein Mcl-1 
 
Given the above observation that R-roscovitine can prevent GM-CSF induced neutrophil 
survival by decreasing the protein level of Mcl-1 we chose to investigate next if this 
phenomenon was also evident in cells treated with other pro-inflammatory mediators, 
namely TNF-  and LPS. Freshly isolated human neutrophils at a final concentration of 5 x 
106 cells/ml in IMDM + 10% autologous serum were either lysed immediately (0 h), or 
lysed after 2.5 h following incubation in a shaking water bath at 37 0C either with GM-CSF 
(50 ng/ml), TNF-  (10 ng/ml), LPS (100 ng/ml), GM-CSF (50 ng/ml) + R-roscovitine (20 
M), R-roscovitine (20 μM) + TNF-  (10 ng/ml), R-roscovitine (20 μM) + LPS (100 
ng/ml) or IMDM + 10% autologous serum (2.5 h control). Samples were then resolved on a 
12 % gel and western blotting carried out according to the protocol in Chapter 2.   
 
The results of this experiment (shown in figure 4.2.7) demonstrate that not only can R-
roscovitine override the ability of GM-CSF to promote neutrophil longevity by Mcl-1 but 
that it can also appears to be able to override the cytoprotective effects of LPS and TNF-  
on neutrophils to induce apoptosis. This is a promising find as a novel anti-inflammatory 
agent must possess the ability to induce neutrophil apoptosis even in the presence of pro-














C = Control, G = GMCSF, T = TNF- , L = LPS, R = R-roscovitine





Figure 4.2.7 Effect of R-roscovitine on GM-CSF, TNF-  and LPS induced neutrophil 
survival and the anti-apoptotic protein Mcl-1 
Mcl-1 levels in neutrophils (final concentration 5x10
6
 /ml) were measured by Western blot 
analysis immediately after isolation (0 h), or after 2.5 h incubation in a shaking water bath 
at 37 
o
C either with GM-CSF (50 ng/ml), TNF-  (10 ng/ml), LPS (100 ng/ml), GM-CSF (50 
ng/ml) + R-roscovitine (20 M), R-roscovitine (20 μM) + TNF-  (10 ng/ml), R-roscovitine 
(20 μM) + LPS (100 ng/ml) or IMDM + 10 % autologous serum (2.5 h control). The 
proteins were separated by SDS PAGE, Western Blotted onto PVDF and probed with anti-
Mcl-1 antibody (1:200). 
 
4.2.8 Effect of proteasome and caspase inhibitors on R-roscovitine and GM-CSF 
mediation of Mcl-1 in neutrophils 
 
There is some debate over the method by which the Mcl-1 protein is turned over. Although 
the protein contains a PEST domain (associated with rapid turn over) deletion of this 
domain does not affect the stability of Mcl-1 (Akgul et al., 2000a). Alternative methods 
which could be responsible for the regulation of the Mcl-1 protein are proteolytic 
degradation by the caspases, or degradation by the proteasome (Derouet et al., 2004, 
Herrant et al., 2004). Therefore, it was decided to further investigate the post-translational 
regulation of Mcl-1. Using the global caspase inhibitor Z-VAD-fmk and the proteasome 
inhibitor MG-132 the effects of caspase and proteasome inhibition on the ability of R-






























































































































































































































































































































































































Figure 4.2.8 Effect of proteasome and caspase inhibitors on R-roscovitine and GM-
CSF mediation of Mcl-1 in neutrophils 
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Figure 4.2.8 Effect of proteasome and caspase inhibitors on R-roscovitine and GM-
CSF mediation of Mcl-1 in neutrophils 
 
Neutrophils at a final concentration of 5 x 10
6 
cells/ml in IMDM + 10 % autologous serum 
were either lysed immediately (0 h) or treated either with MG-132 (20 μM) or Z-VAD (100 
μM). Conditions were incubated for 4 h at 37 
0
C with gentle agitation with either IMDM + 
10 % autologous serum (4 h control), GM-CSF (50 ng/ml), R-roscovitine (20 μM) or GM-
CSF (50 ng/ml) + R-roscovitine (20 μM). Blots were stripped and re-probed with the 
antibodies against cleaved caspase 3 and -actin. Histograms represent the ratio of the 
experimental Mcl-1 bands to the relevant -actin control, analysed by Image J. 
 
Our provisional results indicate that inhibition of the proteasome with MG-132 does not 
affect the anticipated action of R-roscovitine on levels of Mcl-1 (Figure 4.2.8). 
Furthermore, the presence of cleaved caspase 3 following R-roscovitine treatment indicates 
that apoptosis has been initiated in the R-roscovitine condition. This implies that the 
proteasome is not responsible (or is at least redundant) for the modulation of protein levels 
of Mcl-1 in neutrophils treated with R-roscovitine. Interestingly cleaved caspase 3 does not 
appear to be present in the GM-CSF + R-roscovitine treatment conditions, implying that 
competition is occurring between the pro-survival mechanism of GM-CSF and the pro-
apoptotic mechanism of R-roscovitine. This is supported by the results obtained with the 
use of the broad range caspase inhibitor Z-VAD-fmk. In this instance the level of Mcl-1 
protein remains approximately constant despite the addition of R-roscovitine. The 
effectiveness of the caspase inhibitor is evident in the absence of cleaved caspase 3 
following R-roscovitine treatment. When considered as a whole this implies that regulation 
of Mcl-1 protein in neutrophils which have been exposed to the CDK inhibitor R-
roscovitine occurs through activation of the caspases and not via the proteasome.    
 
The results of these experiments are reinforced by studies carried out within our group 
which have demonstrated that R-roscovitine induced neutrophil apoptosis is inhibited by 
pre-incubation with Z-VAD-fmk (as assessed by flow cytometry). In addition Z-VAD-fmk 
prevents the ability of R-roscovitine to enhance the resolution of inflammation in 
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carrageenan-induced pleurisy (Rossi et al., 2006). Taken as a whole, the above results 
implicate that R-roscovitine is either directly or indirectly regulating the level of Mcl-1 
protein through activation of the caspases.  
 
4.2.9 X-IAP levels in neutrophils  
 
The next stage of our investigation was to look at a survival protein X-IAP and see if some 
of the effects of R-roscovitine on Mcl-1 were mirrored with this anti-apoptotic protein.  
 
Following the identification of X-IAP protein in neutrophil lysates the effect of R-
roscovitine, gliotoxin and the pro-survival cytokines GM-CSF and TNF-  on protein levels 
was studied. Freshly isolated neutrophils 5 x 106 cells/ml in IMDM + 10 % autologous 
serum were either lysed immediately (0 h) or incubated with either IMDM + 10 % 
autologous serum (control), 50 ng/ml GM-CSF or 10 ng/ml TNF-  for 4h prior to lysing. 
Samples were then resolved on a 12% gel and western blotting carried out according to the 
protocol in Chapter 2. The same protocol was followed only with an incubation time of 2h 
in Figure 4.2.9 B; and with the additional conditions: 50 ng/ml GM-CSF, 10 ng/ml TNF- , 
20 M R-roscovitine, 0.1 g/ml Gliotoxin, 20 M R-roscovitine + 50 ng/ml GM-CSF,  20 
M R-roscovitine + 10 ng/ml TNF-  or 20 M R-roscovitine + 0.1 g/ml gliotoxin for 4h 
prior to lysing (Figure 4.2.9 C). Blots were stripped and re-probed using an anti-human -
actin antibody, demonstrating equal loading between the conditions. 
 
Representative results are portrayed in Figure 4.2.9, although repetition of findings did 
prove difficult.  
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Key: G=GM-CSF, R=R-roscovitine, T=TNF- , Glio=gliotoxin  
 




 /ml) were either lysed immediately after isolation (0 h), or after 4 h 
incubation in a shaking water bath at 37 
o
C either in IMDM (4 h control), GM-CSF (50 
ng/ml), or TNF-  (10 ng/ml). The proteins were separated by SDS PAGE, Western Blotted 
onto PVDF.  
 




 /ml) were either lysed immediately after isolation (0 h), or after 4 h 
incubation in a shaking water bath at 37 
0
C with either IMDM (4 h control), R-roscovitine 
(20 M), GM-CSF (50 ng/ml), TNF-  (10 ng/ml), Gliotoxin (0.1 μg/ml), R-roscovitine (20 
M) + GM-CSF (50 ng/ml), R-roscovitine (20 μM) + TNF-  (10 ng/ml), or R-roscovitine 
(20 μM) + Gliotoxin (0.1 μg/ml). The proteins were separated by SDS PAGE, Western 




Initial experiments suggested that at 4 h TNF-  appeared to have an inhibitory effect on X-
IAP expression levels. However, further reproductions of the experiment were not as 
convincing. Interestingly, it may be possible that R-roscovitine can also override the cyto-
protective effects of GM-CSF and TNF-  on X-IAP levels in neutrophils. As can be seen in 
Figure 4.2.9 C at 4 h there appears to be an increase in expression of X-IAP compared to 0 
h. The presence of the cytokines GM-CSF and TNF-  also cause an apparent increase in 
levels of X-IAP compared to the 0 h control but not to quite the same extent as 4 h alone. In 
addition R-roscovitine causes a reduction in levels of the X-IAP protein at 4 h reducing it to 
approximately the same level as was present at 0 h. Therefore, this could indicate that the 
cell’s delicate balance between pro and anti-apoptotic proteins has been shifted and now 
favours apoptosis.  
 
Furthermore, gliotoxin also appears to potentially cause a reduction in X-IAP to that of the 
0 h level, which could be due to the inhibition of the transcription factor NF- B. When R-
roscovitine is incubated in conjunction with GM-CSF the level of the X-IAP protein 
decreases to that of when R-roscovitine is incubated alone, and in addition the level of 
protein falls even further when incubated with R-roscovitine and TNF-  or R-roscovitine 
and gliotoxin, with the latter disappearing altogether. This mimics the observations made 
with Mcl-1 when R-roscovitine was co-incubated with GM-CSF, TNF-  and LPS. 
 
Possible explanations for the inconsistency in results achieved when immunoblotting for X-
IAP are that although extensive precautions were taken to ensure that the neutrophil’s 
abundant proteases were inhibited during the experimental process some remained active 
degrading the proteins. Alternatively, X-IAP is known to be important in the terminal phase 







4.2.10 Effects of X-IAP-tat construct and R-roscovitine on neutrophil apoptosis at 18 
h.  
 
Another approach used in this thesis to investigate further the role of X-IAP was an X-IAP-
HIV-tat construct. With this we explored the possibility that X-IAP could block the 
apoptosis inducing effects of R-roscovitine.  
 
The X-IAP-HIV-tat protein was a kind gift from Dr Brigitte Onteniente. It was generated 
by fusing the X-IAP protein to the Protein Transduction Domain (PTD) of HIV-1/Tat. The 
positive charge of the PTD allows the tagged protein to pass through the negatively charged 
plasma membrane of the neutrophil and the nuclear localization signal located within the tat 












   
 
 
Figure 4.2.10.1 Diagrammatic representation of X-IAP-tat entering a neutrophil 
The positive charge of the protein transduction domain attached to the protein of interest 
allows the protein to passively enter the cell through the negatively charged membrane, 
where it can then affect the function of the cell. The tat protein also contains a nuclear 

























5-VGGG CTC GAG ATG ACT TTT AAC AGT TTT GAA GG-3V (sense) and  
5-VGGG GAA TTC TTA AAA CAT AAA AAT TTT TTT GCT TG-3V (antisense)  
The above primers were used to isolate the cDNA reading frame of rat X-IAP by PCR. The 
purified fragments were then cloned into a pPTD-HA vector at the XhoI/EcoRI sites.  
 
Final protein encoded: 
 
6-histidine residues tag, PTD (YGRKKRRQRRR), hemaglutinin (HA) tag 
(YPYDVPDVA), and X-IAP 
 
 
Figure 4.2.10.2 Diagrammatic representation of the XIAP-tat construct 
The X-IAP-tat construct contains the 3 BIR domains of the X-IAP protein, along with the 
RING domain. This is attached to the 6 histidine HIV-tat protein transduction domain at 
the N-terminus of the protein. 
 
X-IAP is a 55 kDa protein; the X-IAP-tat construct provided by Dr Brigitte Onteniente was 
constructed from rat X-IAP. However, as the rat X-IAP protein is 89 % homologous to the 
human protein we decided to test the effects of the rat X-IAP-tat product on the human 
neutrophil, specifically in relation to treatment with R-roscovitine.   
 
The above HIV-tat X-IAP construct was used to introduce additional X-IAP protein into 
the cells. Neutrophils (10x106 /ml) were treated in IMDM + 10 % autologous serum in 
either IMDM (control), 1 M X-IAP-tat, 20 M R-roscovitine or a combination of 1 M X-
IAP-tat and 20 M R-roscovitine (XR) and incubated at 37 ˚C for 18 h before staining with 
Annexin-V and PI, levels of which were assessed by flow cytometry.  
PTD HA BIR1 BIR2 BIR3 RING 










Figure 4.2.10.3 Photomicrograph (x 400) of the effects of X-IAP-tat and R-roscovitine 




 /ml) were treated in IMDM + 10 % autologous serum with either 
IMDM (control), 1 M X-IAP-tat, 20 M R-roscovitine or a combination of 1 M X-IAP-tat 
and 20 M R-roscovitine  and incubated at 37 ˚C for 18 h before staining with eosin and 
haematoxylin. Visualised by oil immersion microscopy. 
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Figure 4.2.10.4 Effects of X-IAP-tat construct and R-roscovitine on neutrophil 




 /ml) were treated in IMDM + 10 % autologous serum with either 
IMDM (control), 1 M X-IAP-tat, 20 M R-roscovitine or a combination of 1 M X-IAP-tat 
and 20 M R-roscovitine (XR) and incubated at 37 ˚C for 18 h before staining with 
Annexin-V and PI, levels of which were assessed by flow cytometry. Data shows the results 





Figure 4.2.10.4 A. shows that Annexin V binding in the control condition at 18 h is ~ 60 %, 
which is comparable to the ~ 58 % binding obtained when treated with R-roscovitine. 
However, when the X-IAP-tat construct was combined with R-roscovitine levels of binding 
reduced to ~ 36 % indicating a reduction in levels of apoptosis, and furthermore when the 
X-IAP construct was incubated alone, Annexin V binding was ~ 15 %. These results 
indicate that the X-IAP-tat construct does appear to be having a protective effect on the 
life-span of the neutrophils and does reduce levels of apoptosis when incubated with R-
roscovitine.  
 
However, in order to draw a firm conclusion it is also necessary that PI staining is taken 
into consideration, which can be seen in figure 4.2.10.4 B. This shows that the control 
exhibited only ~ 8 % necrosis, compared to ~ 32 % induced by R-roscovitine and ~ 37 % 
induced by R-roscovitine + X-IAP-tat. This indicates that the cells have passed through 
apoptosis and into secondary necrosis, which when taken into consideration with the % 
Annexin V binding indicates that X-IAP-tat does not appear to be causing as great a 
decrease in cell death as initially thought. However, when X-IAP-tat was incubated alone it 
does appear to have a cyto-protective effect on neutrophils as levels of necrosis are also low 
at ~ 8 %. When percentage apoptosis and necrosis are combined neutrophil death in the 
control is ~ 67 %, in the R-roscovitine treated condition ~ 90 %, which is reduced to 73 % 
when R-roscovitine is co-administered with X-IAP-tat and when neutrophils were 
incubated with X-IAP-tat alone cell death is decreased to only 22 %. Taken as a whole this 
appears to indicate that the X-IAP-tat construct is having a cyto-protective effect on the 
neutrophils, which can partially overcome R-roscovitine induced apoptosis.  
 
4.2.11 Shape change in neutrophils treated with X-IAP-tat at 18 h. 
 
The analyses of the previous experiment indicated that there appeared to be a change in 
forward scatter. This is demonstrated via a shift to the right in forward-scatter in conditions 
where the X-IAP-tat construct was used, as can be seen in Figure 4.2.11 C (X-IAP-tat) 
where the median of the cells lies at ~ 600 FSC-H and D (X-IAP-tat + R-roscovitine) where 
the median lies at ~ 500 FSC-H compared to Figure 4.2.11 A (control) and B (R-
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roscovitine) which both lie at ~ 350 FSC-H. This implies that either the tat construct is 
having an effect similar to priming and encouraging the neutrophils to spread. Alternatively 
this could indicate LPS contamination of the X-IAP-tat construct from the bacterial system 
which it was derived. This is because LPS causes priming of neutrophils, visualised by a 
change in shape and shift in forward scatter. Because of this observation the next step taken 







Figure 4.2.11.1 Flow cytometric dot plots showing forward scatter versus side scatter 
and FL1 versus FL2 of neutrophils aged for 18 h with R-roscovitine  
Neutrophils (10x10
6 
/ml) were treated in IMDM + 10 % autologous serum in either the 
absence (A) control or presence of 20 M R-roscovitine (B) for 18 h before staining with 
Annexin-V and PI, levels of which were assessed by flow cytometry. Data shows the results 








Figure 4.2.11.2 Flow Cytometric Dot plots showing forward scatter versus side scatter 





 /ml) were treated in IMDM + 10 % autologous serum  in either the 
presence of  1  M XIAP-TAT (C) or 1 M XIAP-TAT + 20 M R-roscovitine (D) for 18 h 
before staining with annexin-V and PI, levels of which were assessed by flow cytometry. 






4.2.12 Effects of X-IAP-tat construct and R-roscovitine on neutrophil apoptosis at 4 h.  
 
To further investigate the effects of the X-IAP-tat construct on R-roscovitine induced 
apoptosis and possible LPS contamination an LPS treated condition was introduced to 
allow comparison with the control and tat treated conditions. In addition a new time point 
of 4 h was chosen as the previous 18 h time point was of such duration that the neutrophils 
had passed through apoptosis and started to enter secondary necrosis. A time point of 4 h 
prevents this whilst still being adequate for the apoptosis inducing effects of R-roscovitine 
to be observed.  
 
Figure A. shows the Annexin V binding and PI staining of neutrophils (10x106 /ml) treated 
in IMDM + 10 % autologous serum with either IMDM (control), 1 M X-IAP-TAT, or 100 
ng/ml LPS for 4 h plus either IMDM (control) or 20 M R-roscovitine after the first h for 
the remaining 3 h. Samples were incubated at 37 ˚C throughout the time point. The 
control/control condition demonstrates ~ 1.25 % apoptosis (assessed by Annexin V 
binding) compared to ~ 3 % when R-roscovitine is present (control/R-roscovitine), 
demonstrating that even at this early time-point R-roscovitine has the ability to induce 
apoptosis in neutrophils. The ability of LPS to inhibit neutrophil apoptosis is evident by the 
% apoptosis reducing to ~ 0.75 % and the presence of R-roscovitine with LPS slightly 
increases this to ~ 0.9 %. The X-IAP-tat construct alone at this time point does not alter the 
percentage apoptosis when compared to the control (~ 1.2 % to ~ 1.25 % respectively) 
which is to be expected as at this time point the neutrophils will not have entered 
spontaneous apoptosis. However, when R-roscovitine is incubated in conjunction with X-
IAP-tat, the tat construct reduces the ability of R-roscovitine to induce apoptosis from ~ 3 
% when incubated alone to ~ 1.5 % when X-IAP-tat is present. This does again initially 
indicate that X-IAP-tat is having a cyto-protective effect on R-roscovitine induced 
neutrophil apoptosis. Interestingly, LPS appeared to inhibit apoptosis both when alone and 
when in conjunction with R-roscovitine. 
 
When PI staining is examined (Figure B.) it can be seen that at 4 h the percentage necrosis 
for the control is low at ~ 0.75 %, this is similar to the level obtained in the control/R-
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roscovitine condition (~ 1.2 %). However, when compared to the control LPS, LPS + R-
roscovitine, X-IAP and X-IAP + R-roscovitine all cause a slight increase in necrosis at ~ 2 
%, ~ 1.9 %, ~ 2.5 % and ~ 1.9 % respectively. Given that the results obtained with LPS, 
LPS + R-roscovitine, X-IAP and X-IAP + R-roscovitine were all fairly similar the flow 
cytometric dot-plots and percentage shape change (a known indicator of priming/activation 
of neutrophils) were examined. 
 
4.2.13 Shape change in neutrophils treated with X-IAP-tat at 4 h. 
 
The change in forward scatter visualised in the flow cytometric dot plots at 4 h indicates a 
distinct shift in the populations to the right when the neutrophils were incubated with LPS, 
LPS + R-roscovitine, X-IAP and X-IAP + R-roscovitine (Figure 4.2.13.1). This was 
examined more objectively through adding a gate on the forward scatter histogram which 
allows the percentage shape change to be examined by comparison of all values to the 
control (Figure 4.2.13.2). When presented as a bar chart it can be seen that both the control 
and control + R-roscovitine cause approximately 10 % shape change whilst LPS, LPS + R-
Roscovitine, X-IAP and X-IAP + R-roscovitine cause approximately 90 %, 85 %, 87 % and 
80 % shape change respectively. This indicates that there is something either intrinsic to or 
contaminating the X-IAP-tat construct and causing priming/activation of the neutrophils 
























































































































































































































































Figure 4.2.12 Effects of the X-IAP-tat construct and R-roscovitine on neutrophil 




/ml) were treated in IMDM + 10 % autologous serum as follows. 
Control/Control in the absence of any agents for 4 h. Control/R-roscovitine in the absence 
of any agents for 1 h and then 20 M R-roscovitine added for 3 h. LPS/Control treated with 
100 ng/ml LPS for 4 h with media added after 1 h for the remaining 3 h. LPS/R-roscovitine 
treated with 100 ng/ml LPS for 4 h with 20 M R-roscovitine added after 1 h for the 
remaining 3 h. X-IAP/Control treated with 1 M X-IAP-TAT for 4 h with media added after 
1 h for the remaining 3 h. X-IAP/R-roscovitine treated with 1 M X-IAP-TAT for 4 h with 
20 M R-roscovitine added after 1 h for the remaining 3 h. Samples were then stained with 
Annexin-V (A) and PI (B) levels of which were assessed by flow cytometry. Data 










Figure 4.2.13.1 Flow Cytometric Dot Plots showing forward scatter verses side scatter 
of neutrophils aged for 4 h with X-IAP-tat or R-roscovitine in the presence or absence 
of LPS.  
Neutrophils (10x10
6
 /ml) were treated in IMDM + 10 % autologous serum as follows. (A) 
in the absence of any agents for 4 h. (B) in the absence of any agents for 1 h and then 20 
M R-roscovitine added for 3 h. (C) treated with 100 ng/ml LPS for 4 h with media added 
after 1 h for the remaining 3 h. (D) treated with 100 ng/ml LPS for 4 h with 20 M R-
roscovitine added after 1 h for the remaining 3 h. (E) treated with 1 M X-IAP-TAT for 4 h 
with media added after 1 h for the remaining 3 h. (F) treated with 1 M XIAP-TAT for 4 h 
with 20 M R-roscovitine added after 1 h for the remaining 3 h. Samples were then stained 
with Annexin-V and PI levels of which were assessed by flow cytometry. Data 












Figure 4.2.13.2 Flow Cytometric histograms showing shape change induced in 





 /ml) were treated in IMDM + 10 % autologous serum as follows. (A) 
in the absence of any agents for 4 h. (B) in the absence of any agents for 1 h and then 20 
M R-roscovitine added for 3 h. (C) treated with 100 ng/ml LPS for 4 h with media added 
after 1 h for the remaining 3 h. (D) treated with 100 ng/ml LPS for 4 h with 20 M R-
roscovitine added after 1 h for the remaining 3 h. (E) treated with 1 M X-IAP-TAT for 4 h 
with media added after 1 h for the remaining 3 h. (F) treated with 1 M X-IAP-TAT for 4 h 
with 20 M R-roscovitine added after 1 h for the remaining 3 h. Samples were then stained 
with Annexin-V and PI levels of which were assessed by flow cytometry. Data 





































































































Figure 4.2.13.3 Histograms showing percentage shape change for neutrophils aged for 




 /ml) were treated in IMDM + 10 % autologous serum as follows. 
Control/Control in the absence of any agents for 4 h. Control/R-roscovitine in the absence 
of any agents for 1 h and then 20 M R-roscovitine added for 3 h. LPS/Control treated with 
100 ng/ml LPS for 4 h with media added after 1 h for the remaining 3 h. LPS/R-roscovitine 
treated with 100 ng/ml LPS for 4 h with 20 M R-roscovitine added after 1 h for the 
remaining 3 h. X-IAP/Control treated with 1 M XIAP-TAT for 4 h with media added after 
1 h for the remaining 3 h. X-IAP/R-roscovitine treated with 1 M X-IAP-TAT for 4 h with 
20 M R-roscovitine added after 1 h for the remaining 3 h. Samples were then stained with 
Annexin-V and PI levels of which were assessed by flow cytometry. Data representative of 
3 separate experiments. 
 
4.2.14 Effect of X-IAP-tat on CD62L expression and shape change in neutrophils. 
 
Because of the similarity of the effects of X-IAP-tat and LPS on neutrophil shape change 
their effects on the selectin CD62L, which is shed upon neutrophil activation, were 
investigated (Figure 4.2.14). Neutrophils were resuspended at 5x106 /ml in PBS + cations. 
Half of the samples were treated with media that contained 10 % autologous serum (+) and 
half were treated without serum (-). Within each of these two conditions one sample was 
treated without any additional reagents (control) one was treated with 100 ng/ml LPS and 
one with 1 M X-IAP-tat for 30 min prior to incubation with anti-human anti-CD62L for 
 143 
30 min. Samples were then analysed using flow cytometry. Samples were treated in either 
the presence or absence of serum as the serum factors LBP, CD14 and MD2 are known to 



































































































Figure 4.2.14 Histograms showing collated data for neutrophil shape change and 
CD62L expression induced by X-IAP-tat and LPS either in the presence or absence of 
autologous serum.  
Neutrophils were resuspended at 5x10
6
 /ml in PBS + cations. Half of the samples were 
treated with media that contained 10 % autologous serum (+) and half were treated 
without serum (-). Within each of these two conditions one sample was treated without any 
additional reagents (control) one was treated with 100 ng/ml LPS and one with 1 M 
XIAP-TAT for 30 min prior to incubation with anti-human anti-CD62L for 30 min. Samples 
were then analyzed using flow cytometry. Data representative of 3 separate experiments. 
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Confirmation of the previous shape change results were observed as demonstrated in figure 
4.2.14 A. where in the presence of 10 % autologous serum LPS and X-IAP-tat caused an 
increase in percentage shape change of approximately 34 % and 30 % respectively when 
compared to the serum control. However, in the absence of 10 % autologous serum LPS 
only causes ~ 2 % increase in percentage shape change compared to the serum free control. 
Whereas, the X-IAP-tat construct causes ~ 34 % increase. This confirms that in order for 
LPS to activate its signaling cascade in neutrophils the serum binding factors must be 
present. In addition the X-IAP-tat construct when in the absence of serum still results in 
shape change, albeit to a lesser extent than in the presence of serum. This indicates that the 
X-IAP-tat construct itself may be responsible for the shape change, or possibly that at some 
point during its construction it was contaminated by LPS and its binding proteins. 
 
In addition when CD62L was investigated (Figure 4.2.14 B) it appears that the presence of 
serum alone affects the rate of CD62L shedding in neutrophils with there being a difference 
in geo mean fluorescence of 225 between the control with and the control without serum. 
However, in both cases LPS and X-IAP-tat result in a decrease in expression of CD62L, 
although when serum is present the decrease caused by LPS and X-IAP-tat is very close 
with both resulting in a reduction of ~ 90. Whereas when serum is absent the effect of LPS 
on CD62L shedding is markedly reduced from the serum negative control value of ~ 350 to 
~ 300 compared to ~ 100 in the serum absent X-IAP-tat construct condition. Again as the 
X-IAP-tat construct causes shape change and CD62L shedding it can be concluded that it is 
having a priming effect on the neutrophil. In addition the similarity between the effects of 
the X-IAP-tat construct and LPS in the serum containing conditions could indicate that the 
possible cause of the X-IAP-tat constructs ability to prime/activate neutrophils could be that 
it is contaminated by LPS and its binding proteins as it still has the power to activate 







4.2.15 Limulus amebocyte lysate (LAL) test of the X-IAP-tat construct 
 
To ascertain conclusively whether the X-IAP-tat construct was contaminated with LPS a 
LAL test was performed.  
 
The LAL assay was developed from the observation of Frederick Bang that intravascular 
coagulation was caused by bacteria in Limulus polyphemus (American horseshoe crab). 
Levin and Bang concluded that this was caused by the bacterial endotoxin causing an 
enzymatic reaction in the amoebocytes. These enzymatic reactions form the basis of the 
LAL assay, upon enzymatic cleavage of the chromophore p-nitroaniline (pNA) the 
colourless substrate will become yellow; this reaction is terminated by the addition of acetic 
acid. The levels of pNA created are proportional to the amount of endotoxin present and the 
colour change is measured at 450 nm with a spectrophotometer. The standard samples can 
be used to create a standard curve from which the endotoxin concentration of the 
experimental conditions is calculated.   
 
                       Endotoxin 
Pro-enzyme                           Enzyme 
 
                                               Enzyme 
Chromogenic Substrate                                 pNA + peptide 
 
The results from this indicate that the X-IAP-tat construct contained contaminating LPS at 
approximately 45.72 g/ml, a significant amount compaired to the 100ng/ml thoroughout 
this thesis. This therefore offers an explanation as to why results obtained in the previous 
experiments were similar to that of LPS. However, it can not be ruled out that the pro-
survival effects of the X-IAP-tat construct were not, at least in part, due to transduction of 
exogenous X-IAP into the neutrophil, inhibiting apoptosis and therefore prolonging the 
lifespan of the cell. If time constraints were not present the X-IAP-tat construct could be 
tagged with green fluorescent protein to confirm whether the construct is actually entering 
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the cell, and the proteins localisation. Columns could also be purify the construct and 
remove any contaminating LPS. 
 
 













































Figure 4.2.15 Standard curve calculated from serial dilutions of standards used to 
calculate the endotoxin concentration of the XIAP-tat construct.  
 
The LAL standard curve indicates that the X-IAP-tat construct was contaminated with 









The mechanism through which R-roscovitine induces apoptosis in neutrophils has yet to be 
fully elucidated. Discovery of this would enable the development of novel CDKis which 
could be honed for treatment of inflammation, targeting specific pathways to induce 
apoptosis in neutrophils, whilst having minimal negative impact on the functions of the 
surrounding cells. In this chapter we aimed to shed light on the potential mechanism(s) of 
action of R-roscovitine in the terminally differentiated neutrophil, which do not require 
CDKs for the traditional function of cell cycle regulation. 
 
Firstly we chose to study the effect of R-roscovitine on the transcription factor NF- B. NF-
B was chosen as it is already known to be a key component in controlling the fate of the 
neutrophil (Ward et al., 1999a), upregulating transcription of anti-apoptotic genes such as 
the inhibitor of apoptosis protein family (IAP) (Gyrd-Hansen and Meier, 2010). Therefore, 
if R-roscovitine blocked NF- B activation it would prevent transcription of anti-apoptotic 
genes helping to tip the delicate balance between the pro and anti-apoptotic proteins 
towards apoptosis. NF- B activation was assessed by I B  degradation as well as by 
following the translocation of the p65 subunit. We chose these two approaches as it has 
been previously reported that NF- B activation can sometimes occur in the absence of I B  
degradation (Jiménez et al., 2000). Whilst analysis of the confocal micrographs following 
the translocation of p65 were performed in a semi-blind manner (i.e. the slide labels were 
not intentionally looked at before viewing) the power of the results could have been 
increased by performing a full blind analysis ensuring the labels were fully covered and the 
order in which they were viewed not revealed until the results had been collated. 
 
Our results demonstrate that R-roscovitine does not directly activate NF- B and 
furthermore it does not prevent activation of NF- B by LPS or by TNF- . From this it can 
be concluded that R-roscovitine is not inducing apoptosis via a pathway that directly 
involves early NF- B activation.  
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These findings challenge Dai’s hypothetical model that CDK inhibitors such as flavopiridol 
cause inactivation of the NF- B pathway leading to JNK activation and inhibition of X-IAP 
expression and therefore apoptosis (Dai et al., 2003). However, R-roscovitine may work 
through a different NF- B independent pathway to flavopiridol, or differences between 
these findings could possibly be explained by variations in the intrinsic pathways of U937 
cells and neutrophils. Having said this, even though NF- B has been ruled out as a 
contender through which R- roscovitine directly signals in neutrophils it may still become 
activated through further downstream events. In addition results obtained from the 
experiments into the effects of R-roscovitine on X-IAP levels in neutrophils were variable 
(discussed in greater detail later in the chapter).  
 
The next stage of our investigation was to explore the effect of R-roscovitine on the anti-
apoptotic proteins Mcl-1 and X-IAP. These were chosen as previous literature has 
identified them as being key players in regulating the fate of neutrophils (Edwards et al., 
2004, Gardai et al., 2004, Hahntow et al., 2004). In addition X-IAP, unlike Mcl-1, is under 
regulation by NF- B therefore allowing the effect of R-roscovitine to be examined on two 
anti apoptotic proteins that are under the regulation of different transcription factors (Gyrd-
Hansen and Meier, 2010, Akgul et al., 2000b).  
 
An observation was made whilst Western Blotting for Mcl-1 (Figure 4.2.5) in the 
neutrophil of two additional bands at a slightly lower molecular weight. Possible 
explanations for these are: they are post translational modifications of the Mcl-1 protein; 
alternatively even though every effort was made to inhibit the vast arsenal of neutrophil 
proteases some break down of the Mcl-1 protein may have occurred; or that the antibody is 
detecting Mcl-1 short as well as Mcl-1 long. The latter proposition is supported by the 
additional band running at a similar molecular weight to that of Mcl-1 short, approximately 
28 kDa. 
 
From the results obtained in this chapter it is evident that R-roscovitine reduces levels of 
Mcl-1 allowing the neutrophils to enter apoptosis, this is made even more fascinating as it 
has been shown that Mcl-1 is essential for the survival of neutrophils playing a non-
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redundant role in the regulation of neutrophil apoptosis (Dzhagalov et al., 2007) which is of 
particular interest in light of our findings as decreases in Mcl-1 levels caused by R-
roscovitine may not be compensated by the other survival proteins present in neutrophils 
resulting in the cell entering apoptosis. In addition R-roscovitine appears to be inducing 
apoptosis in neutrophils by the caspases, as inhibition with the broad spectrum caspase 
inhibitor zVAD-fmk prevented R-roscovitine induced reduction of Mcl-1.  
 
We also found that R-roscovitine has the ability to override the protective effect of GM-
CSF on Mcl-1 levels at 4h. Interestingly, this phenomenon does not seem to be exclusive to 
GM-CSF, as when R-roscovitine is used in conjunction with other inflammatory mediators, 
for example LPS, levels of Mcl-1 are also reduced (the same is potentially true for X-IAP; 
however, further research is required before this can be stated with confidence). This is a 
promising finding as it indicates that R-roscovitine can potentially counteract the anti-
apoptotic effects of inflammatory mediators at sites of inflammation. When examining the 
effects of R-roscovitine on X-IAP via Western Blotting the observation was made that the 
combined effect of R-roscovitine plus the NF- B inhibitor gliotoxin results in maximal X-
IAP reduction. If this is true it would fall in line with Dai’s finding that disruption of NF-
B potentiates the apoptotic effect of the CDK inhibitors implying that NF- B does have a 
role, albeit not a direct one, in apoptosis induction in neutrophils (Dai et al., 2003).  
 
A possible target for R-roscovitine is the PI3-K/Akt pathway and it has been demonstrated 
in the human erythroleukaemia cell line Tf-1 that the Mcl-1 gene is upregulated through 
this pathway (Huang et al., 2000). Therefore, one possible explanation for the decrease in 
Mcl-1 levels in neutrophils treated with R-roscovitine is that R-roscovitine could be 
blocking the PI3-K / Akt pathway. However, it has been previously published that in 
human leukaemic cell lines such as the U937 monocytic leukaemic cell line, CDKis ability 
to induce apoptosis can be enhanced when combined with PI3-K inhibitors, where they 
observed decreases in Mcl-1 and X-IAP, which implys only a partial inhibition of the PI3-
K/Akt pathway by R-roscovitine. This work was primarily carried out on a monocytic 
leukaemic cell lines which may possess different regulatory mechanisms to those of 
neutrophils. However, it does state that similar results have been demonstrated in HL60 
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cells which can be used as a model for neutrophils, although several intrinsic differences 
between HL60 cells and primary neutrophils have been reported making extrapolation of 
results tenuous in some instances (Yu et al., 2003).  
 
Alternatively R-roscovitine could be influencing the ERK pathway, as R-roscovitine has an 
inhibitory effect on both the ERK1 and ERK2 kinases, although in these instances R-
roscovitine was used at a higher concentration than in this thesis (Knockaert et al., 2002, 
Bach et al., 2005). Interestingly, the ERK 1/2 pathway has been implicated in the resolution 
of inflammation in rat carrageenan-induced pleurisy, as inhibition of ERK1/2 kinases by 
PD98059 produced enhanced resolution of inflammation. The proposed mechanism for this 
is that PD98059 prevents activation of ERK by inflammatory mediators which induce 
neutrophil survival (Sawatzky et al., 2006). Given more time this would be investigated 
through the use of an ERK inhibitor such as PD98059 to elucidate if similar effects are 
achieved to those exhibited by R-roscovitine, and if combined administration alters the 
anticipated response of the survival proteins. However, it has since been demonstrated in 
our laboratory (Leitch et al., 2010) that, unlike in vascular smooth muscle cells (Li et al., 
2008), R-roscovitine only has a slight effect on LPS induced ERK phosphorylation, 
whereas PD98059 caused much greater inhibition. This, when considered in conjunction 
with Figures 4.2.2 and 4.2.3 which demonstrates that R-roscovitine does not inhibit LPS 
and TNF-  induced activation of  NF- B, implies that R-roscovitine is overriding the anti-
apoptotic outcome normally produced by these pathways down-stream of these 
occurrences, and that the presence of R-roscovitine is significant enough to over come 
them.  
 
Whilst it is possible that the above could potentially indicate R-roscovitine induces 
apoptosis via more than one pathway (as supported by the observation that it can interfere 
with various inflammatory mediators’ ability to prolong neutrophil survival by effects on 
Mcl-1) it is also plausible that the dramatic induction of neutrophil apoptosis by R-
roscovitine could reflect a more universal effect is being imposed. For example, if 
transcription is compromised by inhibition of CDK7 and CDK9, levels of the subsequent 
protein will decline (MacCallum et al., 2005). This effect will be particularly prominent in 
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proteins which have short half lives such as Mcl-1. Interestingly X-IAP has a considerably 
longer half life than Mcl-1 offering a possible explanation to the lack of conclusive results 
obtained when immunoblotting for the X-IAP protein. 
 
Unfortunately whilst results from the transduction of X-IAP into neutrophils by the use of a 
HIV-tat vector were confounded by the discovery of LPS, a relic of the E-coli production 
vector, the initial administration of the X-IAP-tat construct did appear to have some cyto-
protective effect on neutrophils exposed to R-roscovitine, which could be partially due to 
successful transduction. However, the results could have been further confounded just by 
the presence of R-roscovitine. This is because it has recently been discovered that CDKis 
such as R-roscovitine prevent trans-activation of HIV-tat proteins as they inhibit CDK9, an 
essential mediator of this function in conjunction with its regulatory partner T1 (Canduri et 
al., 2008).  
 
For conclusive results to be obtained in the presence of CDKis an alternative method of 
protein transduction is required. Possible methods include microinjection, complexing the 
X-IAP protein with a lipid or use of virus-like particles which assemble into nanoparticles 
but lack the ability to replicate. Furthermore tagging of the X-IAP protein construct with 
GFP would enable the localisation of the introduced protein to be determined. A recent 
paper by Sabroe et al. has shown effective delivery of proteins into primary human 
neutrophils by lentivirus vectors (Dick et al., 2009). Use of a lentivirus to transduce Mcl-1 
and X-IAP proteins into primary human neutrophils treated with R-roscovitine would 
provide a valuable model to further investigate the roles of these proteins in R-roscovitine 
induced neutrophil apoptosis. 
 
In conclusion, the results from this chapter indicate that loss of Mcl-1 induced by R-
roscovitine is a newly identified mechanism of inducing neutrophil apoptosis. This 
mechanism appears to be regulated by the caspases, demonstrated through use of the 
zVAD-fmk and by R-roscovitine induced cleavage of caspase-3. Interestingly when co-
incubated with GM-CSF, R-roscovitine loses its ability to induce caspase-3 cleavage. A 
possible explanation for this is competition between the pro- and anti–apoptotic pathways. 
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Although a reduction in X-IAP was observed when neutrophils were incubated with R-
roscovitine, results were inconsistent and therefore no conclusive theory can be arrived at. 
This could be, at least in part, due to X-IAP being involved in the concluding stages of 
apoptosis. As results from the investigations into X-IAP were variable we feel that whilst 
X-IAP is undoubtedly implicated in neutrophil apoptosis it is possible that the reduction of 
X-IAP observed is as a result of the neutrophil already being committed to apoptosis and 




























5.1 Summary and General Discussion 
 
The inflammatory response is an evolutionary conserved, tightly regulated series of inter-
related cellular processes, resolution of which is dependent upon effective removal of 
apoptotic cells by professional phagocytes such as macrophages. There is mounting 
evidence suggesting that the apoptotic neutrophil can regulate the inflammatory response 
and stimulate macrophages to form a pro-resolution phenotype capable of releasing pro-
resolution mediators and cytokines (Porcheray et al., 2005, Benoit et al., 2008). 
Furthermore, models of inflammatory disease have demonstrated an anti-inflammatory 
capacity of the apoptotic neutrophil itself (Serhan et al., 2008). All of the above act to halt 
the inflammatory response, preventing inappropriate activation and 
exacerbation/progression of inflammation.  
 
This thesis set out to further understand the mechanism through which the CDKi R-
roscovitine induces apoptosis in neutrophils, a phenomenon previously observed in our 
laboratory. To date CDKis such as R-roscovitine are in late stage clinical trials for use as 
novel anti-cancer treatments and have proved successful at inhibiting proliferation and 
inducing apoptosis in carcinogenic cells (Krystof and Uldrijan, 2010). Our laboratory has 
highlighted a potential novel use for CDKis in the treatment of neutrophil dominant 
inflammatory diseases, through targeted induction of neutrophil apoptosis. A niche in the 
market exists for such a treatment, as diseases such as COPD do not respond well to 
treatment with traditional therapies such as glucocorticoids. A possible reason behind this 
may be that whilst glucocorticoid treatment increases removal of the apoptotic cells via 
macrophage phagocytosis, it actually inhibits neutrophil apoptosis (as demonstrated in 
Chapter 3) (S. Saffar et al., 2011). This creates a two fold problem: firstly neutrophils 
persist at the site of inflammation primed for activation, which in turn draws more 
neutrophils to the affected area (all capable of releasing their histotoxic arsenal of proteases 
and reactive oxygen products); secondly when the abundant neutrophils do finally enter 
apoptosis their copious numbers can overwhelm their removal by the macrophages 
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enabling the apoptotic cells to pass into secondary necrosis. If this occurs, the neutrophil’s 
cytotoxic contents are liberated into the extra-cellular milieu which can result in further 
damage to the surrounding tissue and exacerbation of the inflammatory process.   
 
In order for a novel treatment to be successful, it is essential that it does not impact 
negatively on the surrounding cellular environment. Therefore the first results chapter 
(Chapter 3) was concerned with the effects of R-roscovitine on the activation state of the 
neutrophil and the interaction of the apoptotic neutrophil with the phagocytic macrophage. 
The main observations and subsequent conclusions drawn are as follows: R-roscovitine 
does indeed result in death of neutrophils via apoptosis in as little as 4 h. This is a 
significant decrease compared to their circulating longevity in vivo which ranges from 7-12 
h, and their lifespan in the tissues, which can exceed 24 h. Another aim of this chapter was 
to establish the effects of key inflammatory mediators on neutrophil apoptosis. This 
provided us with base line results from which the effects of the addition of R-roscovitine 
could be examined. Once it had been firmly established that R-roscovitine caused targeted 
apoptosis in neutrophils, the effect of R-roscovitine on several pertinent markers of 
neutrophil activation was investigated, namely neutrophil shape change, CD11b 
upregulation and CD62L shedding. Comparisons were made to the apoptosis inducing 
agent gliotoxin, to see if any similarities were present. It was found that when R-roscovitine 
was administered alone or in conjunction with GM-CSF, LPS, TNF-  or LTB4 the 
anticipated activation parameters were unaffected (unlike gliotoxin). This suggests that R-
roscovitine is acting in a different way to gliotoxin which does not stimulate a priming 
response in neutrophils. It also alludes to the possibility of R-roscovitine being well 
tolerated by neutrophils in vivo, not causing neutrophils to be untimely primed and 
susceptible to activation, which could contribute to tissue damage and exacerbation of the 
inflammatory process. Furthermore, as CD11b and CD62L are important for the processes 
of neutrophil adhesion to the vascular endothelium, the above results also infer that R-
roscovitine is unlikely to disrupt the process of neutrophil recruitment and migration to 
sites of inflammation by inflammatory mediators. If this were to be disrupted, it could 
potentially result in an increased propensity of infection. This is an important and 
 155 
promising finding when considering R-roscovitine as a possible novel treatment for 
neutrophil driven inflammatory disorders.  
 
The potential suitability of R-roscovitine as a novel anti-inflammatory agent is further 
supported by the finding that R-roscovitine does not affect the ability of macrophages to 
phagocytose apoptotic neutrophils, or the phenomenon of dexamethasone increased 
phagocytosis. Interestingly, it appears that R-roscovitine may increase phagocytosis of 
apoptotic cells (observed in both the R-roscovitine condition and when R-roscovitine was 
co-administered with dexamethasone) when compared to the relevant controls. A possible 
explanation for this observation is that R-roscovitine increases the number of apoptotic 
cells present compared to the control condition. Subsequently apoptotic neutrophils are 
more abundant in the R-roscovitine treated conditions therefore, the macrophages engulf 
greater numbers. This is an exciting observation given the importance of the phagocytosis 
of apoptotic cells in triggering resolution of inflammation. 
 
Once the potential suitability for R-roscovitine as a possible novel anti-inflammatory agent 
had been established the next step was to investigate the mechanism through which it acts. 
Due to the complex and redundant nature of the inflammatory response this task proved 
lengthy and intricate. However, in the final results chapter (Chapter 4) the following 
conclusions were arrived at. The initial suspicion that R-roscovitine was not directly 
inhibiting NF- B was investigated and its effects on the classical/canonical pathway were 
assessed by I B  degradation and via the translocation of p65 to the nucleus. Both methods 
confirmed that R-roscovitine does not directly activate the NF- B pathway, nor does it 
inhibit the ability of LPS or TNF-  to activate NF- B. This is an important finding as it 
implies that the canonical pathway, the pathway implicated in the inflammatory response, is 
not directly augmented by R-roscovitine. Furthermore, it indicates that the apoptosis 
inducing effect of R-roscovitine in the inflammatory neutrophil is via a different pathway to 
that proposed by Dai et al. in leukaemic cells (Dai et al., 2003). However, this does not rule 
out the possible involvement of NF- B further downstream in the pathway, for example at 
the point of NF- B dependent transcription. Interestingly though it may suggest that R-
roscovitine’s main mode of action is not through inhibition of one of the survival proteins 
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under the regulation of NF- B (for example A1, X-IAP, cIAP1 and cIAP2) and that any 
subsequent down regulation of these proteins is associated with apoptosis already being 
triggered within the cell. To try and identify which survival proteins R-roscovitine targeted 
in the neutrophil, extensive studies were carried out on the following two survival proteins: 
Mcl-1, chosen because it is not thought to be under direct regulation of NF- B; and X-IAP 
which is proposed to be transcriptionally activated by NF- B. The latter protein was 
chosen, as whilst our provisional investigations eluded the NF- B pathway not being 
directly influenced by R-roscovitine, it is possible that R-roscovitine may be exerting some 
effects further down the NF- B pathway which are influencing levels of NF- B transcribed 
survival proteins. Interestingly, it was found that Mcl-1 levels in the neutrophil decreased 
rapidly (in as little as 2 h) upon culturing with R-roscovitine, which is an important 
observation as this precedes observable apoptosis. Therefore, this implies that loss of Mcl-1 
is caused by exposure to R-roscovitine and maybe important in initiating apoptosis and that 
this decrease is not just an artefact of a cell undergoing active apoptosis. Furthermore, R-
roscovitine was able to over-ride the ability of GM-CSF to maintain Mcl-1 levels and in 
addition it appears that R-roscovitine can also down-regulate Mcl-1 in the presence of 
TNF-  and LPS. The ability of R-roscovitine to over-come powerful survival stimuli such 
as these could prove invaluable in its proposed application as a novel treatment for 
neutrophil dominant inflammatory disorders as it will enable R-roscovitine to induce 
neutrophil apoptosis even in severely inflamed areas where levels of survival factors, such 
as the ones above, are elevated. As it has been previously reported that protein levels of 
Mcl-1 can be regulated by the proteasome (Derouet et al., 2004) as well as by caspases 
(Herrant et al., 2004), provisional experiments were conducted into the mechanism through 
which R-roscovitine decreased levels of Mcl-1. Results imply that R-roscovitine induces 
caspase dependent reduction of Mcl-1. This is supported by the appearance of cleaved 
caspase 3 in R-roscovitine treated conditions. The involvement of X-IAP in R-roscovitine 
induced neutrophil apoptosis is less clear cut. Immunoblotting for X-IAP did suggest that 
X-IAP could potentially be reduced in the presence of R-roscovitine. It is possible that R-
roscovitine may not be acting directly via X-IAP and that reductions observed are as a 
result of the apoptotic process already being initiated in the neutrophil. Results are further 
complicated by the fact that X-IAP is involved in the final stages of apoptosis and where 
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multiple pathways converge. To try and shed more light on the possible involvement of X-
IAP in R-roscovitine induced apoptosis, HIV-tat transduction of an X-IAP-tat construct 
was attempted. Preliminary experiments revealed, as would be expected, that the 
introduction of X-IAP by the use of the tat construct significantly reduced neutrophil 
apoptosis at 18 h. In addition the X-IAP-tat construct appeared to partially reverse the 
induction of apoptosis. However, further investigations revealed contamination of the tat 
construct with LPS, a result of its bacterial vector production. As LPS is known to increase 
longevity of neutrophils the results obtained were confounded. Therefore, whilst it is 
possible that some of the longevity conferred on the neutrophils in the R-roscovitine + X-
IAP-tat could be due to the increase in functional X-IAP protein, the results can not be fully 
contributed to this. In conclusion the results from Chapter 4 indicate that R-roscovitine is 
initiating caspase dependent apoptosis likely caused by a reduction in Mcl-1 resulting in 
subsequent but not causal reduction in X-IAP. Furthermore, whilst NF- B may be 
implicated further down stream, the canonical pathway does not appear to be affected by R-
roscovitine.  
 
In summary, the work performed for this thesis supports the possible use of R-roscovitine 
as a novel treatment for neutrophil dominant inflammatory disorders. It indicates R-
roscovitine would be well tolerated in vivo as an agent which effectively targets neutrophil 
apoptosis whilst not perturbing anticipated neutrophil activation parameters induced by key 
inflammatory mediators. Importantly R-roscovitine appears to have no detrimental effects 
on macrophage phagocytosis of apoptotic neutrophils, enabling effective removal of the 
apoptotic cells preventing them from entering secondary necrosis and further exacerbating 
the inflammatory response. In addition, this thesis begins to shed some light on the 
potential mechanism through which R-roscovitine induces apoptosis in neutrophils. It puts 
forward the idea that direct inhibition of NF- B is not responsible for R-roscovitine driven 
apoptosis and adds to the wealth of literature indicating the importance of the survival 
protein Mcl-1 in neutrophils, implicating an essential role for the protein in R-roscovitine 
induced apoptosis. Excitingly these results hint at a possible novel two pronged approach to 
treatment of neutrophil dominant inflammatory diseases such as COPD, which as yet do 
not have a truly effective course of treatment. Administration of a CDK inhibitor such as R-
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roscovitine would target induction of neutrophil apoptosis whilst subsequent treatment with 
a steroid, such as dexamethasone, would increase macrophage clearance of the apoptotic 
cells, kick starting the process of resolution.     
 
5.2 Limitations  
 
There are several limitations associated with experimentation on primary neutrophils. One 
of the most regularly encountered, and the one which proves particularly troublesome when 
immunoblotting, is the abundance of proteases contained within neutrophils. Whilst these 
are undoubtedly necessary for the neutrophils vital immuno-defensive function they are 
exceedingly difficult to fully inhibit when producing lysates, even when a broad spectrum 
of proteases are employed. As one focus of this thesis was anti-apoptotic proteins, this was 
of particular concern as survival proteins such as Mcl-1 have a very short half life and are 
rapidly turned over, therefore extremely vulnerable to degradation by the proteases. Every 
possible step was taken to ensure the proteases were fully inhibited. However, this may 
help explain, at least in part, the lack of conclusive results when immunoblotting for X-
IAP.  
 
The human promyelocytic leukemia cell line (HL60) established in 1977 resembles 
promyelocytes and can be stimulated to differentiate into granulocyte type cells by 
compounds such as DMSO, retinoic acid and actinomycin D (Birnie, 1988). HL60 cells 
have been widely used as an alternative to primary neutrophils in numerous previous 
studies as they possess benefits such as being a homogenous pool therefore avoiding donor 
variations and, furthermore, inhibition of proteases may prove easier. However, our 
laboratory feels that they are not an ideal alternative for studying the role of the neutrophil 
in inflammation. This is because they are derived from a cancerous cell line and therefore it 
is highly likely that some of the cellular pathways/genes expression profiles will differ from 
wild type cells, especially those involved in apoptosis as cancer cells are immortal. 
Subsequently extrapolation of results to normally functioning cells would be tentative; this 
view is supported by Itoh K et al who, in 1998, demonstrated differential expression of 
genes between HL60 cells and granulocytes (Itoh et al., 1998).  
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5.3 Future Directions 
 
Since the completion of the work reported in this thesis, our laboratory has confirmed and 
further investigated the effects and mechanisms of action of R-roscovitine. Data has been 
produced supporting the proposition in this thesis that R-roscovitine can overcome the 
presence of numerous survival factors, not just GM-CSF, to induce reduction of Mcl-1 
protein. These include TNF- , LPS and dbcAMP. Interestingly, R-roscovitine induced 
reduction of the Mcl-1 protein in the presence of survival factors is more marked than when 
neutrophils are incubated with R-roscovitine alone (Leitch et al., 2010). Furthermore, R-
roscovitine has been found to have only a small effect on ERK phosphorylation in 
neutrophils (Leitch et al., 2010). This is despite reports that R-roscovitine can inhibit ERK 
(Bach et al., 2005). Our laboratory believes that R-roscovitine induces apoptosis at a 
downstream location within the neutrophil with suitable strength to over-come the 
increased survival associated with events upstream, such as activation of survival pathways 
by inflammatory mediators. The observation in this thesis that the reduction of Mcl-1 
protein levels is an important step in the induction of neutrophil apoptosis by R-roscovitine 
is in keeping with this hypothesis. A future direction for this thesis (as noted below) was to 
investigate the effect of R-roscovitine on Mcl-1 transcription and this has since been 
progressed by our laboratory. It has been found that R-roscovitine reduced Mcl-1 mRNA 
and this decrease can be seen in as little as 2 h post treatment. Therefore, it can be 
concluded that R-roscovitine is influencing transcription of the Mcl-1 gene and that the 
decrease in the Mcl-1 protein observed in this thesis is a consequence of this. In addition 
the potential use of R-roscovitine as an anti-inflammatory agent that aides resolution of 
neutrophilic inflammation has been confirmed in our laboratory through the use of murine 
models of arthritis, lung fibrosis and pleurisy, in which therapeutic benefits associated with 
an increase of neutrophil apoptosis were observed (Rossi et al., 2006).  
 
Furthermore, others have shown that neutrophil induced apoptosis by CDKis can be 
beneficial in multiple disease models. For example, in vivo work on murine models of 
pneumococcal infection has found that induction of neutrophil apoptosis by R-roscovitine 
in combination with antibiotic treatment improves resolution of inflammation and recovery 
 160 
from meningitis (Koedel et al., 2009). This highlights the potential benefits of a double 
pronged approach to the treatment of inflammatory diseases in which additional agents 
such as steroids or antibiotics could be used to tailor the actions of CDKis to the specific 
needs of the disease. In addition, R-roscovitine has also been found to induce apoptosis in 
neutrophils from cystic fibrosis patients, a condition characterised by neutrophil dominant 
inflammation driven by powerful CF associated mediators, portraying that R-roscovitine 
can overcome neutrophil induced survival by a plethora of inflammatory mediators, not just 
those reported in this thesis (Moriceau et al., 2010).   
 
It is not just our knowledge regarding the anti-inflammatory effects of CDKis that has 
increased over the past few years; exciting advances have also been made in the techniques 
available to study inflammatory responses. One of the most prevalent advances made is the 
zebrafish model of neutrophilic inflammation which allows the inflammatory response to 
be followed from start to finish. Renshaw et al. devised a model in transgenic zebrafish 
using the myloperoxidase promoter to produce GFP, therefore enabling neutrophils to be 
tracked. This model has been successfully used to portray R-roscovitine induced neutrophil 
apoptosis and subsequent resolution of inflammation (Loynes et al., 2010).  
 
We are also discovering that the anti-inflammatory benefits of R-roscovitine are not limited 
to the induction of neutrophil apoptosis. A current lead being pursued within the laboratory 
is the observed decrease in production of cytokines induced by CDKis in human 
macrophages (data unpublished); this falls in line with observations made by various other 
groups who have reported the anti-inflammatory benefits of CDKis in cells such as the 
macrophages. For example Lloberas and Celada have shown that p21 can act as a negative 
regulator of macrophage activation (Lloberas and Celada, 2009). Another area of research 
in which CDKis have been implicated in the inflammatory response in ways other than an 
increase neutrophil apoptosis is rheumatoid arthritis. Sekine et al. found that flavopiridol 
and a specific CDK4,6 inhibitor could alleviate rheumatoid arthritis in various models by a 
lymphocyte independent mechanism which reduces fibroblast growth and proliferation 
(Sekine et al., 2008). In addition a notable paper has been produced by Schmerwitz et al. 
who found that flavopiridol (a non-specific CDKi) targets endothelial cells inhibiting 
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expression of ICAM-1, vascular cell adhesion molecule-1 (VCAM-1) and E-selectin. This 
has important anti-inflammatory implications as the above factors are necessary for the 
successful migration of neutrophils to sites of inflammation. Furthermore, they found NF-
B dependent transcription was blocked. The latter finding is of particular interest as they 
found p65 translocation, degradation and phosphorylation of I B , and the ability of NF-
B to bind to DNA to be unaffected (Schmerwitz et al., 2011). This is significant as one of 
the observations in this thesis was that R-roscovitine did not affect degradation of I B  or 
the translocation of p65 to the nucleus, therefore did not appear to be having a direct effect 
on NF- B signalling. However, this could indicate that NF- B dependent transcription 
could still be being prevented by R-roscovitine. They elucidated through use of a kinome 
array and kinase activity panel, followed by subsequent inhibition of the identified kinases, 
that flavopiridol was causing the above effects through inhibition of CDK9 (Schmerwitz et 
al., 2011). Interestingly CDK9 is also present in neutrophils and within the specificity of R-
roscovitine. 
 
In summary, all of the above findings highlight the importance of further research into the 
anti-inflammatory capabilities of CDKis such as R-roscovitine. 
 
If time constraints were not present the experiments presented in this thesis would be 
progressed in the following ways: 
 
• Real Time (rt)PCR would be used to investigate expression of survival proteins 
such as Mcl-1 and X-IAP at the level of translation in neutrophils treated with R-
roscovitine. 
 
In this thesis the effects of R-roscovitine on Mcl-1 and X-IAP expression has been 
examined at a translational level. In order to establish if the decrease in Mcl-1 protein 
observed upon neutrophil treatment with R-roscovitine is a consequence of R-roscovitine 
reducing the amount of Mcl-1 mRNA transcribed (rt)PCR would be used thereby allowing 
the transcribed levels of Mcl-1 mRNA to be quantified.  
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It is highly likely that a reduction of Mcl-1 at the translational level would be evident as 
CDK 7 and CDK 9 are required for phosphorylation of the carboxyl-terminal domain of 
RNA Pol II. This is important for the binding of transcription factors and for the 
modification of mRNA (such as splicing and capping), thus perturbation of these essential 
phosphorylations would lead to inhibition of RNA synthesis and thus a decrease in cellular 
levels of the protein which it is translated into. This would have particular impact on 
proteins which are subject to rapid turn over, such as Mcl-1 which has a notably short half 
life for both its mRNA and protein. Given that CDKs 1, 2, 5, 7 and 9 fall within the 
inhibitory range of R-roscovitine it is probable that in cells exposed to this trisubstituded 
purine analogue transcription by RNA Pol II will be disrupted (MacCallum et al., 2005). As 
mentioned above this has since been confirmed by our laboratory; Leitch et al. 
demonstrated in 2010 that Mcl-1 mRNA is reduced by R-roscovitine in just 2 h, therefore 
supporting our hypothesis that a reduction of Mcl-1 is evident before the onset of apoptosis 
and thus is a causative factor in its initiation (Leitch et al., 2010).  
 
• Further investigation into the specific roles of CDK7 and CDK 9 in human 
neutrophils. 
 
The previous implication that R-roscovitine could be inhibiting CDK7 and CDK9 
phosphorylation of RNA pol II would be further investigated by Western Blotting and 
Confocal Microscopy to see if this could be a causative factor in the reduction of Mcl-1 
observed in primary human neutrophils treated with R-roscovitine. In light of the work 
produced by Schmerwitz et al. a kinome assay and kinase activity screen of the neutrophil 
to produce the protein kinases present in the neutrophils genome would also be a beneficial 
exercise. This would allow, through subsequent inhibition of the kinases in the kinome, 
identification of the kinase target of R-roscovitine in human neutrophils.  
 




This would be performed due to the discovery by Schmerwitz et al that Flavopiridol was 
inhibiting NF-kB dependent transcription in endothelial cells in the absence of I B  
degradation and whilst mobilisation of p65 was still evident. This could potentially be due 
to inhibition of CDK9 and again a kinome screen/kinase inhibition approach would help 
determine if this was the case. 
 
• Experiments would be repeated in eosinophils to see if R-roscovitine exhibits a 
similar profile of effects to those it elicits in the neutrophil. 
 
Exploration of the effects of R-roscovitine on eosinophil apoptosis would be used to try and 
establish similarities and differences in the regulation of the two granulocytes which may 
ultimately have the potential to be exploited for therapeutic gain. Our laboratory has 
recently demonstrated that R-roscovitine does indeed induce eosinophil apoptosis in a 
concentration and time dependent manner and that, as with neutrophils, there is a reduction 
in Mcl-1 levels prior to the onset of apoptosis (Duffin et al., 2009). This has promising 
implications for the potential use of R-roscovitine as a novel treatment to aid resolution of 
eosinophil driven inflammation. 
 
• Treatment of neutrophils with the R-roscovitine metabolite in which the hydroxyl-
group at C2 has been converted to carboxylic acid. 
 
Vita M. et al in 2005 demonstrated that rats administered intravenous R-roscovitine 
(14.12μM) metabolise and eliminate it from the plasma and tissue in less than 30 min. 
Three metabolites were observed, of these three the main one found in plasma was termed 
M1 where the hydroxyl-group at C2 has been converted to carboxylic acid. The other two 
were mainly observed in the liver, kidneys and several other organs. It is possible 
neutrophils may be converting R-roscovitine into a metabolite such as M1 and that this 
could potentially be triggering apoptosis. High performance liquid chromatography could 
be used to identify any metabolites produced within neutrophils (Vita et al., 2005). 
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• Use of a protein transduction domain to introduce survival proteins such as Mcl-1 
and X-IAP into neutrophils and observe effects of R-roscovitine.  
 
As R-roscovitine could be inhibiting the transactivation function of HIV-tat proteins which 
requires CDK9 and T1 (Canduri et al., 2008) a different method of protein transduction 
should be attempted, ideally one which can be produced in a non bacterial vector to prevent 
LPS contamination. A potential alternative method of transduction is by lentivirus, Dick et 
al. have successfully and reliably transfected primary human neutrophils with a range of 
constructs via lenivirus, including GFP-fusion proteins (Dick et al., 2009). This would 
enable us to introduce X-IAP-GFP proteins into neutrophils and allow us to locate and 
quantify the tagged protein.  
 
• Investigate the presence of Mcl-1S and its pro-apoptotic role in neutrophil apoptosis, 
and if this is augmented by the presence of R-roscovitine. 
 
This would be performed to help us elicit if it is in fact the pro-apoptotic Mcl-1S splice 
variant (Bingle et al., 2000) that is involved in the rapid induction of apoptosis by R-
roscovitine in neutrophils. It would also enable us to see if there is a preferential Mcl-1 
target for R-roscovitine. 
 
5.4 Concluding Remarks 
 
In conclusion this thesis has confirmed the hypothesis that CDKis such as R-roscovitine 
can efficaciously induce apoptosis in human neutrophils through regulation of critical 
survival proteins, and has identified Mcl-1 as a key player in this process. Furthermore it 
has demonstrated promising results for the tolerability of R-roscovitine as a potential novel 
treatment for human inflammatory conditions arising from neutrophillic inflammation.  
This supports the long-term aim of this thesis, and our laboratory, to take R-roscovitine to 
clinical trial as a potential new therapy for neutrophil dominant inflammatory disorders, 
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Publications arising from this thesis 
Cyclin-dependent kinase inhibitors enhance the
resolution of inflammation by promoting
inflammatory cell apoptosis
Adriano G Rossi1, Deborah A Sawatzky1,3, Annemieke Walker1,3, Carol Ward1, Tara A Sheldrake1,
Nicola A Riley1, Alison Caldicott1, Magdalena Martinez-Losa1, Trevor R Walker1, Rodger Duffin1,
Mohini Gray1, Elvira Crescenzi2, Morag C Martin1, Hugh J Brady2, John S Savill1, Ian Dransfield1 &
Christopher Haslett1
Apoptosis is essential for clearance of potentially injurious inflammatory cells and subsequent efficient resolution of inflammation.
Here we report that human neutrophils contain functionally active cyclin-dependent kinases (CDKs), and that structurally diverse
CDK inhibitors induce caspase-dependent apoptosis and override powerful anti-apoptosis signals from survival factors such as
granulocyte–macrophage colony-stimulating factor (GM-CSF). We show that the CDK inhibitor R-roscovitine (Seliciclib or CYC202)
markedly enhances resolution of established neutrophil-dependent inflammation in carrageenan-elicited acute pleurisy, bleomycin-
induced lung injury, and passively induced arthritis in mice. In the pleurisy model, the caspase inhibitor zVAD-fmk prevents
R-roscovitine–enhanced resolution of inflammation, indicating that this CDK inhibitor augments inflammatory cell apoptosis.
We also provide evidence that R-roscovitine promotes apoptosis by reducing concentrations of the anti-apoptotic protein Mcl-1.
Thus, CDK inhibitors enhance the resolution of established inflammation by promoting apoptosis of inflammatory cells, thereby
demonstrating a hitherto unrecognized potential for the treatment of inflammatory disorders.
Neutrophils have a central role in innate immunity and are rapidly
recruited to sites of infection and injury; however, their many defense
mechanisms that destroy and digest invading microorganisms
are potentially deleterious to tissues1. Thus, it is vital that, once
their physiological function has been achieved, these inflammatory
cells and their potentially histotoxic contents are cleared rapidly.
During spontaneous resolution of inflammation, neutrophils undergo
apoptosis: a pre-programmed and highly regulated cell death process
that results in shutdown of secretory capacity and allows recognition
and removal by macrophages2,3. Neutrophil survival and apoptosis are
profoundly influenced by the inflammatory milieu: inflammatory
mediators such as GM-CSF or lipopolysaccharide (LPS), environ-
mental conditions such as hypoxia, and the presence of pro-apoptotic
stimuli such as tumor necrosis factor-a or Fas ligand markedly alter
neutrophil longevity4,5.
Neutrophil apoptosis is controlled by a complex network of signal-
ing pathways that regulate both the turnover of key molecules,
including the anti-apoptotic protein myeloid cell leukemia 1 (Mcl-1)
and the pro-apoptotic Bcl-2 family member Bax, and activation of the
caspase family of proteases5. Once apoptosis has been engaged, the
neutrophil secretory activity is shutdown; the cells remain intact and
are phagocytosed by macrophages using recognition mechanisms that
fail to elicit a pro-inflammatory response2,6. If macrophage phago-
cytosis or neutrophil apoptosis is impaired, however, chronic inflam-
mation may ensue4,5,7. Consequently, the mechanisms involved in
regulating inflammatory cell survival and apoptosis are the subject of
considerable research endeavor.
Cell division of eukaryotic cells occurs in four phases (G1, S, G2, M)
and in some circumstances, for example where growth factors are
withdrawn or the cell is terminally differentiated, the cell will rest
in G0 phase. The CDKs have been traditionally described as key
regulators of the cell cycle, whereby different CDKs become activated
during cell-cycle progression when complexed with their associated
cyclin partners8. For this reason, targeting CDKs by specific inhibitors
may prevent or limit tumor progression. Indeed, CDK inhibitors are
under clinical trial for esophageal, lung, prostate and non-small-cell
lung cancers9. In contrast, inhibition of CDKs attenuates apoptosis of
terminally differentiated neurons10. The precise mechanisms that
determine the effects of CDK inhibitors on apoptosis remain unclear,
although these inhibitors downregulate Mcl-1 (refs. 11,12), a key
protein regulating apoptosis13 including neutrophil apoptosis14. Neu-
trophils are terminally differentiated cells and therefore CDK inhibi-
tors such as R-roscovitine would be predicted either to have no effect
or, as in neurons, to inhibit apoptosis10.
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Here we have investigated whether CDK inhibitors can influence
neutrophil apoptosis in vitro and consequently the resolution of
neutrophilic inflammation in vivo. We show that human neutrophils
express functional CDKs and that different CDK inhibitors directly
induce caspase-dependent neutrophil apoptosis and inhibit cell
survival induced by several biologically important powerful anti-
apoptotic agents. We also show that the CDK inhibitor R-roscovitine
downregulates Mcl-1 expression induced by survival factors in neu-
trophils. In addition, we demonstrate in vivo that R-roscovitine
markedly enhances resolution of inflammation in mouse models
of carrageenan-induced acute pleurisy, bleomycin-induced lung
inflammation and passively induced arthritis. The R-roscovitine–
enhanced resolution of established pleurisy is driven by a caspase-
mediated pro-apoptotic effect. These findings suggest that CDK
inhibitors may provide a therapeutic strategy to promote resolution
of inflammatory diseases.
RESULTS
CDK inhibitors induce human neutrophil apoptosis
To investigate whether CDK inhibitors can affect apoptosis directly,
human neutrophils were incubated over a 20-h period with the
structurally diverse CDK inhibitors R-roscovitine15–17, NG75 (refs.
18,19) and hymenialdisine20,21 at a range of concentrations similar to
those known to inhibit CDKs specifically15–21. The CDK inhibitors
markedly increased neutrophil apoptosis in a concentration-
dependent (Fig. 1a) and time-dependent (Fig. 1b) manner. After 8 h
of NG75 treatment, a marked increase in annexin-V-positive cells was
observed (Fig. 1c–e); after prolonged treatment (20 h), an increased
number of annexin-V- and propidium iodide (PI)-positive cells
(indicating secondary necrosis) were present and these cells could be
identified morphologically by their nuclear loss and ruffled plasma
membrane (Fig. 1e). Similar profiles were seen with R-roscovitine and
hymenialdisine treatment, and all annexin-V binding data was con-
firmed by morphological assessment of apoptosis (data not shown).
In a time-course study, R-roscovitine (20 mM) and NG75 (10 mM)
increased the rate of apoptosis after 8 h, whereas 10 mM hymenialdi-
sine did not increase apoptosis above the control rate (Fig. 1b).
We deliberately used hymenialdisine at 10 mM, a concentration that
did not affect apoptosis per se, because subsequently we wanted to test
the effect of the CDK inhibitor on delayed apoptosis induced by
survival factors (see below). Systematic study of its cellular targets
has shown that R-roscovitine has high specificity for CDK1,
CDK2 and CDK5, but not for other kinases including CDK4 and
CDK6 (refs. 15–17); in addition, both NG75 (refs. 18,19) and
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Figure 1 Effects of CDK inhibitors on human neutrophil apoptosis. (a) Different CDK inhibitors
induce concentration-dependent apoptosis of neutrophils. Human neutrophils (5  106 cells/ml)
were incubated for 20 h with increasing concentrations of R-roscovitine, NG75 or hymenialdisine (HD).
Apoptosis was assessed by annexin-V–FITC binding and confirmed by morphology. Data represent
the mean ± s.e.m. (n Z 3). **P o 0.01 versus control. (b) Different CDK inhibitors induce time-
dependent apoptosis of neutrophils. Human neutrophils (5  106 cells/ml) were incubated over
20 h with 20 mM R-roscovitine, 10 mM NG75 or 10 mM hymenialdisine. Apoptosis was assessed
as in a (n Z 3). *P o 0.05, **P o 0.01 versus control. (c–e) The CDK inhibitor NG75 enhances
annexin-V binding and induces morphological changes indicative of neutrophil apoptosis. Left,
flow cytometry dot plots of NG75-treated neutrophils, taken at 0 h (c), 8 h (d) and 20 h (e).
Non-apoptotic cells are shown in gray, annexin-V–FITC+ cells in green, and annexin-V+/PI+ cells in
red. Right, corresponding micrographs. In c, typical neutrophil morphology of multi-lobed nuclei is
seen. In d, arrow indicates typically apoptotic neutrophil morphology, showing condensed nuclei. In e, arrow indicates apoptotic neutrophil without nuclear
staining and the cell membrane appears ‘leaky’. This type of morphology may account for the annexin-V+/PI+ cells seen by flow cytometry at 20 h. (f–h) CDK
inhibitors reverse dbcAMP-, GM-CSF– and LPS-mediated survival of neutrophils. Human neutrophils (5  106 cells/ml) were pre-incubated with 0.2 mM
dbcAMP, 50 U/ml of GM-CSF or 1 mg/ml of LPS as indicated for 30 min. Appropriate concentrations of R-roscovitine (f), NG75 (g) or hymenialdisine (h)
were then added and the cells were incubated for a further 20 h. Apoptosis was assessed as in a (n Z 3). #P o 0.05 versus control. *P o 0.05, **P o
0.01 versus control of relevant survival agent.
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hymenialdisine20,21 have high specificity for the same CDKs. The
crystal structure of human CDK2 complexed with R-roscovitine has
been described, together with evidence showing that the R stereo-
isomer of roscovitine is slightly more potent at inhibiting purified
CDK1/cyclin B activity than is the S stereoisomer (half-maximal
inhibitory concentrations of 0.45 mM and 0.95 mM, respectively15).
Our own studies with the stereoisomers used at 20 mM showed that
apoptosis after 6 h was 12.4 ± 0.4% for the control, 12.8 ± 1.3% for
the dimethyl sulfoxide (DMSO; 0.04%) control, 75.9 ± 3.5% for R-
roscovitine and 75.6 ± 3.3% for S-roscovitine (mean ± s.e.m.; n ¼ 4
separate donors, done in triplicate).
CDK inhibitors overcome survival factor delay of apoptosis
Because these CDK inhibitors accelerated apoptosis, we investigated
whether they reversed the effects of agents that delay neutrophil
apoptosis through different signaling pathways5. For example, dbcAMP
penetrates the cell membrane to mimic endogenous cAMP22; GM-CSF
acts through the GM-CSF receptor to activate phosphatidylinositol
3-kinase (PI3K), Janus kinase 2 and the transcription factor STAT1
(ref. 5); and LPS binds to Toll-like receptor-4 to activate mitogen-
activation kinase (MAPK), PI3K and NF-kB signaling to inhibit
apoptosis5,23–26. In addition, LPS-induced delay of neutrophil apop-
tosis is also dependent on contaminating monocytes25,26. The CDK
inhibitors overrode all of these survival signals in a concentration-
dependent manner (Fig. 1f–h) without directly inducing apoptosis
per se (see 10 mM hymenialdisine data). Thus, overriding of survival
signals by CDK inhibitors occurs independently of, or is more
sensitive to, direct effects of the inhibitors on apoptosis and takes
place irrespective of the signaling pathways triggered in neutrophils.
CDK inhibitors induce caspase-dependent apoptosis
We found that CDK inhibitor–induced apoptosis was caspase depen-
dent because pre-incubating neutrophils with the broad-
range caspase inhibitor zVAD-fmk prevented R-roscovitine–induced
apoptosis (Fig. 2a). R-Roscovitine treatment resulted in caspase-3
cleavage, directly verifying that this CDK inhibitor activates
caspases in neutrophils (Fig. 2b). In addition, we found that
R-roscovitine–induced caspase-3 cleavage was attenuated by the
pro-survival factor GM-CSF (Fig. 2b), probably because of competing
pro- and anti-apoptotic pathways. At the early time point of 4 h,
the rate of basal apoptosis was low (o5%; Fig. 1b) and consequently
caspase-3 cleavage was minimal (Fig. 2b); however, caspase-3
cleavage was already very evident at 4 h when the neutrophils were
treated with R-roscovitine alone. At 20 h, the pro-apoptotic effect
of R-roscovitine was dominant over survival factor–mediated
effects (Fig. 1f).
Human neutrophils express functionally active CDKs
Because neutrophils are terminally differentiated and do not undergo
cell division, little is known about CDKs and their associated partners
in these cells. CDK1 and CDK2 were found to be present in
neutrophils (Fig. 2b,c) and there was no difference in CDK protein
Figure 2 CDK protein and activity in neutrophils
and mechanisms governing the pro-apoptotic
effect of CDK inhibitors. (a) The caspase inhibitor
zVAD-fmk inhibits R-roscovitine–induced
apoptosis of neutrophils. Human neutrophils
(5  106 cells/ml) were incubated for 6 h with
R-roscovitine (20 mM) with or without zVAD-fmk
(100 mM). Apoptosis was assessed as in Fig. 1a
(n ¼ 4). *P o 0.05 versus control. (b) CDK1
and CDK2 proteins are expressed in neutrophils
and R-roscovitine induces caspase cleavage in
neutrophils. Human neutrophils (5  106 cells/
ml) were lysed after isolation (0 h) or after
treatment (4 h) with buffer, GM-CSF (50 ng/ml),
R-roscovitine (20 mM), or GM-CSF (50 ng/ml)
plus R-roscovitine (20 mM). Proteins were
subjected to western blotting with antibodies
to caspase 3, CDK1, CDK2 or b-actin. Blots
are representative of at least three separate
experiments. (c) CDK1 and CDK2 protein
expression does not change during neutrophil
apoptosis. Human neutrophils (5  106 cells/ml)
were lysed after isolation (0 h) or after treatment
(20 h) with buffer, GM-CSF (50 U/ml) or
gliotoxin (0.1 mg/ml). Proteins were subjected
to western blotting with antibodies to CDK1 or
CDK2. Blots are representative of at least three
separate experiments. (d,e) CDK1 activity is
present in neutrophils and decreases after
apoptosis induced by the activating antibody to
Fas (CH11). Neutrophils (5  106 cells/ml) were
treated with CH11 (500 ng/ml) for the indicated
times. Subsequently, 107 cells were lysed for
each sample, the lysate was incubated with antibody to CDK1, and CDK1 activity was measured by 32P transfer to histone H1 (d,e). Apoptosis
(annexin-V+/PI+) (e) and CDK1 activity (d,e) were measured every 2 h over 8 h. CDK1 activity was detected at time 0 and at 2 h, but not at later time
points as apoptosis increased (d,e). Again, no difference in CDK1 expression was detected over time (d). Results are representative of at least three separate
experiments. (f) R-Roscovitine reduces survival factor–induced Mcl-1 protein expression in neutrophils. Human neutrophils (5  106 cells/ml) were treated
with buffer, GM-CSF (50 ng/ml), R-roscovitine (20 mM), or GM-CSF (50 ng/ml) plus R-roscovitine (20 mM) for 2 h. After cell lysis, proteins were subjected to
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quantities in freshly isolated neutrophils, aged neutrophils (4 h), or
neutrophils treated with GM-CSF, R-roscovitine or both (4 h). Even
when neutrophils were incubated for 20 h with buffer or GM-CSF, or
when apoptosis was induced with gliotoxin23, the quantities of CDKs
did not change (Fig. 2c). Thus, although CDKs seem to be important
for inducing apoptosis, CDK1 and CDK2 are not targets for degrada-
tion during apoptosis.
In other cell systems, CDK1 and CDK2 have been shown to bind to
various cyclin subtypes, whereas CDK5 does not seem to bind to
cyclins but is activated by the non-cyclin p35 and p39 regulatory
proteins. Because R-roscovitine can also inhibit CDK5
(ref. 16), we verified that CDK5 is expressed in human neutrophils
(data not shown), in agreement with a previous study27 that demon-
strated the presence of CDK5 mRNA and protein. CDK1 (Fig. 2d,e),
CDK2 (not shown) and CDK5 (ref. 27) activity has been shown in
neutrophils. We found that CDK1 activity in neutrophils decreased
rapidly during apoptosis induced by the activating Fas antibody CH11
(Fig. 2e). The CDK-binding partners and regulatory proteins in
neutrophils remain to be identified.
CDK inhibitors reduce neutrophil Mcl-1 expression
We further probed the effect of R-roscovitine on the expression of a
key regulator of apoptosis, Mcl-1(refs. 13,14), and found that Mcl-1
quantities in isolated cells fell rapidly within 2 h of culture, an effect
that was prevented by GM-CSF treatment. R-Roscovitine inhibited
GM-CSF–mediated upregulation of Mcl-1 (Fig. 2f).
Roscovitine-induced apoptosis enhances inflammatory resolution
Having shown in vitro that neutrophil apoptosis was markedly
influenced by CDK inhibitors, we determined the effects of
R-roscovitine on the resolution of neutrophil-dominant inflammation
in vivo. We used a well-established acute resolving mouse model
of carrageenan-induced pleural inflammation28–31 to assess the
effects of the CDK inhibitor on the kinetics of inflammatory
cell recruitment and to investigate inflammatory mechanisms.
R-Roscovitine accelerated the resolution of established inflammation
when administered intraperitoneally (i.p.) 24 h after intrapleural
injection of 1% carrageenan (Fig. 3). Thus, treatment with 10 mg
per kg body weight of R-roscovitine (i.p.) inhibited the total
inflammatory cell number by more than 50% as compared with
vehicle control (Fig. 3a), and also reduced the number of monocytes/
macrophages and neutrophils (Fig. 3b). Of note, R-roscovitine
at 100 mg per kg reduced the inflammatory cells to near basal
numbers normally found in the naive mouse pleural cavity.
Anti-inflammatory effects of R-roscovitine were also evident because
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Figure 3 Effect of the CDK inhibitor R-roscovitine on resolution of carrageenan-
induced pleurisy. (a–c) R-Roscovitine dose-dependently promotes resolution
of inflammation in vivo. Twenty-four hours after intrapleural injection of 1%
carrageenan, male C57/bl6 mice were treated with saline, DMSO, or 10 or
100 mg per kg body weight (mg/kg) of R-roscovitine (i.p.). Mice were killed
36 h after carrageenan injection and the total pleural inflammatory cell
numbers (a), mononuclear (Mono/Mf) and polymorphonuclear cell (PMNs)
numbers (b) and exudate volumes (c) were measured. Data represent the mean
± s.e.m. (n ¼ 8–10 mice per group). **P o 0.01 and ***P o 0.001 versus
DMSO control. (d–f) R-Roscovitine reduces pro-inflammatory cytokines in vivo.
Mice were treated as in a–c, and IL-6 (d), IFN-g (e) and MCP-1 (f) were
measured in pleural exudates with a cytokine bead assay (n ¼ 8–10 mice
per group). **P o 0.01 and ***P o 0.001 versus DMSO control. (g) R-
Roscovitine promotes resolution of inflammation in vivo in a time-dependent
manner. Twenty-four hours after intrapleural injection of 1% carrageenan, male C57/bl6 mice were treated with vehicle control (DMSO) or 100 mg per kg
body weight of R-roscovitine (i.p.). Mice were killed 24 h, 48 h or 168 h after carrageenan injection and the total pleural inflammatory cell numbers were
determined (n ¼ 5–6 mice per group). **P o 0.01 and ***P o 0.001 versus DMSO control.
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washouts) decreased markedly with R-roscovitine treatment as
compared with saline control (*P o 0.05; Fig. 3c). In parallel, release
of the pro-inflammatory mediators IL-6 (Fig. 3d), IFN-g (Fig. 3e)
and MCP-1 (Fig. 3f) in the exudate was also diminished
by R-roscovitine.
We next determined the effect, over a period of 7 d, of adminis-
tering R-roscovitine (100 mg per kg i.p.) at the peak of inflammation
(24 h). We observed a reduction in total cell numbers in the pleural
cavity at all time points (Fig. 3g) and in neutrophil and monocytes/
macrophages numbers at 36 h after carrageenan injection (Fig. 3a,b),
providing further evidence that this CDK inhibitor enhances inflam-
matory resolution. Because R-roscovitine induced caspase-dependent
apoptosis of human neutrophils in vitro (Fig. 2a,b), we established
whether the enhanced resolution of inflammation by R-roscovitine
was mediated by a similar induction of caspase-dependent
inflammatory cell apoptosis in vivo. Systemic administration of
the broad-spectrum caspase inhibitor zVAD-fmk prevented the
R-roscovitine–induced decrease in inflammatory cells and edema
formation in the pleural cavity in carrageenan-induced pleural
inflammation (Fig. 4). Administration of zVAD-fmk prevented the
resolution of inflammation in vivo by increasing the total inflamma-
tory cell number (Fig. 4a) and edema formation (Fig. 4b) as
compared with saline or vehicle controls. In addition, the increase
in inflammatory cell apoptosis (Fig. 4c) and macrophages containing
apoptotic bodies (see Fig. 4d,e) observed with R-roscovitine treatment
in the pleural cavity was inhibited markedly by treatment with zVAD-
fmk. We also noted that lungs of mice treated intrapleurally with
carrageenan had a consequent marked inflammatory infiltrate
(Fig. 4f), which was reduced by R-roscovitine treatment (Fig. 4g).
Roscovitine enhances inflammatory resolution in other models
The anti-inflammatory and pro-resolving effects of R-roscovitine were
further confirmed in another two inflammatory models. In the
bleomycin-induced lung injury model, R-roscovitine (100 mg per kg
i.p.), given after inflammation was established, reduced the total
number of neutrophils in the bronchoalveolar fluid 3 d after bleomy-
cin administration (**P o 0.01; Fig. 5a). Histological examination
showed that, when bleomycin-induced lung injury was allowed to
persist for 7 d, R-roscovitine reduced bleomycin-induced inflamma-
tion (Fig. 5b–d). R-Roscovitine, when administered with the sham
intratracheal saline control, had no obvious detrimental effects on the
lung pathology (Fig. 5b). R-Roscovitine also reduced bleomycin-
induced lethality (3 out of 8 mice treated with bleomycin alone died
by day 12, as compared with none of the R-roscovitine- and bleo-
mycin-treated mice). In addition, in a model of passively induced
arthritis, we observed that arthritis, as assessed by clinical scores,
resolved more quickly in R-roscovitine–treated than in control
mice (Fig. 5e).
DISCUSSION
Specific induction of inflammatory cell apoptosis represents a








































































































































































Figure 4 Role of caspase-dependent apoptosis in R-roscovitine–enhanced resolution of carrageenan-induced pleurisy. (a,b) The caspase inhibitor zVAD-fmk
prevents R-roscovitine–induced resolution of carrageenan-induced inflammation. Twenty-four hours after intrapleural injection of 1% carrageenan, male
C57/bl6 mice were treated with 10 mg per kg of R-roscovitine (i.p.) and/or 5 mg per kg of zVAD-fmk (i.p. at 4-h intervals). Mice were killed 36 h after
carrageenan injection and total pleural inflammatory cell numbers (a) and exudate volumes (b) were measured. Data represent the mean ± s.e.m.
(8–10 mice per group). *P o 0.05, **P o 0.01 and ***P o 0.001 versus DMSO control. (c) zVAD-fmk prevents apoptosis during R-roscovitine–induced
resolution of carrageenan-induced inflammation. Mice were treated as in a,b, and apoptosis was analyzed in pleural inflammatory cells by annexin-V labeling
and flow cytometry (n ¼ 8–10 mice per group). *P o 0.05 versus DMSO control. Inflammatory cell apoptosis was also assessed by morphology using
cyto-centrifuge preparations stained with hematoxylin and eosin. (d–g) R-Roscovitine reduces inflammation in pleural lavage exudates and lung tissue, and
decreases the numbers of macrophages containing apoptotic bodies in pleural lavage. Twenty four hours after intrapleural injection of 1% carrageenan,
male C57/bl6 mice were treated i.p. with vehicle control (d,f) or 100 mg per kg of R-roscovitine (e,g). Mice were killed 36 h after carrageenan injection.
Cyto-centrifuge preparations stained with hematoxylin and eosin (d,e) and tissue sections of pleural lavage and lungs (f,g) were assessed morphologically
by microscopy (original magnification 40). Asterisks indicate viable neutrophils (d); arrows indicate phagocytosed apoptotic neutrophils (e).
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coordinated cascade of events that follows inflammatory insult is
highly regulated from onset to resolution through checkpoints that
control cell migration, infiltration and survival and perpetuation
of the inflammatory response. Migratory cells either die in a
pre-programmed manner through apoptosis or may persist in situ
in a potentially detrimental manner to promote tissue destruction by
continued excessive secretory activity or through the consequences of
cell death by secondary necrosis. The ingestion of apoptotic cells
by inflammatory macrophages also promotes the synthesis and release
of mediators with anti-inflammatory properties (such as TGF-b1
and IL-10)4,5. CDKs are essential cell signaling proteins that tradi-
tionally have been thought to control exclusively the fate of prolifer-
ating cells, in which CDK dysfunction is probably involved in
increased cell turnover and tumor progression. Current therapies
aimed at inhibiting CDKs are being developed for the treatment of
various cancers.
Our study identifies a mechanism for both accelerating apoptosis of
human neutrophils by CDK inhibitors in vitro and facilitating resolu-
tion of neutrophil-dependent inflammation in vivo. We have shown
that human neutrophils possess CDK1, CDK2 and CDK5, and that
specific inhibitors of CDKs (namely, R-roscovitine, NG75 and hyme-
nialdisine) induce caspase-dependent apoptosis in a time- and con-
centration-dependent manner. The CDK inhibitors induced apoptosis
even in the presence of diverse powerful pro-survival agents (dbcAMP,
GM-CSF and LPS) that retard human neutrophil apoptosis through
distinct molecular mechanisms. Compelling evidence suggests
that contaminating monocytes contribute to LPS-mediated neutro-
phil survival25,26, triggering monocyte synthesis and release of
neutrophil survival factors. Regardless of the precise mechanisms
of LPS action, our data clearly show that the CDK inhibitors
can overcome them. Thus, the ability of CDK inhibitors to override
endogenous pro-survival factors further suggests their potential use
in inflammatory diseases where concentrations of such mediators
are increased.
We found that the expression of CDK1 and CDK2 proteins did not
change during apoptosis, but that treatment of neutrophils with the
pro-apoptotic activating antibody to Fas (CH11) resulted in loss of
CDK1 activity before the onset of apoptosis. By contrast, a previous
study has shown that non-cycling neuronal cells require activation
of CDK for the induction of apoptosis and that CDK inhibitors
can prevent cell death10. Our results suggest that CDK activity is
necessary and fundamental to neutrophil survival. We have also shown
that R-roscovitine–induced apoptosis is caspase dependent and is
associated with a loss of expression of the Bcl-2 family protein
Mcl-1 (ref. 14). The loss of Mcl-1 caused by CDK inhibitors is
probably an important mechanism controlling apoptosis11–13. In
addition, because CDK5 is also a target for R-roscovitine16 and this
CDK has been reported in human neutrophils27, we confirmed that
CDK5 protein is expressed in human neutrophils (data not shown).
Gene array experiments have reported the expression of several CDK
mRNAs, endogenous CDK inhibitors and associated proteins in


























































Figure 5 Effect of R-roscovitine on resolution of bleomycin-induced lung inflammation and
serum-induced arthritis. (a) The total number of neutrophils in the lung is reduced by R-
roscovitine after bleomycin-induced lung inflammation. Mice were given 100 mg per kg of R-
roscovitine (i.p.) 48 h after intratracheal administration of bleomycin. Neutrophil and monocyte/
macrophage (Mono/Mf) numbers were established by differential cell counts obtained from BAL
fluid 3 d after bleomycin administration. Data represent the mean ± s.e.m. (n ¼ 6 mice per
group). **P o 0.01 versus DMSO control. (b–d) R-Roscovitine inhibits inflammation and tissue
damage in a chronic model of bleomycin-induced lung injury. Mice were given 100 mg per kg
of R-roscovitine (i.p.; d) or vehicle control (0.5% DMSO, i.p.; c) 48 h after intratracheal
administration of bleomycin or saline (sham control; b). Seven days after bleomycin treatment,
lung inflammation and histological tissue damage were assessed by morphological examination
(original magnification  40) of formaldehyde-fixed lung sections stained with hematoxylin and
eosin. Images are representative of six mice per group. (e) R-Roscovitine enhances the resolution of passively induced arthritis. Mice (n ¼ 10 in each group)
were injected twice (days 0 and 2) with K/BxN serum derived from arthritic (day 60) K/BxN transgenic mice. Clinical scores were assessed on the days
indicated. Control mice received vehicle (0.5 ml, i.p.) and treated mice received R-roscovitine (0.5 ml, 10 mg per kg, i.p.) on days 3, 5, 7, 9, 11, 13, 15, 17
and 19. Data represent the mean ± s.e.m of the clinical score obtained on day 3 before the first injection of R-roscovitine. ***P o 0.001 by two-way ANOVA.
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We previously showed that inhibiting pro-survival molecules from
the MAPK and Bcl-2 families (namely, ERK1/2 and Bcl-xL) promotes
resolution of inflammation by inducing inflammatory cell apoptosis
in an acute rat model of carrageenan-induced pleurisy, whereas
inhibition of the pro-apoptotic molecule Bax prevents resolution of
inflammation30. We have now shown that R-roscovitine promotes
resolution of inflammation in carrageenan-induced pleurisy in a
dose-dependent manner. R-Roscovitine induced apoptosis in vivo,
as assessed by annexin-V labeling and morphological analysis.
R-Roscovitine also inhibited the release of pro-inflammatory
cytokines, including IL-6, MCP-1 and IFN-g, further supporting its
pro-resolution role. In addition, R-roscovitine, administered at
the peak of inflammation, enhanced the resolution of bleomycin-
induced lung inflammation. This model was used for its clinical
relevance37 and because progression of the marked acute inflamma-
tory response induced by bleomycin leads to chronic inflammation
and fibrosis38,39. Early accumulation of neutrophils in the BAL fluid
and subsequent lung inflammation and injury were attenuated by
R-roscovitine treatment. R-Roscovitine also reduced bleomycin-
induced lethality, indicating that CDK inhibition attenuates prolonged
inflammation, leading to lung damage and consequent death.
R-Roscovitine also caused enhanced inflammatory resolution in
serum-induced arthritis as assessed by improved clinical scores.
Our in vitro work showing that the CDK inhibitors promote
neutrophil apoptosis adds to the evidence indicating that neutrophils
are essential in regulating the inflammatory responses in vivo,
including models of carrageenan-induced pleurisy30, bleomycin
induced-lung injury38,39 and arthritis7. We also showed that inhibition
of apoptosis with zVAD-fmk prevents the enhanced resolution
of inflammation by R-roscovitine in carrageenan-induced pleurisy.
The dosing regime for zVAD-fmk administration is paramount to
elicit an effect in vivo and was based on studies where injections were
administered every 3 h (ref. 40). Notably, R-roscovitine–induced
apoptosis and its anti-inflammatory effects were reversed in vivo by
the caspase inhibitor zVAD-fmk, providing further evidence that
the anti-inflammatory mechanism of the CDK inhibitor is due to
the induction of caspase-dependent inflammatory cell apoptosis.
Although neutrophils are terminally differentiated, evidence indi-
cates that during the early stages of resolution of inflammation they
are capable of phenotypic alteration, switching from a phenotype that
generates pro-inflammatory mediators to one generating mediators
that are anti-inflammatory and/or pro-resolving. For example, neu-
trophils can produce and respond to agents, such as lipoxins and
resolvins, that have anti-inflammatory and pro-resolution proper-
ties41–43. In addition, accelerated resolution of inflammation has been
reported for endogenous lipid mediators such as protectin D1 (ref.
44), suggesting that control of inflammation can be achieved physio-
logically through production of endogenous mediators. Our hypo-
thesis that manipulation of pro-resolution mechanisms can have
profound effects on established inflammation is strongly supported
by data showing that pharmacological manipulation of apoptosis
and/or macrophage clearance can be achieved30,45 and our present
finding that modulation of granulocyte apoptosis with CDK inhibitors
promotes resolution of inflammation.
Thus, systemic administration of a specific inhibitor of CDKs induces
apoptosis of inflammatory cells in situ and promotes inflammatory
resolution. In vivo studies investigating the effect of CDK inhibition in
cancer have shown that systemic administration of R-roscovitine
reduces tumor size46 and that R-roscovitine (even at high doses of
2 g per kg) is well tolerated. It is widely acknowledged that tumor cells
have defective CDK pathways that promote cell proliferation and
prevent cell apoptosis8,9, suggesting that CDK inhibitors specifically
target these pathways to elicit their therapeutic action. Our study has
shown that CDK inhibitors also promote apoptosis in non-proliferating
inflammatory cells in vitro and accelerate inflammatory resolution
by promoting apoptosis and subsequent safe clearance of neutrophils
by macrophages in vivo. In conclusion, given the renewed interest in
the close association between inflammatory processes and cancer47,48
and the potential problems with using monoclonal antibodies and
other biological agents, this newly identified role of the small-molecule
anti-cancer CDK inhibitors may have potential for the treatment of
diseases associated with increased or persistent inflammatory responses.
METHODS
Neutrophil isolation and assessment of apoptosis. We isolated human blood
neutrophils23,49, a process that takes B2 h, and cultured the cells (5  106/ml,
37 1C) in Iscove’s modified Dulbecco’s medium (IMDM) containing 10%
autologous serum. The cells were incubated with the following reagents:
R-roscovitine, (R)-2-[[9-(1-methylethyl)-6-[(phenylmethyl)amino]-9H-purin-
2-yl]amino]-1-butanol (A.G. Scientific); hymenialdisine, 4-(2-amino-4-oxo-2-
imidazolidin-5-ylidene)-2-bromo-4,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one
(from L. Meijer, Roscoff, France); NG75, 2-(1R-isopropyl-2-hydroxyethyl-
amino)-6-(4-metoxy-benzylamino)-9-isopropylpurine (from N. Gray, Univer-
sity of California, Berkeley); db-cAMP (Sigma); GM-CSF (R&D Systems); and
LPS (Escherichia coli 0127:B8, Sigma). We assessed apoptosis by flow cytometry
using annexin-V-conjugated fluorescein isothiocynate (FITC; Roche) in com-
bination with PI (Sigma) and used light microscopy to confirm the presence of
morphological changes characteristic of apoptosis2,23.
Western blotting.We lysed cells (5  106) for 15 min with 0.1% Nonidet P40
in 1 ml of TBS containing a protease inhibitor cocktail23 before centrifugation
(23,100g, 4 1C, 20 min). Protein samples (40 mg or the equivalent of 1.5  106
cells per lane) were resolved by SDS-PAGE and then transferred to polyvinyli-
dene difluoride (PVDF) membranes. Blots were blocked with 5% skimmed
milk powder in TBS plus Tween before probing with antibodies to CDK1
(Transduction Laboratories), CDK2 (Transduction Laboratories), CDK5 (San-
ta-Cruz Biotechnology), caspase-3 (Cell Signaling Technologies), Mcl-1 (Santa-
Cruz Biotechnology) or b-actin (Sigma).
Kinase assays. We assayed kinase activity by immunoprecipitation of CDK1
(A17 antibody; Pharmingen) or CDK2 (M2 antibody; Santa Cruz Biotechno-
logy), followed by incubation with histone H1 and [g-32P]ATP (ref. 50).
Immunoprecipitates were resolved by SDS-PAGE, stained with Coomassie blue
to visualize the histone H1 bands, dried and exposed for autoradiography.
Carrageenan-induced pleurisy. Male C57BL/6J mice (aged 8–12 weeks) were
injected intrapleurally with 0.1 ml of 1% l-carrageenan (Marine Colloids),
followed 24 h later by 0.5 ml of saline control, 0.5 ml of 0.5% DMSO vehicle con-
trol, or 10 or 100 mg per kg of R-roscovitine (i.p.). Mice were killed and pleural
cavities were lavaged with 1 ml of 3.15% (w/v) sodium citrate in PBS. Edema
formation was measured by pleural exudate weight. Cell counts, apoptosis and
macrophage phagocytosis in pleural cell samples were assessed microscopically.
Administration of zVAD-fmk. Twenty-four hours after intrapleural injec-
tion of carrageenan, mice were injected i.p. with 10 mg per kg of
R-roscovitine and/or 5 mg per kg of zVAD-fmk (z-Val-Ala-DL-Asp-
fluoromethylketone; Bachem) at a final concentration of 1 mg/ml in saline,
or with appropriate amounts of DMSO vehicle control. Two additional doses of
zVAD-fmk were given i.p. 4 and 8 h later, and all mice were killed after 12 h.
Cytokine analysis.We measured cytokine levels by using a mouse inflammation
cytokine bead kit (BD Biosciences) according to the manufacturer’s instructions.
Bleomycin-induced lung injury.Male C57BL/6J mice (aged 8–12 weeks) were
given either 0.05 ml of 0.1 U of bleomycin (Apollo Scientific) or saline
intratracheally (sham control), and then treated 48 h later with either 0.5 ml
of 0.5% DMSO vehicle control or 100 mg per kg of R-roscovitine. The mice
were killed 72 h or 7 d after bleomycin or saline administration. In the acute
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72-h experiments, bronchoalveolar lavage were performed with three sequential
washes with 0.8 ml of ice-cold saline before perfusion with 4% formaldehyde
for tissue histological analysis. Differential cell counts were done on cytocen-
trifuge preparations with eosin and hemotoxylin staining. Histological analysis
of the 7-d experiments was done without bronchoalveolar lavage to maintain
tissue integrity. Experiments were done on untreated control, sham control
(saline and DMSO treatment), R-roscovitine control (saline and 100 mg per kg
of R-roscovitine), bleomycin plus vehicle (DMSO) control, and bleomycin plus
R-roscovitine treatment groups, with six mice per group. Lungs were inflated,
fixed with 1 ml of 4% formaldehyde and then decalcified with 5% nitric acid
for 3 h, and lung injury was assessed by histological examination of paraffin-
embedded lung sections stained with hematoxylin and eosin.
Induction and assessment of arthritis. Female C57BL/6J mice (aged 6–8
weeks) received two i.p. injections at 48-h intervals of sera (100 ml) from
arthritic K/BxNmice (aged 60 d) and R-roscovitine or vehicle was administered
i.p. every 48 h. Arthritis was scored by clinical examination: a score of 1
represents erythema alone or swelling of 1 digit; 2 represents erythema plus
swelling of the tarsal joints, or swelling of the hock or wrist joint alone;
3 represents swelling in both tarsal and hock joints, both wrist and digits, or
more than two digits and the tarsal joints. The mean cumulative limb scores for
each mouse were calculated for each group, and data are expressed as the
percentage of the clinical score obtained on day 3 before the first injection
of R-roscovitine.
Statistical analysis. We analyzed in vitro experiments by analysis of variance
(ANOVA) and Student-Newman-Keuls comparison tests. All in vivo experi-
ments included at least six mice per group and experiments were repeated to
verify the original findings. Statistical analysis was done by a one-way ANOVA
with a Bonferroni multiple comparison post hoc test with a 95% confidence
interval. Data are expressed as the mean ± s.e.m. and values of P o 0.05 were
considered significant.
ACKNOWLEDGMENTS
We thank M. Clay and K. Miles for help with the in vivo models. We thank the
Arthritis Research Campaign, the Medical Research Council, UK, the Norman
Salvesen Emphysema Trust, Asthma UK, and the Juan Esplugues Foundation for
financial support.
AUTHOR CONTRIBUTIONS
A.G.R. initiated, designed, directed and performed experiments and took overall
responsibility for planning and writing the manuscript. D.A.S. helped design,
perform and analyze the in vivo experiments and contributed to the writing of
the in vivo component. A.W. helped design, perform and analyze the in vitro
experiments and contributed to the writing of the in vitro component. C.W.
contributed intellectually to the manuscript and helped with the in vitro work.
T.A.S. performed some in vitro apoptosis and western blotting experiments.
N.A.R. performed the Mcl-1 western blot experiments. A.C. and M.M.-L.
performed some in vitro apoptosis experiments. T.R.W. helped in the design
of the western blotting and kinase experiments. R.D. helped in the bleomycin
experiments. M.G. helped in the design and execution of the arthritis
experiments. E.C. helped in the design and execution of the kinase experiments.
M.C.M. performed preliminary apoptosis experiments with the CDK inhibitors.
H.J.B. provided intellectual input and provided significant input to the design
and execution of the kinase experiments. J.S.S. provided intellectual input. I.D.
provided intellectual input and contributed to the design of the experiments and
the writing of the manuscript. C.H. provided intellectual input and helped in the
design and coordination of the project.
COMPETING INTERESTS STATEMENT
The authors declare that they have no competing financial interests.
Published online at http://www.nature.com/naturemedicine/
Reprints and permissions information is available online at http://npg.nature.com/
reprintsandpermissions/
1. Nathan, C. Points of control in inflammation. Nature 420, 846–852 (2002).
2. Savill, J.S. et al. Macrophage phagocytosis of aging neutrophils in inflammation.
Programmed cell death in the neutrophil leads to its recognition by macrophages.
J. Clin. Invest. 83, 865–875 (1989).
3. Savill, J., Dransfield, I., Hogg, N. & Haslett, C. Vitronectin receptor-mediated phago-
cytosis of cells undergoing apoptosis. Nature 343, 170–173 (1990).
4. Gilroy, D.W., Lawrence, T., Perretti, M. & Rossi, A.G. Inflammatory resolution: new
opportunities for drug discovery. Nat. Rev. Drug Discov. 3, 401–416 (2004).
5. Riley, N.A. et al. Granulocyte apoptosis and macrophage clearance of apoptotic cells as
targets for pharmacological intervention in inflammatory diseases. Anti-Inflamm. Anti-
Allergy Agents Medicinal Chem. 5, 3–12 (2006).
6. Whyte, M.K., Meagher, L.C., MacDermot, J. & Haslett, C. Impairment of function in
aging neutrophils is associated with apoptosis. J. Immunol. 150, 5124–5134 (1993).
7. Jonsson, H., Allen, P. & Peng, S.L. Inflammatory arthritis requires Foxo3a to prevent
Fas ligand-induced neutrophil apoptosis. Nat. Med. 11, 666–671 (2005).
8. Vermeulen, K., Van Bockstaele, D.R. & Berneman, Z.N. The cell cycle: a review of regu-
lation, deregulation and therapeutic targets in cancer. Cell Prolif. 36, 131–149 (2003).
9. Senderowicz, A.M. Small-molecule cyclin-dependent kinase modulators. Oncogene 22,
6609–6620 (2003).
10. Monaco, E.A., III. & Vallano, M.L. Cyclin-dependent kinase inhibitors: cancer killers to
neuronal guardians. Curr. Med. Chem. 10, 367–379 (2003).
11. MacCallum, D.E. et al. Seliciclib (CYC202, R-Roscovitine) induces cell death in
multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription
and down-regulation of Mcl-1. Cancer Res. 65, 5399–5407 (2005).
12. Raje, N. et al. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent
kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.
Blood 106, 1042–1047 (2005).
13. Michels, J., Johnson, P.W. & Packham, G. Mcl-1. Int. J. Biochem. Cell Biol. 37,
267–271 (2005).
14. Moulding, D.A., Quayle, J.A., Hart, C.A. & Edwards, S.W. Mcl-1 expression in
human neutrophils: regulation by cytokines and correlation with cell survival. Blood
92, 2495–2502 (1998).
15. De Azevedo, W.F. et al. Inhibition of cyclin-dependent kinases by purine analogues:
crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. 243,
518–526 (1997).
16. Meijer, L. et al. Biochemical and cellular effects of roscovitine, a potent and selective
inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 243,
527–536 (1997).
17. Bach, S. et al. Roscovitine targets, protein kinases and pyridoxal kinase. J. Biol. Chem.
280, 31208–31219 (2005).
18. Gray, N.S. et al. Exploiting chemical libraries, structure, and genomics in the search for
kinase inhibitors. Science 281, 533–538 (1998).
19. Chang, Y.T. et al. Synthesis and application of functionally diverse 2,6,9-trisubstituted
purine libraries as CDK inhibitors. Chem. Biol. 6, 361–375 (1999).
20. Meijer, L. et al. Inhibition of cyclin-dependent kinases, GSK-3b and CK1 by hyme-
nialdisine, a marine sponge constituent. Chem. Biol. 7, 51–63 (2000).
21. Williams, O., Gil-Gomez, G., Norton, T., Kioussis, D. & Brady, H.J. Activation of Cdk2 is
a requirement for antigen-mediated thymic negative selection. Eur. J. Immunol. 30,
709–713 (2000).
22. Martin, M.C., Dransfield, I., Haslett, C. & Rossi, A.G. Cyclic AMP regulation of
neutrophil apoptosis occurs via a novel protein kinase A-independent signaling path-
way. J. Biol. Chem. 276, 45041–45050 (2001).
23. Ward, C. et al. NF-kB activation is a critical regulator of human granulocyte apoptosis
in vitro. J. Biol. Chem. 274, 4309–4318 (1999).
24. Ward, C. et al. Interleukin-10 inhibits lipopolysaccharide-induced survival and extra-
cellular signal-regulated kinase activation in human neutrophils. Eur. J. Immunol. 35,
2728–2737 (2005).
25. Sabroe, I., Jones, E.C., Usher, L.R., Whyte, M.K. & Dower, S.K. Toll-like
receptor (TLR)2 and TLR4 in human peripheral blood granulocytes: a critical role for
monocytes in leukocyte lipopolysaccharide responses. J. Immunol. 168, 4701–4710
(2002).
26. Sabroe, I. et al. Selective roles for Toll-like receptor (TLR)2 and TLR4 in the regulation
of neutrophil activation and life span. J. Immunol. 170, 5268–5275 (2003).
27. Rosales, J.L., Ernst, J.D., Hallows, J. & Lee, K.Y. GTP-dependent secretion from
neutrophils is regulated by Cdk5. J. Biol. Chem. 279, 53932–53936 (2004).
28. Gilroy, D.W. et al. Inducible cyclooxygenase may have anti-inflammatory properties.
Nat. Med. 5, 698–701 (1999).
29. Gilroy, D.W. et al. Inducible cyclooxygenase-derived 15-deoxy(D)12–14PGJ2 brings
about acute inflammatory resolution in rat pleurisy by inducing neutrophil and
macrophage apoptosis. FASEB J. 17, 2269–2271 (2003).
30. Sawatzky, D.A., Willoughby, D.A., Colville-Nash, P.R. & Rossi, A.G. The involvement of
the apoptosis-modulating proteins ERK 1/2, Bcl-xL and Bax in the resolution of acute
inflammation in vivo. Am. J. Pathol. 168, 33–41 (2006).
31. Cailhier, J.F. et al. Resident pleural macrophages are key orchestrators of neutrophil
recruitment in pleural inflammation. Am. J. Respir. Crit. Care Med. 173, 540–547
(2006).
32. Klausen, P., Bjerregaard, M.D., Borregaard, N. & Cowland, J.B. End-stage differentia-
tion of neutrophil granulocytes in vivo is accompanied by up-regulation of p27kip1
and down-regulation of CDK2, CDK4, and CDK6. J. Leukoc. Biol. 75, 569–578
(2004).
33. Tsukahara, Y. et al. Gene expression in human neutrophils during activation and
priming by bacterial lipopolysaccharide. J. Cell. Biochem. 89, 848–861 (2003).
34. Zhang, X. et al. Gene expression in mature neutrophils: early responses to inflammatory
stimuli. J. Leukoc. Biol. 75, 358–372 (2004).
35. Subrahmanyam, Y.V. et al. RNA expression patterns change dramatically in human
neutrophils exposed to bacteria. Blood 97, 2457–2468 (2001).
36. Kobayashi, S.D., Voyich, J.M., Whitney, A.R. & DeLeo, F.R. Spontaneous neutrophil
apoptosis and regulation of cell survival by granulocyte macrophage-colony stimulating
factor. J. Leukoc. Biol. 78, 1408–1418 (2005).
ART ICL ES


































37. Azambuja, E., Fleck, J.F., Batista, R.G. & Menna Barreto, S.S. Bleomycin lung toxicity:
who are the patients with increased risk? Pulm. Pharmacol. Ther. 18, 363–366 (2005).
38. Nagase, T. et al. A pivotal role of cytosolic phospholipase A2 in bleomycin-induced
pulmonary fibrosis. Nat. Med. 8, 480–484 (2002).
39. Teder, P. et al. Resolution of lung inflammation by CD44. Science 296, 155–158
(2002).
40. De Paepe, M.E., Mao, Q., Embree-Ku, M., Rubin, L.P. & Luks, F.I. Fas/FasL-mediated
apoptosis in perinatal murine lungs. Am. J. Physiol. Lung Cell. Mol. Physiol. 287,
L730–L742 (2004).
41. Levy, B.D., Clish, C.B., Schmidt, B., Gronert, K. & Serhan, C.N. Lipid mediator class
switching during acute inflammation: signals in resolution. Nat. Immunol. 2, 612–619
(2001).
42. Serhan, C.N. et al. Resolvins: a family of bioactive products of omega-3 fatty acid
transformation circuits initiated by aspirin treatment that counter proinflammation
signals. J. Exp. Med. 196, 1025–1037 (2002).
43. Serhan, C.N. & Savill, J. Resolution of inflammation: the beginning programs the end.
Nat. Immunol. 6, 1191–1197 (2005).
44. Serhan, C.N. et al. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its
natural stereoisomers: assignments of dihydroxy-containing docosatrienes. J. Immu-
nol. 176, 1848–1859 (2006).
45. Pinho, V. et al. Phosphoinositide-3 kinases critically regulate the recruitment and
survival of eosinophils in vivo: importance for the resolution of allergic inflammation.
J. Leukoc. Biol. 77, 800–810 (2005).
46. McClue, S.J. et al. In vitro and in vivo antitumor properties of the cyclin dependent
kinase inhibitor CYC202 (R-roscovitine). Int. J. Cancer 102, 463–468 (2002).
47. Coussens, L.M. & Werb, Z. Inflammation and cancer. Nature 420, 860–867 (2002).
48. Karin, M. & Greten, F.R. NF-kB: linking inflammation and immunity to cancer
development and progression. Nat. Rev. Immunol. 5, 749–759 (2005).
49. Haslett, C., Guthrie, L.A., Kopaniak, M.M., Johnston, R.B., Jr. & Henson, P.M.
Modulation of multiple neutrophil functions by preparative methods or trace concen-
trations of bacterial lipopolysaccharide. Am. J. Pathol. 119, 101–110 (1985).
50. Gil-Gomez, G., Berns, A. & Brady, H.J. A link between cell cycle and cell death:
Bax and Bcl-2 modulate Cdk2 activation during thymocyte apoptosis. EMBO J. 17,
7209–7218 (1998).
ART ICL ES













































































This article appeared in a journal published by Elsevier. The attached
copy is furnished to the author for internal non-commercial research
and education use, including for instruction at the authors institution
and sharing with colleagues.
Other uses, including reproduction and distribution, or selling or
licensing copies, or posting to personal, institutional or third party
websites are prohibited.
In most cases authors are permitted to post their version of the
article (e.g. in Word or Tex form) to their personal website or
institutional repository. Authors requiring further information




Novel pharmacological strategies for
driving inflammatory cell apoptosis
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Resolution of inflammation requires the effective
downregulation of key inflammatory cells such as neu-
trophils and eosinophils, which normally undergo pro-
grammed cell death (apoptosis) to enable their detection
and removal by phagocytes such as macrophages. Dys-
regulation of this process is thought to contribute to the
pathogenesis and progression of chronic inflammatory
disorders such as chronic obstructive pulmonary dis-
ease, asthma, rheumatoid arthritis, allergic rhinitis and
inflammatory bowel disease. Importantly, knowledge of
the signalling pathways responsible for the induction
and execution of granulocyte apoptosis and the phago-
cytic removal of apoptotic cells continues to increase
and, with it, the potential for incisive pharmacological
intervention. In this article, we highlight pharmacologi-
cal strategies that could be used to drive the resolution
of inflammation by augmenting apoptosis of inflamma-
tory cells.
Introduction
The inflammatory process is a complex series of inter-
related, ideally tightly controlled, cellular and biochemical
events that has evolved to eliminate or contain infectious
agents and to repair damaged tissue. An ineffective or
uncontrolled inflammatory response contributes to the
cellular dysfunction, tissue damage and inadequate repair
that occurs in many chronic inflammatory diseases. Cur-
rently, knowledge of the triggers and progression of the
inflammatory process exceeds that of the events respon-
sible for the termination and ultimate resolution of inflam-
mation [1,2].
A central paradigm of inflammation research has been
that the resolution of inflammation depends on apoptosis
of inflammatory cells (e.g. neutrophils and eosinophils) and
their subsequent clearance by phagocytes (especially
macrophages) [3]. This process is synchronized by an inter-
connecting web of signalling pathways that not only down-
regulates the inflammatory response but also generates
agents capable of driving its resolution. In this review, we
focus on the granulocyte, which we consider to be the
archetypal inflammatory cell, and discuss the pharmaco-
logical interventions that have stemmed from a greater
understanding of its role [4].
The granulocyte life cycle
Granulocytes – the collective name given to neutrophil,
eosinophil and basophil leukocytes – have a prominent role
in immune defence [5]. As the most abundant circulating
granulocyte in human blood, neutrophils have a key role in
the defence against bacterial, fungal and viral infections.
Eosinophils account for <5% of the circulating granulo-
cytes and confer resistance to parasitic invasion, in
addition to their involvement, with basophils (the third,
and numerically scarce, type of granulocyte), in the allergic
response [6].
Granulocytes are derived from pluripotent haemato-
poietic stem cells in the bone marrow. If a cell is destined
to become a granulocyte, it must differentiate from a
common myeloid progenitor cell to become a common
granulocyte progenitor cell, which, following appropriate
stimulation, can produce any granulocyte lineage. Gra-
nulocytes are terminally differentiated and, having effec-
tively completed the cell cycle, they remain in the G0 phase
of growth for the remainder of their relatively short lives
[7]. It is believed that, once they have discharged their
function, extravasated granulocytes in the tissues die by
apoptosis (see next section), whereas non-migratory, cir-
culating granulocytes leave the blood and return to the
liver, spleen or bone marrow, where they meet an ill-
defined fate (possibly apoptosis) [8]. The life cycle of the
granulocyte and its differentiation in particular are under
increasing scrutiny. A new pharmacological intervention –
cyclin-dependent kinase inhibition – targets the cell-cycle
machinery and drives granulocyte apoptosis [9].
Granulocyte apoptosis
Apoptosis is a complex physiological mechanism in which a
cell undergoes programmed death as a result of survival-
factor withdrawal or exposure to pro-apoptotic signals (Box
1). The alternative to granulocyte apoptosis (Figure 1)
is necrosis, which can be a primary event or which can
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supersede apoptosis when phagocytosis is delayed.
Apoptosis, in contrast to necrosis, ensures that the cell
membrane retains its integrity, preventing spillage of the
inherently pro-inflammatory and, especially in the case of
neutrophils, histotoxic contents of the cell into the sur-
rounding tissues. The release of histotoxic products [e.g.
proteases or reactive oxygen species (ROS)] from over-
recruited, inappropriately activated and/or necrotic gra-
nulocytes probably contributes to the tissue damage
observed in chronic inflammatory and autoimmune dis-
eases [2–4,10]. However, there is growing evidence that
potentially harmful neutrophil granule contents such as
ROS or cathepsin G have important pro-apoptotic roles in
the successful resolution of inflammation [10,11]. Another
important component of granulocyte apoptosis is the prep-
aration of the cell for recognition and removal by phago-
cytes. During apoptosis, receptors for pro-inflammatory
signals are removed from the cell membrane, whereas
‘eat me’ signals [including phosphatidylserine (PS) resi-
dues], which are recognized by phagocytes, are displayed.
A standard tool for the identification of apoptotic cells
involves annexin-V binding to PS residues. Interestingly,
a putative phagocyte receptor for PS has proved difficult to
define, and three recently identified receptors (Tim4,
stabilin2 and BAI1) indicate that the complexity of this
process might have been underestimated [12–16].
Phagocytosis should be non-phlogistic, implying that a
professional phagocyte such as the macrophage – which,
in other circumstances, can propagate inflammation – on
recognizing an apoptotic cell, is programmed to upregulate
the production of anti-inflammatory mediators such as
transforming growth factor (TGF)-b and interleukin (IL)-
10 [17]. Developing an understanding of granulocyte beha-
viour has been a research priority, and has indicated that a
therapeutically tractable approach to the modulation of
granulocyte functional responsiveness might be to influ-
ence the longevity of these cells by inducing apoptosis [18].
Additionally, research is generating an increasingly
detailed picture of the apoptotic machinery at a molecular
level. This information is crucial for the accurate identifi-
cation of apoptotic cells and could provide novel opportu-
nities for intervention.
Key signalling pathways as targets for
pharmacological intervention
Granulocyte apoptosis is a sensitive, responsive and highly
regulated process. These features are conferred by various
signalling pathways. Each pathway is responsive to
specific endogenous stimuli and mediates pro- or anti-
apoptotic effects. As such, a key area for pharmacological
intervention is the inhibition or augmentation of key gra-
nulocyte signalling pathways (Table 1).
Box 1. Apoptotic pathways and the role of caspases
The extrinsic pathway
The extrinsic apoptotic pathway is initiated by stimulation of the
TNF receptor (TNFR) superfamily of cell-surface ‘death receptors’,
which includes TNF-related apoptosis-inducing ligand receptor,
TNFR and Fas. On binding to TNFR1, TNF-a induces receptor
trimerization, which co-localizes death domains and enables further
binding to TNFR-associated death domain-containing proteins
(TRADDs). TRADD mediates clustering of procaspase-8 molecules
and their proximity to one another initiates an autocatalytic
activation cascade leading to apoptosis. (Similarly, Fas-associated
death domain protein, FADD, mediates the same reaction following
Fas-receptor ligation.) Interestingly, via binding through TNFR-
associated factor-2 and receptor-interacting protein, TRADD can
activate the transcription factors AP-1 and NF-kB, with the latter
having a pivotal role in the immune response. Caspase-8 can either
directly cleave procaspase-3 to caspase-3 (the terminal step in the
cascade preceding cleavage of DNA and chromatin) or–in an
example of cross-talk between extrinsic and intrinsic pathways–
truncate the Bcl-2 family member Bid: a step that contributes to
MOMP [73,74]. CD137 is another member of the TNFR family
(despite lacking a death domain), which seems to have varying
effects on eosinophil and neutrophil survival signalling [65].
The intrinsic pathway
MOMP, which is mediated by a predominance of pro-apoptotic over
anti-apoptotic Bcl-2 family members, is the central event in the
intrinsic pathway, which is stimulated by genotoxic stress (e.g.
cytotoxic agents, UV radiation or oxidative stress). Cytochrome c,
apoptotic-protease-activating factor-1, apoptosis-inducing factor,
endonuclease G and Smac/DIABLO are released following MOMP.
Smac/DIABLO is required for the release of procaspase-9 from IAPs,
enabling formation of the apoptosome and activation of caspase-3,
which initiates apoptosis. It has been suggested that, whereas
caspase-9 is essential for neutrophil and eosinophil apoptosis,
caspase-3 and caspase-8 could have less significance in eosinophil
apoptosis – a difference that was hoped might have potential for
exploitation. It should be noted, however, that the importance of
caspases to constitutive apoptosis has not yet been satisfactorily
confirmed [21,66–68].
Figure 1. Electron micrographs of granulocytes. (a) A healthy neutrophil,
identifiable by its three-lobed nuclei and heavily granular structure (with a 2-mm
scale bar taken at 4700 magnification). (b) An apoptotic neutrophil with dense
chromatin condensation and smooth cell membrane (with a 1-mm scale bar taken
at 9500 magnification). (c) A healthy eosinophil with two-lobed nuclei, large
granules and Charcot–Leyden crystals (crystals comprising eosinophil
lysophospholipase: a hallmark of eosinophilic infiltration) (with a 2-mm scale bar
taken at 4700 magnification). (d) An apoptotic eosinophil showing chromatin
condensation, peripheral granular distribution, smooth cell membrane and
vacuolated appearance (with a 1-mm scale bar taken at 9500 magnification).
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NF-kB: a crucial regulator of granulocyte apoptosis
The transcription factor nuclear factor-kB (NF-kB) has a
pivotal role in the inflammatory response, and a plethora of
molecules – including cytokines, chemokines, adhesion
molecules and stress response proteins – is dependent
on it for synthesis. The synthesis of several proteins under
the direct transcriptional control of NF-kB are anti-apop-
totic in nature, including B-cell lymphoma-2 [Bcl-2 (which
is less relevant in neutrophils, in which it is not
expressed)], inhibitor of apoptosis proteins (IAPs) and X-
ray-inducible immediate–early-response factor-1-long
[19]. Specific inhibition of NF-kB is an attractive pharma-
cological target that is made viable by the ever-increasing
understanding of its activity and regulation.
Inactive NF-kB is held in the cytoplasm bound to its
inhibitor protein, inhibitor of kB (IkB). However, once
activated by pro-inflammatory stimuli such as tumour
necrosis factor (TNF)-a or lipopolysaccharide (LPS), the
IkB kinase (IKK) complex phosphorylates IkB. IkB then
dissociates from NF-kB to be ubiquitylated and targeted
for proteasomal degradation. As a result of IkB degra-
dation, nuclear-localization sequences (NLSs) on NF-kB
are revealed and NF-kB subunits are free to translocate to
the nucleus and begin the process of protein transcription.
From a pharmacological perspective, an obvious interven-
tion would be to augment IkB suppression of NF-kB;
however, this would be difficult because IkB is rapidly
biodegraded [18,19].
Several pharmacological inhibitors of NF-kB are avail-
able and have been shown to enhance apoptosis when
applied to neutrophils in vitro. These inhibitors include
cell-permeable inhibitory peptide of NF-kB, SN-50, curcu-
min, pyrrolidine–dithiocarbamate and MG132 (a protea-
some inhibitor the impact of which could be considered
nonspecific). A widely studied inhibitor is the fungal metab-
olite gliotoxin, which induces neutrophil apoptosis in vitro
and canovercometheneutrophil survival effect conferredby
LPS. The effects of TNF-a on granulocyte apoptosis are
perplexing, although it has been shown that, in combination
with gliotoxin, it induces marked neutrophil and eosinophil
apoptosis [20]. In addition, cycloheximide-mediated
inhibition of protein synthesis augments the effect of
TNF-a, implying the presence of a TNF-a-induced survival
protein that isunder the transcriptional control ofNF-kB. In
the search forphysiological inhibitors ofNF-kB, itwasnoted
that arachidonic acid metabolites and the cyclopentenone
prostaglandin (PG)D2 could inhibit NF-kB activation by
LPS or TNF-a and induce caspase-dependent granulocyte
apoptosis. This effect was independent of the peroxisome–
proliferator-activated-receptor-g and probably occurred by
direct IKK inhibition [19,21]. There is now in vivo evidence,
from a rat pleurisy model, that PGD2 can contribute to the
resolution of inflammation and could be a natural retardant
of inflammation progression [22].
An innovative and encouraging use of the HIV tat
protein transduction method has facilitated the transduc-
tion of neutrophils with HIV-tat-linked NF-kB essential
modulator domain (NEMO), which is a specific inhibitor of
the IKKg–IKKb interaction [23]. A similar approach was
used to transduce eosinophils with an HIV-tat–IkBa
super-repressor that is resistant to phosphorylation and
proteasomal degradation [24]. This highly specific inhi-
bition resulted in the augmentation of apoptosis and the
suppression of NF-kB-mediated survival, lending credence
to the pursuit of NF-kB as a pharmacological target.
However, an apparent contradiction is emerging in the
literature because NF-kB has been shown to have an anti-
inflammatory and pro-resolution role in acute inflam-
mation. The contradiction revolves around detailed
analysis of IKKa inhibition of NF-kB activity, in which
induction of the NF-kB subunits RelA and c-Rel using a
super-repressor IkBa fused to a membrane-transducing
domain of HIV tat protein suppressed NF-kB interaction
with pro-inflammatory gene promoters in vivo. It is now
recognized that there are two phases of NF-kB activation.
The first phase, which occurs within 6 h of the onset of
inflammation, is coincident with the formation of com-
plexed inducible nitric oxide synthase (iNOS) and cRel–
p50 heterodimer; these bind to and regulate the mouse
iNOS promoter, and macrophages from knockout mice
Table 1. Current pharmacological agents proven to drive granulocyte apoptosis or resolution of inflammation





Gliotoxin NF-kB inhibition Decreased NF-kB activation Yes Possible, but probably
nonspecific toxicity
[20]
MG132 Proteasome inhibition Increased Mcl-1, decreased
NF-kB activation
No No [36,69]
PGD2 metabolites Block IkB degradation Decreased NF-kB activation Yes Yes [22,70–72]
PD098059 Decreased ERK
phosphorylation
ERK inhibition Yes Yes [31,32]
SB203580 p38 MAPK inhibition p38 MAPK inhibition No No [33–36]
Sodium salicylate p38 MAPK activation Decreased Mcl-1 Yes Yes [36]
SP600125 JNK inhibition TNF-a-mediated apoptosis Yes Yes [37–39]
Wortmannin PI3K inhibition Decreased Akt
phosphorylation and IL-5
Possible Possible, but probably
nonspecific toxicity
[44]
Ly294002 PI3K inhibition Decreased Akt
phosphorylation and IL-5
Possible Possible, but probably
nonspecific toxicity
[44]
IC87114 PI3K-d inhibition Decreased chemotaxis No Possible [45]
AS605240 PI3K-g inhibition Decreased chemotaxis No Possible [45]
CDKi ? Decreased Mcl-1–X-IAP Yes Yes [9,58–62]
Smac–DIABLO mimetics Decreased X-IAP Increased ease of apoptosis Unknown Unknown [51,52]
Glucocorticoids Decreased Mcl-1 in
eosinophils
Eosinophil apoptosis Eosinophil apoptosis only Eosinophilic inflammation [1,3,49]
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show increased iNOS expression in response to NF-kB
during the induction of inflammation in vivo. During the
resolution phase, however, there is no expression of iNOS
or cRel–p50 heterodimers despite substantial NF-kB acti-
vation, which indicates a switch to a second, pro-resolution
phase [25–27].
It seems that the dominant impact of NF-kB inhibition
is to drive granulocyte apoptosis and the resolution of
inflammation, but a note of caution is warranted because
it is conceivable that inhibition of the later, pro-resolution
phase of NF-kB activation might prolong and/or prevent
the successful resolution of inflammation.
The role of MAPK pathways in granulocyte apoptosis
There is considerable evidence of the involvement of the
mitogen-activated protein kinase (MAPK) signalling cas-
cade in diverse aspects of the inflammatory response,
including cell recruitment, activation and apoptosis. The
three main MAPK subtypes activated by MAPK kinases
(MEKs) 1–7 are extracellular-signal-related kinase [ERK
(which includes p42/p44 MAPK)], c-Jun N-terminal
kinases (JNKs) and p38 MAPK. All have been implicated
in the regulation of granulocyte apoptosis [28–30].
The ERK pathway is involved in negotiating survival
conferred by inflammatory mediators such as granulocyte
macrophage-colony stimulating factor (GM-CSF), IL-8, IL-
15, C5a and LPS but it is non-essential for the regulation of
constitutive apoptosis. PD098059 (20-amino-30-methoxyfla-
vone) is a specific pharmacological ERK inhibitor that
mediates its effect by binding to the ERK-specific MAP-
kinase, thereby preventing the phosphorylation of ERK1/2
(p44/p42 MAPK) by MEK1. PD098059 has been used in
vitro to reverse GM-CSF-mediated and LPS-mediated neu-
trophil survival, and its in vivo efficacy has been demon-
strated in a rat carrageenan-induced pleurisy model, in
which it enhanced the resolution of inflammation by pro-
moting neutrophil apoptosis within the pleural cavity. It is
likely that the pro-apoptotic effects of this compound are
conferred by inhibition of survival-factor-induced anti-
apoptotic effects because it seems to have no direct effect
on constitutive neutrophil apoptosis in non-inflammatory
conditions [31,32].
The p38 MAPK and JNK cascades are involved in the
cellular response to stresses, including heat shock, hyper-
osmolarity, UV radiation, protein-synthesis inhibitor
drugs and inflammatory cytokines. p38 MAPK might also
have a role in superoxide anion production and chemotaxis
[33]. There is indirect evidence of a pro-survival role for p38
MAPKbecause it has been shown to inhibit, by phosphoryl-
ation, caspase-3 and -8 and it is specifically cleaved in
mature neutrophils undergoing apoptosis [34]. However,
it is unclear whether it is sufficiently influential to be
considered a pharmacological target in inflammatory
states because its inhibition (by the pyridinyl imidazole
inhibitor SB203580) fails to overcome cell-survival signals
from GM-CSF. It has been suggested that this controver-
sial pathway could generate a neutrophil death signal
through the reduction ofMcl-1, as observedwhen apoptosis
is triggered by sodium salicylate. Perhaps there are further
opportunities for the pharmacological augmentation of p38
MAPK to promote neutrophil apoptosis. There is certainly
an opportunity for further study of this pathway, which
seems to have been under-investigated compared with
other signalling systems [35,36].
The JNK pathway is also controversial and insuffi-
ciently investigated, but researchers have demonstrated
that the activation of JNK signalling is a component of
LPS- and TNF-a-mediated neutrophil apoptosis. Addition-
ally, an in vivo rat model of smoke inhalation injury
responded favourably to JNK inhibition by SP600125
{anthra [1,9-cd]pyrazol-6(2H)-one}, with decreased airway
inflammation and increased rates of survival [37–39].
PI3K pathway as a regulator of granulocyte apoptosis
The phosphoinositide-3-kinase (PI3K) pathway is an
important cell-surface-receptor-controlled signal-trans-
duction pathway that catalyses phosphorylation of the
30-OH position of the inositol ring of phosphoinositides,
resulting in the formation of the 30-phosphatidylinositol
(PtdIns) lipids. PI3K is involved in the regulation of all
major leukocyte events, including growth, proliferation,
recruitment, activation and survival [40]. From the
perspective of granulocyte survival, PI3K has a role in
mediating the anti-apoptotic–pro-inflammatory signals
triggered by LPS, GM-CSF and TNF-a. It generates the
important signalling lipid PtdIns(3,4,5)P3, which activates
Akt and influences NF-kB and cAMP-response-element-
binding protein (CREB); these produce anti-apoptotic sig-
nals in granulocytes [41–43].
Pharmacological inhibition was initially achieved with
the use of wortmannin and LY294002, which are general
PI3K family inhibitors. Work is in progress to determine
which isoforms of PI3K are responsible for its diversity of
function and to delineate their mechanisms of action. To
this end, PI3K-isoform-specific knockout mice have been
developed alongside new pharmacological inhibitors. For
example, the involvement of PI3K in the recruitment and
survival of eosinophils in a model of allergic pleurisy in
PI3Kg-deficient mice with the use of wortmannin and
LY294002 has been evaluated [44]. They found that, fol-
lowing the induction of allergic pleurisy, eosinophil
accumulation was not different from that in wild-type mice
at earlier time-points (6 and 24 h). However, there was a
marked reduction in eosinophil numbers at a later time-
point (48 h). Wortmannin and LY294002 administered
systematically before antigen challenge led to a decrease
in Akt phosphorylation, IL-5 production and eosinophil
release from the bone marrow and, consequently, pre-
vented the recruitment of eosinophils. Importantly, local
(intrapleural) treatment with the PI3K inhibitors 24 h
after antigen challenge (at the peak of inflammation)
enhanced the clearance of accumulated eosinophils – an
effect associatedwith the inhibition of Akt phosphorylation
and an increased number of apoptotic events (assessed
microscopically and using annexin-V binding). This study
highlights an important role for the PI3K family in the
accumulation and survival of eosinophils and implies a
specific role in the maintenance (possibly by influencing
eosinophil apoptosis) of eosinophilic inflammation in vivo.
The same group has now used the specific PI3K-d inhibitor
IC87114 and the PI3K-g inhibitor AS605240 to demon-
strate that, whereas chemokine receptor (CXCR)2 requires
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both isoforms to recruit neutrophils to the alveolar space,
C5a and formyl-methionyl-leucyl-phenylalanine (fMLP)
require only PI3Kg [45].
Pharmacological inhibitors of specific PI3K isoforms
and the development of knockout mice have demonstrated
the importance of this signalling pathway to the granulo-
cyte and the wider inflammatory response.
The Bcl-2 family
The Bcl-2 family, which contains >20 members, comprises
a series of cell-death-receptor proteins. These are further
classified into three subgroups depending on their function
and the number of Bcl-2 homology domains that they
contain: the multidomain pro-apoptotic members, the
Bcl-2 homology 3 (BH3)-only domain pro-apoptotic mem-
bers and the anti-apoptotic family. Neutrophils and eosi-
nophils express the multidomain pro-apoptotic family
members Bcl-2-associated X protein (Bax) and Bcl-2 hom-
ologous antagonist/killer (Bak), and the BH3-only domain
pro-apoptotic members BH3-interacting domain death
agonist (Bid) and Bcl-2-associated death promoter (Bad),
which are essential components of the apoptotic machin-
ery. Neutrophils also express the pro-apoptotic BH3-only
domain proteins Bim and p53 upregulated modulator of
apoptosis (PUMA). These pro-apoptotic Bcl-2 family
proteins are thought to function either by translocation
to the mitochondria, where they can influence mitochon-
drial outer-membrane permeabilization (MOMP), or by
binding to and downregulating pro-survival proteins. In
fact, the role of mitochondria in neutrophils and eosino-
phils seems to be geared predominantly towards the induc-
tion of apoptosis rather than cellular respiration [46].
Anti-apoptotic members of the Bcl-2 family are also
present in granulocytes. Neutrophils express the Bcl-2
homologue A1 and the anti-apoptotic proteins myeloid cell
leukaemia-1 (Mcl-1), Bcl-XL and X-linked mammalian IAP
(X-IAP). Survival signals, in the form of cytokines and
other mediators found at sites of inflammation, induce
de novo synthesis of these anti-apoptotic proteins [47,48].
Mcl-1 was initially isolated from a human myeloblastic
leukaemia cell line and it is increasingly recognized as a
key regulator of immune-cell proliferation and longevity.
In human neutrophils, Mcl-1 is thought to be important for
cytokine-regulated survival but does not seem to be tran-
scribed by NF-kB, which (as discussed) is one of the most
important inflammatory transcription factors. Levels of
Mcl-1 in human neutrophils correlate closely with neutro-
phil survival kinetics. Mcl-1 levels are elevated in viable
cells and decrease before the induction of apoptosis. This
protein also has the fastest turnover rate and, therefore,
the shortest half-life of the anti-apoptotic members of the
Bcl-2 family: a feature that is compatible with the necess-
arily short half-life of the neutrophil. Mcl-1 is targeted for
degradation in the proteasome following ubiquitylation
and undergoes significant post-translational modification,
providing further opportunities for pharmacological inter-
vention. Glucocorticoids are well-established anti-inflam-
matory agents that promote eosinophil apoptosis but
extend neutrophil longevity. They are important in the
management of eosinophil-dominant diseases such as
asthma but are less effective in neutrophil-dominant
diseases such as chronic obstructive pulmonary disease.
Partial efficacy in neutrophil-dominant disease is probably
achieved by effects on the downregulation of inflammatory
cytokines and the enhancement of macrophage phagocy-
tosis of apoptotic neutrophils [75]. The glucocorticoid
dexamethasone has recently been shown to stabilize
Mcl-1 levels in neutrophils but to reduce levels in eosino-
phils, which might account for this dichotomous effect on
granulocytes [50]. An important development in Mcl-1
research has been the advent of a myeloid-specific
Mcl-1-knockout mouse, which has a normal, functional
macrophage population but which lacks neutrophils –
demonstrating the pivotal survival role of Mcl-1 in neu-
trophils [51]. A putative inhibitor should induce neutrophil
apoptosis but enable the effective clearance of apoptotic
cells by macrophages. As such, Mcl-1 could be a key
pharmacological target. Our experience with the cyclin-
dependent kinase (CDK) inhibitor R-roscovitine indicates
that it adequately fulfils the criteria [9].
Members of the IAP family of proteins, of which X-IAP
seems to be the most potent, inhibit both caspase-9 (an
initiator caspase) and the effector caspases-3 and -7,
thereby promoting cell survival. In addition, overexpres-
sion of X-IAP protects cells from apoptosis (see Refs [51–
54]). X-IAP is negatively regulated by X-IAP-associated
factor 1, which is found predominantly in the nucleus, and
by Smac/DIABLO (second-mitochondria-derived-activator
of caspase/direct inhibitor of apoptosis-binding protein
with low pI), which is located in the mitochondria
[52,53]. Using NMR and X-ray crystallography, recent
characterization of the Smac–IAP interaction has enabled
the design and testing of Smac/DIABLO mimetics that
have in vitro and in vivo activity [52,53]. The implications
for granulocyte apoptosis have not yet been established.
Interestingly, stabilization of X-IAP by the ERK pathway
has been described, and this effect could be reversed by
oxidant-induced p38 MAPK [54]. This provides an import-
ant insight into the signalling pathway cross-talk that is
present at inflammatory loci [54].
Bcl-XL is a Bcl-2 homologue that conserves all four BH
domains. Experiments using in vivo rat carrageenan-
induced pleurisy models have shown that, during the onset
of inflammation, increased expression of Bcl-XL is accom-
panied by significantly decreased levels of Bax expression.
Conversely, during resolution of inflammation, Bax expres-
sion was increased and negligible levels of Bcl-XL were
found. In the same experiment, the inhibition of Bax by
V5 (a Bax inhibitory peptide) resulted in prolonged inflam-
mation, supporting the hypothesis that Bax has a crucial
role in the induction of neutrophil apoptosis, and thereby
facilitates the resolution of inflammation [31]. There is
clearly a delicate balance between the influence of pro-
survival and anti-apoptotic proteinswithin the granulocyte,
whereby processes that mediate the effective clearance of
inflammatory stimuli compete with those that result in a
counter-productive prolongation of inflammation.
Lipoxins, resolvins and protectins: pro-resolution lipid
mediators
Polyunsaturated fatty acids can be metabolized to arachi-
donic acid, eicosapentaenoic acid and docosahexaenoic
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acid, which can be processed to lipoxins, resolvins and
protectins, respectively. These lipid mediators are increas-
ingly recognized for their potent anti-inflammatory and pro-
resolution roles andmighthave amodulatory role in several
inflammatory conditions such as atherosclerosis, chronic
liver disease, inflammatory bowel disease, glomerulone-
phritis and asthma [1]. Lipoxins have diverse actions, in-
cluding the inhibition of neutrophil chemotaxis, adhesion
and transmigration. Additionally, they mediate normaliza-
tion of vascular permeability, non-phlogistic recruitment of
mononuclear cells and stimulation of macrophage phagocy-
tosis of apoptotic neutrophils. Aspirin-triggered lipoxins
seem to target the same seven-transmembrane G-protein-
coupled receptor as does glucocorticoid-induced annexin-1.
Annexin-1 induces granulocyte apoptosis but is also
released by both neutrophils and macrophages to enhance
the phagocytosis of apoptotic cells. This is interesting
because it implies that lipoxins might participate in an
interconnected anti-inflammatory network and pro-resol-
ution cascade [55,56]. Resolvins and protectins share some
of the actions of lipoxins and have protective roles in many
organ systems. Importantly, the resolution of inflammation
has been reported in vitro and in a mouse peritonitis model
with resolvin E1 and protectin D1 [57]. The anti-inflamma-
tory and pro-resolution effects of this family of mediators
have been demonstrated in vitro and, latterly, in vivo,
indicating that it will be an important target for novel
anti-inflammatory pharmacotherapeutics [49].
CDK inhibition as a novel anti-inflammatory approach
CDK inhibitors have been used for the selective induction
of apoptosis in actively proliferating cells for several
years. Several CDK inhibitors, including R-roscovitine,
flavopiridol and SU9516, can induce apoptosis in cancer
cell lines. R-roscovitine alone reduces the proliferation
index of 19 distinct cancer cell lines in vitro [58]. The
induction of apoptosis by CDK inhibitors seems to be
mediated by the modulation of Bcl-2 family members
and to be executed in a caspase-dependent manner. A
wealth of research has meant that confidence in CDK
inhibitor safety and efficacy has increased to the extent
that clinical trials are underway for conditions such as B-
cell malignancy, non-small-cell lung cancer and breast
cancer. So far, the side-effect profile of CDK inhibitors has
been promising but it includes tolerable gastrointestinal
disturbance, minor hepatic dysfunction and hypokalae-
mia [59–61].
Logically, in terminally differentiated cells such as gra-
nulocytes, CDK inhibitors should have no effect because
the cell-cycle machinery ought to be redundant. In fact, in
post-proliferation neurons, CDK inhibitors have been
shown to have a protective effect against apoptosis [62].
Nonetheless, we recently demonstrated in vitro that a
panel of CDK inhibitors induces neutrophil apoptosis in
a time- and concentration-dependent manner and that this
effect is sufficient to overcome the anti-apoptotic effects of
survival factors such as GM-CSF, dibutyryl-cAMP and
LPS [9]. When neutrophils were treated with R-roscovitine
and the caspase inhibitor zVAD-fmk (N-benzyloxycarbo-
nyl-Val-Ala-Asp-fluoromethylketone) cells failed to enter
apoptosis, indicating that R-roscovitine functions in a
caspase-dependent manner. Furthermore, in vitro studies
have demonstrated the presence of CDK1 and CDK2 in
human neutrophils and have shown that levels of both
remain constant throughout ageing, treatment with GM-
CSF or gliotoxin, which indicates that these kinases are
not targeted for degradation during apoptosis [9]. In
addition, a reduction in Mcl-1 levels after treatment of
neutrophils with R-roscovitine was noted, offering a tan-
talizing insight into its mechanism of action [9]. The same
study [9] assessed the impact of R-roscovitine on models of
neutrophil-dominant inflammation, including carragee-
nan-induced pleurisy, bleomycin lung injury and arthritis
in mice. The results indicated a resolution of inflammation
– as assessed by several parameters, including cytokine
levels, inflammatory cell numbers, histology and arthritis
scores. Caspase inhibition in vivo with zVAD-fmk, which
reversed the pro-resolution effect, confirmed the integral
role of granulocyte apoptosis in resolution. In addition,
recent studies have identified a role for CDK5 in neutro-
phils, and CDK inhibition has been shown to influence
inflammatory cell recruitment [63,64]. Further elucidation
of the mechanism of action of CDK inhibitors could enable
this therapy to be refined and might highlight further
targets for pharmacological intervention.
Concluding remarks
Research into granulocyte apoptosis and its role in the
resolution of inflammation has revealed a complex web of
signal-transduction pathways. Work has begun on the
pharmacological manipulation of these pathways to pro-
vide novel treatments for inflammatory disorders. Clearly,
the rate of neutrophil or eosinophil apoptosis can be
increased or reduced in vitro by several agents. Impor-
tantly, this rate can be matched by appropriate clearance
of apoptotic cells. There is now conclusive evidence that
inhibition or promotion of granulocyte apoptosis by
pharmacological agents in vivo can delay or enhance the
resolution of acute inflammation, respectively. Ways to
limit the toxicity of some of these agents must be found
but we can be confident of the transition of others, in the
near future, to clinical trials.
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The cyclin-dependent kinase inhibitor R-roscovitine
down-regulates Mcl-1 to override pro-inflammatory
signalling and drive neutrophil apoptosis
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Successful resolution of inflammation requires inflammatory cells such as neutrophils to
undergo apoptosis prior to non-inflammatory phagocytosis by professional phagocytes.
Recently, cyclin-dependent kinase (CDK) inhibitors (e.g. R-roscovitine) have been shown to
induce neutrophil apoptosis and enhance the resolution of inflammation. Interestingly,
NF-jB and MAPK pathways and key endogenous survival proteins (typified by Mcl-1) are
involved in the regulation of neutrophil apoptosis and, in cancer-cell lines, have been
implicated as possible targets of CDK inhibitors. Here, we demonstrate that R-roscovitine
over-rides TNF-a and LPS-induced survival (determined by morphological examination
and binding of fluorescently labelled annexin-V) of isolated peripheral blood neutrophils.
This effect did not appear to be mediated via effects on early markers of neutrophil acti-
vation (e.g. surface marker expression, shape change, aggregation and superoxide anion
generation), by direct inhibition of NF-jB activation (assessed by cytoplasmic IjBa
proteolysis and NF-jB p65 subunit translocation) and ERK activation (determined by
specific ERK phosphorylation) but due to down-regulation (at protein and mRNA level) of
the survival protein Mcl-1 but not the pro-apoptotic bcl-2 homologue Bim. These findings
suggest that key endogenous survival proteins may be the targets of CDK inhibitors and
consequently may be of critical importance in the resolution of inflammation.
Key words: Apoptosis . Cyclin-dependent kinase inhibition . Inflammation . Neutrophil
Introduction
It is essential for the timely resolution of inflammation that
neutrophils undergo apoptosis and are effectively cleared by
phagocytes [1]. At sites of inflammation, augmented neutrophil
survival is conferred by cytokines (e.g. IL-6, IL-8, TNF-a and GM-
CSF), bacterial products (e.g. LPS) and local factors such as
oxygen tension [2]. These signals greatly extend neutrophil
lifespan and facilitate the appropriate up-regulation of neutrophil
response to an inflammatory challenge. If this up-regulation is
sustained and becomes persistent it can lead to chronic
inflammatory or autoimmune pathology [3, 4]. In the develop-
ment of anti-inflammatory pharmacological agents that drive
neutrophil apoptosis, it is essential to consider the powerfully
pro-survival inflammatory milieu that must be overcome [2, 5].
By elucidating the processes responsible for the regulation of
neutrophil survival it should be possible to harness them with the
aim of driving resolution of inflammation [6]. Activation of the
archetypal inflammatory transcription factor NF-kB has been
shown to prolong neutrophil lifespan [7]. NF-kB is usually bound
and held within the cytoplasm by its physiological inhibitor IkBa
and appropriate pro-inflammatory signalling can promote
degradation of IkBa and allow NF-kB to translocate to the
nucleus where it binds DNA and initiates transcription. NF-kB is
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responsible for the transcription of the neutrophil survival protein
XIAP, which inhibits caspases 3, 7 and 9 [8]. It has recently been
suggested that XIAP may be the critical discriminator between
type I (e.g. lymphocytes) and II (e.g. granulocytes) apoptosis [9].
It has also been implicated in neutrophil survival mediated by
G-CSF [10] and is degraded in oxidant-induced neutrophil
apoptosis [11]. Inhibitors of NF-kB promote neutrophil apoptosis
while pro-inflammatory signals such as LPS and TNF-a activate
NF-kB to enhance survival [7].
The ERK pathway is involved in negotiating survival conferred
by inflammatory mediators such as GM-CSF, IL-8, IL-15, C5a and
LPS, but appears to be non-essential for regulation of constitutive
apoptosis. PD098059 (20-amino-30-methoxyflavone) is a specific
pharmacological ERK-inhibitor and mediates its effect by binding
to the ERK-specific MAP-kinase MEK, thus preventing phosphory-
lation of ERK1/2 (p44/p42 MAPK) by MEK1. It has been used in
vitro to reverse GM-CSF and LPS-mediated neutrophil survival
[12]. In vivo efficacy of PD098059 has been demonstrated in a rat
carrageenan-induced pleurisy model where it enhanced resolu-
tion of inflammation by promoting neutrophil apoptosis within
the pleural cavity. It is likely that pro-apoptotic effects of this
compound are conferred by inhibition of survival factor-induced
anti-apoptotic effects as it seems to have no direct effect on
constitutive neutrophil apoptosis in non-inflammatory conditions
[13, 14].
Neutrophils are the front-line of the innate immune response
and therefore possess an array of functions that come to the fore
when they become activated by microbes or microbial products.
Some of these activation parameters have down-stream conse-
quences in terms of intracellular signaling and cell viability. For
example, production of reactive oxygen species typified by the
superoxide anion can promote apoptosis [15] while neutrophil
activation, typified by shape change and increased adhesiveness,
can promote longevity [16]. In assessing a new compound that
drives neutrophil apoptosis it is therefore essential to consider
these parameters.
The inflammatory response is renowned for multiple layers
of complex, redundant regulation and it is therefore not
surprising that an important neutrophil survival protein, Mcl-1, is
not under the direct transcriptional control of NF-kB. Mcl-1 is a
Bcl-2 homologue that promotes neutrophil survival by main-
tenance of the outer mitochondrial membrane against pro-
apoptotic Bcl-2 family members. It is a rapidly transcribed, short-
lived protein that is subject to prompt turnover by the proteasome
[17]. Mcl-1 transcription and stability can be influenced by
various signalling pathways (PI3K, ERK, glycogen synthase
kinase, RAF), cytokines (GM-CSF, TNF-a) and pharmacological
agents (dexamethasone, sodium salicylate) [18–21]. It is this
sensitivity to the cell’s environment and facility for rapid up or
down-regulation that place Mcl-1 in the vanguard of apoptotic
decision-making.
By contrast, the pro-apoptotic Bcl-2 homologues such as
Bim, Bax, Bid and Bad have much longer half-lives and it has
usually been assumed that they are a constant but passive
presence held in check by anti-apoptotic Bcl-2 homologues. The
active process has been considered to be the depletion of anti-
apoptotic proteins allowing their pro-apoptotic counterparts to
become effectors almost by default. Recently, it has been
demonstrated that Bim plays an important role in the induction
of apoptosis in neutrophils stimulated towards enhanced long-
evity by cytokines such as GM-CSF and IL-3 [22]. Bim was shown
to be actively transcribed in the presence of pro-survival cyto-
kines, a finding that was ascribed to a novel function as a
physiological brake on cytokine-mediated enhanced neutrophil
longevity.
R-roscovitine is a CDK inhibitor that has recently been
found to have powerful anti-inflammatory properties [23].
Importantly, R-roscovitine is capable of overcoming survival
signals such as GM-CSF to promote neutrophil apoptosis in vitro
and resolution of inflammation in established animal models.
R-roscovitine has been investigated previously from an anti-
cancer perspective and has been found to promote apoptosis in
myeloma cell-lines by down-regulation of Mcl-1 [24]; indeed
R-roscovitine and other CDK inhibitors are undergoing Phase I
and II clinical trials for the treatment of various types of cancers.
Recently, it was shown that R-roscovitine could directly inhibit
NF-kB at late time-points in cancer cell-lines [25], a finding that,
if applicable to neutrophils, might provide insight into the anti-
inflammatory properties of R-roscovitine. In this paper we show
that R-roscovitine can overcome powerful pro-survival signals to
promote neutrophil apoptosis, without directly affecting activa-
tion status or key signalling pathways, but by down-regulating
the important pro-survival protein Mcl-1 at the level of trans-
cription.
Results
R-roscovitine promotes a rapid induction of neutrophil
apoptosis in vitro
R-roscovitine promotes significant classical apoptosis in neutro-
phils by 4–8h (Fig. 1a). The majority of neutrophils are apoptotic
by 8 h (7572.7%) and by 20 h secondary necrosis (60.572.1%)
is evident. Time-course experiments are shown to demonstrate
that cells transition through apoptosis to necrosis, indicating that
secondary as opposed to primary necrosis is induced. Time-lines
showing constitutive fate of neutrophils (Fig. 1A), in our
laboratory using our methodology, are shown for comparison
given the considerable heterogeneity of such data in the
literature.
R-roscovitine over-rides survival mediators TNF-a and
LPS to augment neutrophil apoptosis
TNF-a in contrast to its early pro-apoptotic effects is known to
promote neutrophil survival at late time-points [7, 26]. LPS is
also known to promote neutrophil longevity [27]. In order
to investigate the efficacy of R-roscovitine in the presence of
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Figure 1. (A) Time-course showing effect of R-roscovitine on neutrophil viability over 20h. Neutrophils were cultured at 5106/mL in IMDM
containing 10% autologous serum and R-roscovitine at a concentration of 20 mM. At 4, 8, 12 and 20h samples of cultured neutrophils were removed
for generation of cytocentrifuge preparations for examination of morphological changes associated with apoptosis and for preparation of samples
for flow cytometric analysis of Annexin V binding and PI staining. Data are presented as a time-course showing the change in untreated neutrophil
viability (defined as Annexin Vve/PIve) in (i), apoptosis (Annexin V1ve/PIve) and necrosis (Annexin V1ve/PI1ve) both depicted in (ii) over a
20h time period. The effect of R-roscovitine on the various populations as defined above is shown in (iii) and (iv). Lines showing development of
apoptosis and necrosis are superimposed to demonstrate that necrosis follows apoptosis (secondary necrosis). (B) Effect of R-roscovitine on LPS
and TNF-a induced neutrophil survival. Neutrophils were cultured at 5 106/mL in IMDM containing 10% autologous serum alone as control (i) or
with R-roscovitine (20 mM) (ii), LPS (100ng/mL) (iii), R-roscovitine1LPS (iv), TNF-a (10ng/mL) (v), or R-roscovitine1TNF-a (vi) as indicated above for
20h. Apoptosis was assessed using Annexin V, PI staining and confirmed by morphological examination under light microscopy. Results represent
n5 6, with each experiment being performed in triplicate. Representative flow cytometry plots (lower left quadrant is annexin Vve/PIve, lower
right is annexin V1ve/PIve and upper right is annexin V1ve/PI1ve) are shown along with examples of neutrophil morphology from the
appropriate experimental condition. Plots show effect of R-roscovitine on neutrophil viability in the presence of LPS (vii) and TNF-a (viii).
Statistically significant difference to po0.001 between LPS/TNF-a and R-roscovitine1LPS/R-roscovitine1TNF-a is shown as . Statistically
significant difference to po0.001 between R-roscovitine1LPS/R-roscovitine and control is shown as ]]] (ANOVA with a Student Newman–Keuls
multiple comparison post hoc test with a 95% confidence interval).
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these pro-inflammatory mediators we cultured neutrophils with
R-roscovitine7LPS or TNF-a. Even in the presence of these
powerful pro-inflammatory, anti-apoptotic mediators, R-roscov-
itine significantly reduced neutrophil viability by promoting
apoptosis. Viability data and representative examples of neutro-
phil morphology are shown along with flow cytometry profiles
(Fig. 1B).
R-roscovitine does not directly activate NF-jB and has
no impact on LPS or TNF-a-driven activation of NF-jB
R-roscovitine does not directly activate NF-kB as assessed by
Western blotting for the cytosolic, physiological NF-kB inhibitor
IkBa (Fig. 2A). This is demonstrated by the presence of IkBa in
R-roscovitine-treated neutrophil lysate (lane 4). In addition,
R-roscovitine does not interfere with the ability of LPS or TNF-a
to activate the NF-kB pathway, demonstrated by the loss of IkBa
in neutrophil lysates treated with these mediators (lanes 5 and 6,
respectively, and compare with mediators alone in lanes 2 and 3).
Gliotoxin is a known NF-kB inhibitor and is included for
comparison (lanes 7–9); gliotoxin completely inhibited the loss
of IkBa induced by LPS and TNF-a.
R-roscovitine does not affect p65 translocation stimu-
lated by TNF-a or LPS
NF-kB activation was investigated by observing with confocal
microscopy, the translocation of a green fluorescent-labelled NF-
kB subunit, p65, from the cytoplasm to the red, PI-stained
nucleus. The translocation of p65, which is representative of NF-
kB activation, makes the nucleus appear yellow (Fig. 2B). This
method was utilized to ensure that NF-kB activation was not
occurring independently of IkBa degradation as has been
previously reported [28]. Neutrophils treated with R-roscovitine
have a green cytoplasm and a red nucleus, an appearance that
contra-indicates activation. However, when neutrophils were co-
incubated with R-roscovitine and either TNF-a or LPS the nucleus
turned yellow, indicating translocation of the p65 subunit. These
confocal microscopy images support our immunoblotting results
and indicate that the anti-inflammatory action of R-roscovitine is
not mediated by direct inhibition of NF-kB.
R-roscovitine has no major effect on ERK
phosphorylation
Neutrophils from healthy volunteer donors were incubated with
R-roscovitine alone, PD98059 (an ERK-inhibitor) alone or co-
incubated with LPS. Neutrophils were cultured with the relevant
agents for 4 h. Western blotting reveals complete inhibition of
LPS-induced ERK phosphorylation by PD98059 whereas
R-roscovitine has a much smaller effect on LPS-induced ERK
phosphorylation (Fig. 2C).
R-roscovitine has no effect on markers of neutrophil
activation
Neutrophil activation status can determine longevity; so it was
important to determine whether R-roscovitine could directly
influence the activation status of the cell [16]. Therefore,
the effects of R-roscovitine on the cell surface markers CD11b,
CD62L and on neutrophil shape change were investigated
by flow cytometry. As shown in Fig. 3A, R-roscovitine has
virtually no effect on neutrophil activation as assessed by
these parameters. On comparison of control samples to
R-roscovitine, CD62L shedding (average geometric mean fluor-
escence value) only altered from 377 to 298, while CD11b up-
regulation (average geometric mean fluorescence values)
only altered from 40 to 41. Neutrophil shape change as assessed
by shift in forward scatter changed from 9 to 16. In addition,
R-roscovitine did not affect activation mediated by GM-CSF,
LPS, leukotriene B4 (LTB4) and TNF-a when compared with
control conditions (Fig. 3A). In contrast, incubation with
gliotoxin caused significant alterations in CD11b and CD62L
expression and shape change (data not shown). Complementary
to this data we have also shown that neutrophil aggregation
stimulated by the chemotactic peptide N-formyl-methionyl-
leucyl-phenylalanine (fMLP) or the phorbol ester PMA is
unaffected by treatment with R-roscovitine (Fig. 3B). Addition-
ally, R-roscovitine, in contrast to the protein kinase C inhibitor,
Ro-31,8220 [29], had no significant effect on the ability of PMA
to stimulate production of superoxide anion as measured by
intracellular oxidation of dihydrorhodamine (DHR) by flow
cytometry (Fig. 3C). In this assay it was also noted that
neutrophil shape change as assessed by forward scatter was
unaffected by R-roscovitine. It can be concluded that there is no
direct effect of R-roscovitine on multiple, pertinent markers of
neutrophil activation.
R-roscovitine down-regulates Mcl-1 even in the
presence of survival factors
We confirm results previously published by Edwards and
colleagues that show levels of Mcl-1 protein decline by 4 h
and that the cytokine GM-CSF has a protective effect against
Mcl-1 decline (Fig. 4A) [18]. We subsequently demonstrated
that R-roscovitine augmented the decrement in levels of Mcl-1 in
neutrophils at 4 h (effect also evident at 2 h; results not shown)
and that it had the ability to over-ride the protective effect of
LPS, TNF-a and GM-CSF on Mcl-1 (Fig. 4A). However, when
R-roscovitine was co-incubated with TNF-a, levels of Mcl-1
were reduced more substantially than with R-roscovitine alone
(Fig. 4A). No consistent pattern was discernable when the same
experiment was performed probing for XIAP protein levels.
We believe that this occurred because changes in levels of
XIAP appear very close to the final stages of apoptosis and
this physiological event makes interpretation of these results
difficult.
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Figure 2. (A) Effect of R-roscovitine on IkBa degradation in neutrophils. Neutrophils (5 106/mL in IMDM containing 10% autologous serum) were
treated in either the absence (control) or presence of R-roscovitine (20 mM) or gliotoxin (0.1 mg/mL) for 30min following which, control (IMDM110%
autologous serum), LPS (100ng/mL) or TNF-a (10ng/mL) treatments were added to each of the previous conditions for a further 30min. The blots
were probed for IkBa. Blot shown is representative of three experiments. (B) Effect of R-roscovitine on p65 translocation. Neutrophils (2.5 106/mL
in IMDM containing 10% autologous serum) were treated in either the absence (control) or presence of R-roscovitine (20 mM) or gliotoxin (0.1mg/mL)
for 30min following which, control (IMDM110% autologous serum), LPS (100ng/mL) or TNF-a (10ng/mL) treatments were added to each of the
previous conditions for a further 30min. The nuclei were stained using PI and the movement of green fluorescence-labelled p65 was assessed
using confocal microscopy. The confocal images show p65 as green fluorescence, nuclei as red fluorescence and yellow fluorescence indicates co-
localization. (C) Effect of R-roscovitine on LPS induced ERK activation. Neutrophils at 5106/mL were incubated in IMDM containing 10%
autologous serum alone or with the addition of DMSO (Vehicle control), LPS (100ng/mL), PD98059 (50 mM), R-Roscovitine (20 mM) or combinations of
these as designated above. After 4h incubation they were lysed and immunoblotted for total and phorphorylated ERK. Blot shown is representative
of three similar experiments.
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R-roscovitine has no effect on the key pro-apoptotic
Bcl-2 homologue Bim
R-roscovitine has no effect on the protein levels of Bim.
Neutrophils treated for 4 h in the presence or absence of the
survival factors LPS, TNF-a and GM-CSF maintained constant
levels of Bim long and Bim extra long (Fig. 4B). It can be
concluded that R-roscovitine either directly or indirectly down-
regulates two key neutrophil survival proteins without affecting
the pro-apoptotic protein Bim, tipping the delicate balance of
viability towards apoptosis.
R-roscovitine down-regulates Mcl-1 at the mRNA level
We hypothesized that R-roscovitine was mediating its effects
on neutrophil survival by influencing production of key survival










































































































































Figure 3. (A) Changes in expression of CD11b, CD62L and shape change. Neutrophils at 5 106/mL in PBS were treated in the absence (control) or
presence of R-roscovitine (20 mM) for 30min and then with either PBS (control), GM-CSF (50ng/mL), LPS (100ng/mL), leukotriene B4 (1 mM) or TNF-a
(10ng/mL) for a further 30min. Samples were then labelled with antibodies for CD11b, CD62L or the control antibodies APC and PE. Shape change
was assessed bymeasurement of change in forward scatter. Labelling was assessed by flow cytometry and all experiments were performed at least
three times. There was no statistically significant difference between R-roscovitine-treated cells and control (p40.1 ANOVA with a Student
Newman–Keuls multiple comparison post hoc test with a 95% confidence interval). (B) Changes in neutrophil aggregation. Neutrophils (5106 cells/
mL; 500mL) were pretreated with R-roscovitine (20 mM), DMSO (1:2500) or control buffer for 7min then stimulated by PMA (300nM) or fMLP (300nM)
and aggregation assessed after a further 7min. Data are expressed as percentage of maximum aggregation induced by either PMA or fMLP using a
four-channel optical aggregometer (Chronolog, Labmedics, UK). Results are mean1SEM of n5 4 separate experiments (ANOVA with a Student
Newman–Keuls multiple comparison post hoc test with a 95% confidence interval). (C) Changes in superoxide production. Neutrophils at 1106/mL
in HBSS were pre-treated with R-roscovitine (20 mM), Ro-31,8220 (1 mM) or vehicle (0.0004% DMSO) control prior to stimulation of superoxide anion
generation (i–iii) and shape change (iv) by PMA (300nM) for 15min. Representative overlay flow-cytometric plots for DHR fluorescence (FL-1) are
depicted in (i) and (ii). In (i), unstained (black), vehicle (blue), PMA (red), Ro-31,8220 (light green) and Ro-31,8220 plus PMA (dark green). In (ii),
unstained (black), vehicle (blue), PMA (red), R-roscovitine (light green) and R-roscovitine plus PMA (dark green). For comparison, unstained, vehicle
and PMA plots are the same in (i) and (ii). In panels (iii) data are mean FL-11SEM of n5 4 separate donors with each sample done in duplicate for
each experiment where  represents po0.001 versus vehicle control and ]]] represents po0.001 versus PMA alone. In panel (iv), data are mean
FSC1SEM of n5 4 separate donors with each sample done in duplicate for each experiment where  and  represent po0.001 and po0.01 versus
vehicle control, respectively, and ]] represents po0.01 versus PMA alone (ANOVAwith a Student Newman–Keuls multiple comparison post hoc test
with a 95% confidence interval).
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the use of semi-quantitative PCR. R-roscovitine down-regulates
Mcl-1 at the mRNA level even in the presence of survival
factors such as LPS and TNF-a (Fig. 5). By contrast, R-roscovitine
did not significantly affect basal levels of XIAP mRNA at 4 h but
did seem to prevent its up-regulation by LPS (not quite
statistically significant when all samples were analysed as per
methods). TNF-a did not appear to up-regulate transcription of
XIAP.
Discussion
R-roscovitine is a 2,6,9-substituted purine analogue that, in
common with other CDK-inhibitors, competes for the ATP-
binding site on CDK [30]. CDK are important regulators
of cell-cycle progression but also gene transcription [31].
R-roscovitine has been extensively evaluated as a cancer
therapeutic both independently and in combination with other
drugs [31, 32]. We have shown previously that R-roscovitine not
only promotes neutrophil apoptosis in vitro but does so in the
presence of powerful survival factors [23]. This is despite the fact
that neutrophils are terminally differentiated cells and were
thought not to have functionally active CDK. R-roscovitine also
dramatically enhanced the resolution of established animal
models of neutrophil-dominant inflammation such as: carragee-
nan elicited acute pleurisy, bleomycin lung injury and passively-
induced arthritis. Peripheral neutrophil counts were unaffected
indicating a reassuring specificity for stimulated inflammatory
neutrophils [23]. Interestingly, in a recent study R-roscovitine
has been used to induce neutrophil apoptosis in vitro and in vivo
and shown to resolve inflammation after pneumococcal menin-
gitis and accelerate recovery in mice treated with antibiotics [33].
The molecular mechanism by which R-roscovitine achieves these
promising results has not yet been elucidated. R-roscovitine is
known to promote apoptosis in cancer cell lines by inhibition of
RNA polymerase-II leading to down-regulation of the key survival
protein Mcl-1 [24]. It has also been suggested that NF-kB
activation at the level of IkB kinase kinase activity is inhibited by
R-roscovitine [25]. Given that both Mcl-1 and NF-kB are key
components of neutrophil survival regulation we were keen to
address the hypothesis that R-roscovitine might act via similar
mechanisms in the inflammatory neutrophil. We propose that
down-regulation of the survival protein Mcl-1 at the level of
transcription is responsible for the pro-apoptotic action of
R-roscovitine. We show that this effect is counter-intuitively
enhanced in the presence of powerful survival mediators such as
GM-CSF, LPS and TNF-a. However, despite the evidence that
R-roscovitine may directly inhibit NF-kB activation in some
cancer cell lines we could find no evidence of this in resting or
stimulated neutrophils. We performed dual experiments, IkBa
Western blotting and confocal microscopy for labelled p65,
because recent reports had suggested that NF-kB activation could
occur independently of IkBa inhibition [28, 34]. We also
examined mRNA and protein levels of XIAP, an NF-kB-regulated
survival protein. We could achieve no consistent results immuno-
blotting for XIAP, perhaps because XIAP acts in the final stages of
apoptosis and results are confounded by the conclusion of this
process. We feel that in our system down-regulation of XIAP was
more consistent with concluded apoptosis. Additionally, we have
shown that ERK activation induced by LPS is minimally affected
by R-roscovitine. This finding is important as it suggests that the
documented pharmacological activity of R-roscovitine against
ERK 1 and 2 is not relevant to neutrophil apoptosis.
Despite failing to confirm a role for R-roscovitine-induced
inhibition of NF-kB activation in neutrophils, as suggested by a
recent study of cancer cell-lines, we did find that R-roscovitine
significantly down-regulated Mcl-1. We demonstrated enhanced
activity in the presence of the survival agents LPS and TNF-a,
although only an attenuation of the survival effect of GM-CSF
was seen. Mcl-1 is extensively regulated and has been associated
with various signalling systems including PI3K, MAPK and
glycogen synthase kinase [21, 35]. It can be down-regulated at
the level of transcription, translation and even degradation [17].
Mcl-1 may be degraded in the proteasome following phosphory-
lation and ubiquitination or may be disposed of in a caspase-
dependent manner [17–20]. It is also possible that a splice




































































































































Figure 4. (A) Effect of R-roscovitine on the survival protein Mcl-1.
Neutrophils at 5106/mL in IMDM containing 10% autologous serum
were either lysed immediately (time 0) or incubated in either the
absence (control) or presence of GM-CSF (50ng/mL), LPS (100ng/mL),
TNF-a (10ng/mL), R-roscovitine (20 mM), R-roscovitine1GM-CSF,
R-roscovitine1LPS or R-roscovitine1TNF-a, gliotoxin (0.1mg/mL),
R-roscovitine1gliotoxin for 4h and then lysed and immunoblotted
for Mcl-1 or b-actin. Blot shown is representative of three experiments.
(B) Effect of R-roscovitine on the pro-apoptotic bcl-2 homologue Bim.
Neutrophils treated as in Fig. 4A and probed with anti-Bim antibody.
Blot shown is representative of three experiments.
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explain the rapid apoptosis that can accompany Mcl-1 down-
regulation.
We felt it was important to consider the effect of R-roscovitine
on neutrophil activation status. Agents that cause neutrophil
priming render them susceptible to activation. Ultimately, this
may lead to release of superoxide anion and other toxic products
detrimental to the process of resolution of inflammation. The
effects of R-roscovitine on the markers of activation CD11b
(which becomes up-regulated upon activation by granule move-
ment to the surface membrane), CD62L (which is shed upon
priming/activation) and neutrophil shape change (neutrophils
when stimulated re-organize their cytoskeleton resulting in cell
polarization) were investigated using flow cytometry. Similarly,
neutrophil aggregation was assessed by measurement of light
transmission through populations of stimulated neutrophils.
Results demonstrated that R-roscovitine caused no significant
alteration in the activation status of neutrophils on its own or in
combination with neutrophil-activating stimuli, a promising
finding when considering its potential therapeutic use as a novel
anti-inflammatory agent. Additionally, the ability of neutrophils
to generate superoxide anion in response to stimulation was not
compromised by treatment with R-roscovitine. The preservation
of neutrophil activation status in co-treatments of R-roscovitine
and the stimuli GM-CSF, LPS, leukotriene B4 and TNF-a also
infers important information regarding the recruitment and
migration of neutrophils from the circulation to sites of inflam-
mation as the neutrophil surface molecules CD11b and CD62L
are important regulators of cell adhesion to vascular endothe-
lium. It is pertinent that neutrophils are recruited to sites of
infection and inflammation, as dysregulation in this process is
associated with increased susceptibility to infection [36].
It was previously shown that guanosine triphosphate (GTP)-
dependent secretion in the neutrophil is regulated by CDK5 and
that R-roscovitine blocks lactoferrin secretion and reduces
expression of CD63 and CD66b on the surface membrane. This
implies that CDK5-p35 activity is required for optimum levels of
GTP-induced secretion from primary (azurophil) and secondary
(specific) granules [37, 38]. We found no change in levels of
CD11b localization (which resides in secondary granules) upon
treatment with R-roscovitine when compared with control. This
could be because GTP-induced secretion regulated by CDK5-p35
activity is redundant or it may reflect sub-optimal inhibition of
CDK5 by R-roscovitine. Only partial inhibition occurred in
previous studies, indicating that alternative mechanisms are
capable of compensating.
We have also shown that R-roscovitine has a much smaller
effect than the ERK-specific inhibitor PD50890 on LPS-induced
ERK phosphorylation. This contrasts with work on vascular smooth
muscle cells where R-roscovitine inhibited ERK activation by
angiotensin II [39]. It seems likely that the early, dramatic effects
of R-roscovitine on neutrophil survival are unlikely to be due to


























































































































































Figure 5. PCR for XIAP and MCL-1. RNA extracted from neutrophils treated for 2h (MCL-1) and 4h (XIAP) with treatments as designated at the
same concentrations as described in Fig. 4A. Gels shown are representative and densitometry is from three experiments. Statistically significant
difference for MCL1 between R-roscovitine and control, LPS and R-roscovitine/LPS, TNF-a and R-roscovitine/TNF-a po0.001  (ANOVA with a
Student Newman–Keuls multiple comparison post hoc test with a 95% confidence interval).
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the observed effect is more likely to be due to downstream effects
of R-roscovitine as opposed to direct inhibition especially as even
powerful inhibition of ERK phosphorylation does not induce
neutrophil apoptosis [14]. We have shown that R-roscovitine
induces neutrophil apoptosis and also that it can resolve animal
models of inflammation [23]. Interestingly, the ERK inhibitor
PD50890 was also shown to have a pro-resolution effect in
carrageenan-induced pleurisy without having a direct effect on
neutrophil apoptosis per se [14]. Pro-resolution effects were felt to
be conferred by inhibition of inflammatory mediator-triggered ERK
activation responsible for neutrophil survival. Given that ERK 1
and 2 fall within the pharmacological specificity of R-roscovitine it
was possible that ERK inhibition could account for some of its
effects [31]. However, our findings suggest that ERK inhibition is
not relevant to CDK-inhibitor-mediated resolution of inflamma-
tion. R-roscovitine allows LPS and TNF-a-mediated activation of
both NF-kB and ERK and yet overcomes the survival signalling
usually associated with these pathways. This suggests that the pro-
apoptotic effect of R-roscovitine occurs down-stream of these
events and is of sufficient magnitude to over-ride them. In keeping
with this hypothesis we have shown that the key survival protein
Mcl-1 is significantly down-regulated.
We have shown that Mcl-1 is down-regulated at the mRNA
level by R-roscovitine and this change is readily detected at 2h and
is more pronounced at 4 h. We believe that MCL-1 down-regula-
tion precedes and is responsible for the initiation of apoptosis
because we detect changes in the level of this mRNA/protein at 2 h
but only detect apoptosis by annexin-V binding at 4h and caspase
cleavage at 2.5–3h (Western blotting and fluorometric caspase
assay, data not shown). By contrast R-roscovitine does not appear
to decrease basal levels of XIAP but there was a trend toward
prevention of up-regulation by LPS at the mRNA level. These data
are not as clear-cut as the Mcl-1 findings, possibly because the half-
life of XIAP mRNA is significantly longer than that of MCL-1 [40].
The interpretation of results for TNF-a is complicated but inter-
esting because of the dual and directly opposing effects of TNF-a
on neutrophil apoptosis [7, 21]. TNF-a both directly activates the
extrinsic apoptotic program and enhances transcription of key
survival proteins via the NF-kB pathway. The combination of
R-roscovitine and TNF-a leads to very early initiation of and bias
towards the extrinsic apoptotic program detectable by annexin-V
binding at 2 h (data not shown). XIAP is up-regulated and stabi-
lized in response to caspase cleavage; so it might be expected that
we would find enhanced mRNA/protein levels of XIAP. However,
there is no detectable up-regulation as measured by PCR, which
probably represents a degree of up-regulation in response to the
early initiation of apoptosis that is balanced by inhibition of tran-
scription by R-roscovitine. We have shown that de novo transcrip-
tion of XIAP as stimulated by LPS is prevented by R-roscovitine.
By demonstrating that the important survival protein Mcl-1 is
down-regulated at transcriptional level, we corroborate our finding
that direct inhibition of NFkB is not responsible for CDK-inhibitor-
driven neutrophil apoptosis. We hypothesize that a more central,
generalized effect on neutrophil transcription is responsible for the
induction of apoptosis. This effect is particularly evident in granu-
locytes because of the importance of rapidly transcribed and
degraded, short-lived protein Mcl-1 to their survival. Pro-apoptotic
Bcl-2 homologues such as Bim have much longer half-lives and in
excess drive neutrophil apoptosis via the intrinsic (mitochondrial)
pathway. Our work adds to the literature, suggesting the funda-
mental importance of these proteins to neutrophil survival and
further illuminates the mechanism of action of R-roscovitine.
It can be concluded from this study that R-roscovitine induces
apoptosis in human neutrophils by decreasing levels of pro-
survival proteins to over-ride the cyto-protective effects of
inflammatory mediators without directly influencing key inflam-
matory signalling pathways. In addition, data provided enhance
the claim that R-roscovitine would be well tolerated in vivo
(corroborated by the use of R-roscovitine in clinical trials as an
anti-cancer agent) and provide support for a therapeutic trial of
R-roscovitine in neutrophil-dominant inflammatory disease.
Materials and methods
Reagents
Hanks balanced salt solution (HBSS) and IMDM were obtained
from PAA. Dextran T500 obtained from Pharmacosmos, Percoll
and ECL Western blotting detection reagents were obtained from
GE Healthcare. AnnexinV-fluos from Roche and PI from Sigma-
Aldrich. Recombinant human TNF-a and human GM-CSF from
R&D Systems. R-roscovitine, PD98059 and LT-B4 were from
Merck, Dexamethasone was obtained from Organon. LPS (E. Coli
serotype O127:B8), Gliotoxin, PMA (phorbol 12-myristate 13-
acetate) and fMLP from Sigma-Aldrich, DHR from Invitrogen and
Ro-31,8220 from Calbiochem. XIAP primers from eurofins (XIAP
forward gga acc ttg tga tcg tgc ct, XIAP reverse aat cag tta gcc ctc
ctc ca). Mcl-1 primer pair commercially available from R&D
Systems (See: http://www.rndsystems.com/), 18S competimers
from Applied Biosystems and PCR Master-mix purchased from
Promega, GelRed from Biotium.
Antibodies
Anti-Mcl-1, Anti-XIAP and Anti-Bim antibodies were purchased
from Santa Cruz, R&D Systems and Cell Signalling, respectively.
Anti- IkBa was from Abcam. Monoclonal anti-b-actin antibody
was from Sigma-Aldrich. Goat anti-mouse and -rabbit HRP-
conjugated antibodies were obtained from Dako. Anti-CD62L-PE
and anti-CD11b-APC from BD Bioscience, anti-p65 primary
antibody from (R&D Systems).
Cell isolation and culture
Polymorphonuclear leukocytes were isolated from peripheral blood
of healthy donors as described previously [7]. Polymorphonuclear
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leukocytes were 495%; neutrophils assessed using morphologic
criteria and cell viability (499%) was assessed by trypan blue
exclusion. Cells were re-suspended at 5 106/mL in IMDM plus
10% autologous serum (apart from where otherwise stated) and
treated in 2mL Eppendorf tubes at 371C on a shaking heat block or
cultured in flat-bottomed flexible well plates in a 5% CO2
atmosphere at 371C.
Assessment of granulocyte apoptosis
Neutrophil apoptosis was assessed by cyto-centrifuging 100 mL of
5 106 cells/mL at 300 rpm for 3min. The cells were then fixed
for 1min in methanol and stained with Diff-Quik
TM
(Gamidor).
Morphology was assessed at 100 objective on an oil immersion
microscope. Additionally FITC-labelled rh-annexin V and PI were
used to assess apoptosis and necrosis, respectively. Annexin V
was diluted 1/500 in binding buffer (HBSS1Ca21) and 280 mL
added to 20 mL of cells (5106 cells/mL). Samples were then
incubated on ice at 41C for 10min. Immediately prior to
processing on the FACSCaliber flow cytometer, 1 mL of PI
(1mg/mL) per sample was added.
Assessment of CD62L, CD11b and shape change
Neutrophils were resuspended at 5 106/mL in PBS1cations
and treated with reagents as detailed in the appropriate
figure legend. Treatments took place on a 371C shaking heat
block; 50 mL of cells were then added to 150 mL ice cold PBS
without cations containing 0.1% BSA and treated with 2 mL of
either the control PE/APC antibodies or with antibodies for
CD62L and CD11b for 30min prior to assessment by flow
cytometry.
Measurement of reactive oxygen species generation
Superoxide anion generation was estimated as an increase in
reactive oxygen species as determined by DHR fluorescence.
Neutrophils were resuspended at 2106 cell/mL in HBSS medium
and kept at 371C. Cells were pre-incubated with DHR (1mM)
for 5min then diluted to 1106/mL for the treatment with
R-roscovitine (20mM) or the protein kinase C inhibitor Ro-31,8220
(1mM) for 30min. Cells were then stimulated by the addition of
PMA (300nM) for a further 15min and placed on ice. Changes in
mean fluorescence (FL-1) and mean forward scatter were
measured by flow cytometry to determine superoxide anion
generation and shape change, respectively.
Neutrophil aggregation
Neutrophils were prepared at 5106 neutrophils/mL in HBSS
medium. Analysis of aggregation was performed using a four-
channel optical aggregometer (Chronolog, Labmedics) and data
were captured using an analogue-digital converter (Maclab 4c,
AD Instruments).
Western blotting
Cells at a concentration of 5106/mL per condition were
incubated at 371C on a shaking heat block. For times and reagent
concentrations please refer to figure legends. Lysates, prepared as
described previously [7], were run on a 12% SDS gel and
transferred onto PVDF (Immobilon-P, Millipore). Membranes
were blocked for 1 h in 5%wt/vol dried milk/TBS/0.1% Tween-
20 or 5%wt/vol BSA/TBS/0.1% Tween-20 (Anti-Bim) prior to
overnight incubation at 41C (or 1.5 h at room temperature for
b-actin) with primary antibodies for Mcl-1 diluted 1:200, b-actin
diluted 1:10 000, XIAP diluted 1:1000, IkBa diluted 1:2500, Bim
1:1000. Following 35min washes in TBS/0.1% Tween-20 the
blots were incubated with the appropriate HRP-conjugated
secondary antibody diluted 1:2500 for 1 h at room temperature
prior to incubation with ECL reagents, exposure to BioMax MS-1
light–sensitive film, and processing through an x-ray developer
(X-Ograph Imaging Systems).
RT-PCR (semi-quantitative)
Total neutrophil RNA was isolated with the use of a Nucleospin
RNA II kit (Macherey-Nagel) as per the manufacturer’s instruc-
tions. Two micrograms of RNA were made up to a final volume
of 25mL with DEPC-ddH2O. Reaction mix for each sample
prepared as follows: 10 mL 5 M-MLV reaction buffer, 5 mL
100mM DTT, 5mL 100mg/mL oligo(dT) primer, 4 mL 10mM
dNTPs, 0.5 mL Rnasin, 0.5 mL M-MLV reverse transcriptase; 25 mL
of this mix added to each 2mg RNA sample prior to incubation for
90min at 371C to allow cDNA synthesis. Reaction stopped by
incubating at 901C for 10min; 2 mL Primers and 5mL cDNA added
to 25 mL Master mix and volume made up to 50 mL with
diethylpyrocarbonate H2O. Tubes placed in thermal-cycler with
following program: 941C for 4min then: 941C for 45 s, 551C for
45 s, 721C for 45s 30–35 cycles, 721C for 10min. Products
separated by agarose gel electrophoresis using GelRed nucleic-
acid detection dye prior to visualization and image capture with
UV-light camera.
Immunohistochemistry and confocal analysis
Freshly isolated neutrophils at 2.5 106/mL were treated as
above; 100 mL of sample was centrifuged at 400 g, 41C for 4min
in a flat-bottomed flexi-well plate. Supernatants were removed
and cells re-suspended and fixed for 20min in 3% paraformalde-
hyde. After washing and quenching with 50mM glycine, the cells
were re-suspended in 50 mL of 10% goat serum and blocked for
1 h. Cells were centrifuged again, supernatant removed and cells
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re-suspended and incubated with 50mL of anti-p65 primary
antibody diluted 1:50 and 50 mL of PI (2 mL in 1mL) for 1 h.
Following washing the cells were incubated with 50 mL of alexa
488 Fab2 fragment (Invitrogen) 1:500 for 1 h, washed and
resuspended at 150 mL. Aliquots of 100 mL volume were removed
and cyto-centrifuged onto slides prior to visualization on confocal
microscope (Zeiss LSM510meta).
Statistical analyses
All experiments were performed at least three times unless stated
otherwise and each treatment done in triplicate and the results
are expressed as the mean7SEM. Data were analysed by a one-
way ANOVA with a Student Newman-Keuls multiple comparison
post hoc test with a 95% confidence interval (InStat software).
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